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Introduction 
The interface between chemistry and biology is certainly one of the most challenging 
and fruitful areas of research in life sciences at present. Biology has become more and more 
focused in understanding the natural processes of life at molecular level, with particular 
interest in determining the molecular structures of the biological entities and how they rule the 
intrinsic interactions with other biomolecules and small compounds. Therefore biology is 
moving towards chemistry and the frontiers between the two disciplines are intercalating. 
Chemistry not only plays an important role in the development of the pharmaceutical industry 
through drug design and delivery,   but also provides exciting new ways to understand the 
mechanisms of complex living systems which could lead to future insights for the 
improvement of health care.  
As classical biological techniques can not always supply the tools to study many 
biological phenomena in molecular details, the search of novel chemical methodologies that 
can address these issues is nowadays one of the topic research areas in biomedical science. In 
this field, the chemical-mediated synthesis and engineered modification of proteins have 
gained a lot of attention from the scientific community, reflecting new advances in biological 
research. Furthermore, whereas many biological assays employ specific non-covalent 
interactions that provide recognition between biomolecules in order to detect or localize a 
certain protein inside bioenvironments, the application of selective chemical reactions 
promises to emulate such high specificity by using small molecules that covalently bind to each 
other. In this sense, specificity is achieved by introduction of a reactive group into a particular 
protein that will uniquely modify a complementary chemical moiety of a target and then form 
a tight and irreversible junction between the two reaction partners. 
This work describes the application of one of the most classical organic reactions, the 
Diels-Alder cycloadditions, for the strategic functionalization of complex biomacromolecules 
as proteins. The use of Diels-Alder reactions in protein science may appear paradoxical: the 
conditions in which these reactions are traditionally carried out during organic synthethic 
procedures (organic solvents, heating, use of catalysts) are contradictory with the type of 
reactions which are applied for protein chemistry (aqueous media, room temperature). 
Nevertheless Diels-Alder transformations can indeed be conducted in aqueous medium and 
the chemoselective nature of these reactions has been explored hereby to promote coupling of 
peptide segments and selective modification of proteins. The scope of the Diels-Alder ligation 
approach has been investigated using model peptides and proteins. The proposed 
methodology promises the possibility to equip a given protein (or polypeptide) with 
appropriate functionalities that may facilitate the investigation of a particular biological system. 
 3
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4
Theoritical Background 
 
 
 
 
 
 
 
 
 
  2. THEORETICAL BACKGROUND   
 
 
 
 
 
 
 
 
 
 
 5
Theoritical Background 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6
Theoritical Background 
 
 
2.1. In the world of protein science[1-5] 
 
 An important objective of the biomedical science is to understand the molecular basis 
of proteins biological function. Since the explosive success of the genome-sequencing 
projects, this goal has been dramatically increased as hundreds of thousands of new proteins 
have been revealed, but only as predicted sequence data.  A complete elucidation of the task 
of proteins within a biological system requires a full description of the protein structure and 
how their properties affect the inherent function as well as interactions with other molecules. 
To better understand these correlations, scientists are often confronted with the need of 
systematically altering the covalent structure of proteins with the intention to, for instance:  
 introduce post-translational modifications, such as glycosilation, phosphorilation, 
lipidation, etc, which are fundamental transformations that rule protein activity inside and 
outside cells; 
 incorporate appropriate biophysical probes into the protein molecule such as 
fluorescence markers or other reporter tags (biotin, epitopes, small ligands, etc) that permit 
protein detection and tracking within complex biological environments. Important biological 
events like protein-protein interactions, membrane/cytoplasm localization and cellular uptake 
of labeled proteins can be thus easily monitored in in vitro or in vivo assays; 
 substitute strategically naturally occurring amino acids inside the protein structure 
by another amino acid or by an unusual scaffold which can then answer questions on the role 
of the specific amino acids in protein activity; 
 alter protein properties in a specific manner to enhance activity or other physical 
characteristics like stability, solubitity, etc.  
 
Proteins are a class of molecules characterized by both complexity and diversity, 
making their production a great challenge. However, for the last years, a range of biosynthetic 
and chemical synthetic approaches came out in the field of protein science which has led to a 
significant expansion of the spectrum of methods available for production of proteins either 
in their natural form or holding engineered modifications. An overview of the most important 
technologies that permit the covalent incorporation of unnatural molecules into proteins is 
illustrated in Figure 1 and discussed here in the next pages. 
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Figure 1. Methods for the covalent incorporation of non-natural molecules into proteins and 
their importance in biological sciences. 
 
 
 
2.2. Biosynthetic methods for protein production[6-11] 
 
 Isolation of a particular protein among a myriad of other proteins and molecules 
found inside cells is not a trivial task either by laboratory synthesis or cell population 
purification. For the past 20 years, this task has been enormously facilitated by the 
development of biotechnological methods involving the recombinant DNA-based expression 
of proteins in genetically engineered cells. From its introduction until today, this powerful 
method revolutionized the study of proteins by enabling the production of large amounts of 
proteins of defined molecular composition and from different organism sources.  It also 
allows the systematic variation of the peptide sequence of proteins with the diverse encoded 
amino acids (site-directed mutagenesis).  
The ribosomal biosynthesis is usually performed employing the bacterium Escherichia 
coli as protein factory[12], although other organisms can be applied as well. Because the cell is 
used to manufacture the desired protein, the production of the macromolecule using this 
technology is limited to the 20 genetically encoded amino acids. Attempts to overcome this 
tRNA 
engineering 
bioconjugation 
chemical 
ligation 
=   modifier 
structural 
biology 
novel 
functional 
proteins 
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limitation have been made to include noncoded amino acids as building blocks, in a method 
known as nonsense suppression mutagenesis or unnatural amino acid mutagenesis (Figure 
2).[9] In this method, a desired point mutation is generated by replacing the codon of interest 
with an amber stop codon. Separetely, a tRNA is prepared that can recognize the amber stop 
codon. This tRNA is then charged with the desired amino acid derivative using both chemical 
and enzymatic coupling steps. Together these components are translated either in vitro or in 
vivo, and the unnatural amino acid is incorporated at the desired site. Over 100 different amino 
acids have been incorporated into dozens of soluble and transmembrane proteins using this 
technique.[6-8] Although this method promises to become a potential tool for production of 
artificial proteins, it is still in progress and, so far, can not find yet general applicability due to 
the low yields of mutant protein, technical demanding procedures and incompatibility of many 
unnatural amino acids with the ribosomal synthesis.  
 
  
Figure 2. Key components for incorporation of unnatural amino acids into proteins using 
nonsense codon suppression.[8] 
  
 
 
2.3. Chemical tools for assembly of proteins 
 
The lack of general biotechnological tools to generate proteins enclosing noncoded 
modifications such as targeting probes, post-translational modifications, unnatural amino acids 
and other artificial modifiers has driven the development of different protein manufacturing 
approaches. In this scenario chemical synthesis has emerged as a powerful tool for protein 
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engineering. Because of its unmatched flexibility, chemical access to proteins provides the 
ability to incorporate unnatural alterations into proteins in a completely general fashion and 
has opened many new paths for the study of protein function.  
 
 
2.3.1. Bioconjugation methods 
 
 Chemical reactions are the basis of the bioconjugation methods, a technology that has 
affected nearly every discipline in the life sciences, including scientific research, clinical 
diagnostics and human therapeutic markets. [13] Bioconjugation is the simplest and longest 
standing method for introduction of non-natural molecules into proteins. These methods 
make use of reactive functionalities found inside proteins to chemically connect a desired 
modification into the structure, thus creating unique conjugates that are able to interact with 
particular analytes in solution, cells or tissues. The amino, sulfhydryl and carboxylic acid 
groups present in the polypeptidyl molecules are the most used attachment points for protein 
targeting, due to their relative high reactivity in comparison with other groups present in 
amino acids. An overview of the most important reactions found in bioconjugation chemistry 
is outlined in Figure 3.  
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Figure 3. Overview of the most used bioconjugation reactions. 
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Despite their widespread application and versatility, the bioconjugation methods are 
quite limited in respect to the power of promoting site-specific protein modification. 
Uncontrolled alteration of a given protein molecule may perturb its structure in a way that it 
can not be longer functional. Also it may be very useful if one can introduce an appropriate 
target into a specific position of the protein structure in order to investigate the role of this 
particular region for the protein function. To overcome these problems, some approaches 
have been developed to provide moderate or even complete control over the bioconjugate 
derivatization, including: 
 sequential combination of two or more bioconjugation steps which permits greater 
control over the conjugation process by using of heterobifunctional cross-linkers; [13]
 introduction of an unique cysteine into a particular position of the protein structure 
by site-directed mutagenesis, allowing the selective modification of this residue via thiol-
reactive reagents; [14]
 moderate selective N-terminus derivatization by carrying out the amine-acylation 
reactions under slightly acidic conditions. [15]
 
The combination of biosynthetic methods for protein production and subsequent 
bioconjugation can not always provide the tools for all kinds of protein derivatization. A lot of 
efforts have been made in the last years to develop new technologies in this field. Scientists 
have found a way out to solve this problem by constructing protein molecules totally or 
partially by benchtop chemical reactions, permitting the production of proteins that possess 
either natural conformation or site-specific modifications.  
 
 
2.3.2. Chemical protein synthesis
 
 The first attempts to build up a protein molecule by chemical means were based on 
standard methods of peptide chemistry.[16] The application of classical solution-phase synthetic 
chemistry - where fully protected peptide segments are convergently condensed to form a 
large polypeptide - showed to be a quite demanding process. Most of the problems rely on the 
laborious preparation of the fully protected segments and their poor solubility in the coupling 
reaction medium. With the introduction of solid-phase peptide synthesis methods (SPPS), this 
area gained a great improvement. Together with the development of appropriate protecting 
groups and efficient coupling reagents, SPPS is nowadays capable to assemble polypeptides up 
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to 60 amino acid residues with relative facility. Moreover the method permits complete 
freedom to introduce modifications anywhere in the peptide sequence. Nevertheless, this 
number of amino acid residues that can be assembled via SPPS corresponds only to the very 
smallest proteins and protein domains. Different approaches involving the combination of 
solid-phase and solution-phase synthesis has been reported to construct larger proteins, yet 
they were achieved only after great efforts and laborious procedures. Noteworthy is also the 
development of enzymatic ligation methods for the preparation of proteins with enzymes 
specifically engineered to perform reverse proteolysis and to act as “ligases”.[17] Nevertheless, 
despite some notable successes,[18-19] such methods have not found widespread use (yet) after 
the development of the more simple and versatile chemical ligation methods. 
  
 
2.3.3. Chemical ligation methods[1,20-24] 
 
  The size of proteins which can be chemically synthesized has been increased 
considerably by the introduction of chemical ligation methods since early 1990´s in the area of 
protein chemistry. The innovative key concept of these methods is based on the linkage of 
peptide segments through chemoselective nonamide reactions in order to construct larger 
proteins. More specifically, these reactions involve the coupling in aqueous environment of 
two unprotected peptide segments bearing unique and complementary functional groups that 
are mutually reactive with each other, but unreactive with all other functionalities present in 
the segments to be coupled (Figure 4). Due to the chemoselectivity of the linking reaction, 
protection groups are unnecessary. The unprotected peptide segments to be used for the 
chemical ligation can be, in principle, easily synthesized either by chemical or biochemical 
means.  
Because the mutually reactive groups (or at least one of them) are functionalities not 
normally found in peptides, the price to be paid for applying such chemoselective ligation is 
the formation of an unnatural structure at the ligation site. However, in practice, these 
unnatural structures are often well tolerated within the context of a folded protein and 
numerous examples of fully active proteins were prepared using these methods. Nevertheless, 
a very elegant approach called native chemical ligation has also been established which is able to 
generate true peptide bond-forming ligation.  
 Along the last years the chemical ligation methods have been shown to be a simple 
and highly effective strategy to construct large polypetides and proteins. Hundreds of 
 12
Theoritical Background 
engineered proteins have been produced by means of this technology. The ligation strategies 
have found great application not just for the “clicking” of peptide segments to build a given 
protein macromolecule enclosing natural or unnatural properties; but also to tactically equip 
proteins with special functions that allow their discriminating targeting in vitro and in vivo 
experiments through chemoselective reactions. A variety of ligation chemistries has been used 
to perform such kind of reactions. Most of these reactions are based on imine or thiol 
chemistries, although new approaches involving the azido function have been recently 
developed.  These techniques are briefly described in the next sections.  
 
Peptide fragment 
or protein
Peptide fragment 
or specific target
chemical 
ligation
mutually reactive 
groups 
 
 
 
 
 
 
 
 
 
Figure 4. Principles of chemical ligation. 
 
 
Aldehyde/ketone mediated ligations 
 
 The absence of aldehydes and ketones on the side chain of the naturally occurring 
amino acids makes this electrophilic functionality a candidate to perform unique reactions 
with a variety of nucleophiles. Selective peptide ligation has been obtained by reaction of 
aldehydes (or ketones) with hydroxylamines and hydrazines in the presence of protonated 
amino functions to form, respectively, oximes or hydrazones linkages (Figures 5A and 5B).[25-
26] A recent application of this ligation method includes the synthesis of a glycoprotein human 
hormone erythropoietin protein polymer.[27] Because hydrazones are known to hydrolyze 
rather easily in water, the resulting backbone-engineered peptidyl hydrazone can be reduced 
with sodium cyanoborohydride to produce the more stable peptidyl hydrazide. Furthermore, 
the hydrazone ligation concept was explored for the development of a novel bioconjugation 
system (HydralinKTM) which is based on the reaction of a 2-hydrazinopyridyl moiety with a 
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benzaldehyde moiety to yield a stable bis-aromatic hydrazone (Figure 5C).[28] The chemistry is 
highly selective and stable in solution, making it superior to conventional methods of 
bioconjugation such as maleimide/thiol and avidin/biotin. 
 Aldehydes can also react with β-amino thiols or alcohols (Cys, Ser or Thr) to form 
pseudoproline linkages (Figure 5D). The ligation involves an imine capture step that results 
from the coupling of the aldehyde group and the N-terminal amino group. Chemoselectivity is 
provided by the presence of –SH or –OH groups at the β-carbon position of the side chain, 
which permits the formation of a stable ring structure that can in turn rearrange to a 
pseudopropyl imide bond.[23] Tam and co-workers have demonstrated the effectiveness of the 
thiaproline ligation in the synthesis of analogues of TGF and HIV-1 protease.[29] 
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C. HydraLinKTM bioconjugation
pH 3-5
O
+
pH 4.7-7.2
O
H
O
NN
H
H2N
O
N
O
NN
H
O
O
H
O H2N
XH
O
R
X = S, O
O
O
N
HX
O
R
O
O
X
HN
O
R
X
O O
RHO
+
D. Pseudoproline ligation
H
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Figure 5. Aldehyde-based chemical ligations. 
 
 
Thioacid and thioester mediated ligations 
 
 The thioester-forming ligation was the first example of backbone-engineered ligation, 
established by Schnolzer and Kent in 1992.[30] It is based on the generation of a thiocarboxyl 
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group at the C-terminus of a peptide segment that reacts at acidic pH with the N-terminal 
bromoacetyl group of the second peptide segment, forming a thioester moiety at the ligation 
site (Figure 6A). Under these conditions, all free amino groups are protonated and the reaction 
proceeds selectively. However the thioester linkage is only stable at pH range 3-6, being 
hydrolyzed at higher pH values. The synthesis of a HIV-1 protease analogue was the first 
example of application of this method. 
 The desire to assemble proteins with native backbone structures by chemoselective 
ligation reaction inspired Kent and co-workers to develop a novel thiol capture ligation 
approach[31] that generates amide bonds at the ligation site. The chemoselective step involves 
the reversible transthioesterifcation of a thioester modified C-terminus peptide with the thiol 
group of an N-terminal cysteine residue (Figure 6B). [32] A spontaneous, irreversible and rapid 
intramolecular S→N shift converts the thioester bond into a normal peptide bond, leading a 
cysteine residue at the ligation position. Internal Cys residues, if present in the peptide 
sequences, are not modified because the initial transthioesterification step is reversible and the 
S→N shift only occurs in the presence of the N-terminal amino group. To prevent oxidation 
of the N-terminal thiol, the reaction is carried out in the presence of thiols or other reducing 
reagents. While the presence of a Cys residue at the N-terminus is mandatory, almost all 20 
amino acids can occupy the position of C-terminal thioester residue, excepting Val, Ile and 
Pro which react slowly and Asp and Glu which are prone for side-reactions.[33-34] This method, 
named native chemical ligation (NCL), is nowadays the most applied ligation strategy for the 
chemical-mediated construction of proteins.[1, 35]  
Two variants of this approach were presented by Tam et al..[36] Both methods are also 
based on the sequential capture and intramolecular acyl transfer principle where a thioacid is 
alkylated to form an intermediate thioester that will rearrange to give the cysteine at the 
ligation site (Figure 6C). Raines et al. have showed that the concept of NCL can also be 
extended to include selenocysteines.[37] 
 The main disadvantage of NCL is the necessity of a cysteine residue at the ligation site. 
The occurrence of this amino acid in proteins is very low and the insertion of additional Cys 
residues can alter the protein structure and thus its function by formation of unwanted 
disulfide bridges. Several approaches have been developed in the last years to circumvent this 
limitation. Cys-mimetic auxiliaries have been used to generate an amide bond leaving a glycine 
residue at the ligation position.[38-40] However, the native peptide conformation is only 
achieved after removal of the auxiliary under acidic or photolytic conditions. Furthermore, if 
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the presence of a Cys residue resultant from NCL is not desired, it can be transformed to an 
alanine residue by desulfurization mediated by palladium or Raney-nickel.[41]  
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Figure 6. Thioester mediated ligations. 
 
 
Azide mediated ligations 
 
 The first chemical ligation involving the azido group was based on the Staudinger 
reaction, where a phosphine reacts with an azide to form an aza-ylide intermediate that can 
rearrange to produce a stable amide bond (Figure 7A). In their pioneering studies involving 
the Staudinger ligation, Bertozzi and co-workers devised an appropriate phosphane ligand that 
allows effective coupling of this moiety with azido-derivatized molecules in aqueous media.[42] 
In just few years after its establishment, the Staudinger ligation approach has proved to be a 
valuable tool for the preparation of bioconjugates in vitro and for the targeting of biomolecules 
in the complex environment of living cells.[43] Furthermore, approaches to find a traceless 
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Staudinger ligation method, where a phosphane ligand is cleaved by hydrolysis thus leaving a 
native bond at the ligation site, are currently under development.[44-45] Although the Staudinger 
ligation can potentially be applied for noninvasive imaging and therapeutic targeting,[46] the 
reaction has some drawbacks. The required phosphines are susceptible to air oxidation and 
the optimization of their water solubility and increased reaction rate has proven to be 
synthetically challenging. 
 Sharpless et al. have demonstrated that the Huisgen [3+2] dipolar cycloaddition of 
azides and alkynes to give 1,2,3-triazoles are biocompatible and can be explored to promote 
selective linkage of proteins with chemical probes (Figure 7B).[47] The technique is nowadays 
known as “click chemistry” and has been applied for modification of virus particles, nucleic 
acids and proteins from complex tissues lysates.[48] The click ligation, however, requires the 
presence of a copper catalyst and other additives (reducing reagents and ligand) to be 
performed in reasonable reaction times. This condition may limit the general application of 
this methodology due to toxicity of the copper compounds and/or the additives to some 
biological systems. Nevertheless a recent approach reported by Bertozzi and co-workers 
promises to circumvent this problem by utilizing a strain-promoted azide-alkyne ligation, 
where the [3+2] cycloaddition reaction is driven by resultant ring stabilization of a strained 
cyclooctyne after ligation with an azido moiety.[49] 
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Figure 7. Azide-mediated ligations. 
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2.4. Combination of chemical ligation and biosynthetic methods 
 
 The combination of ligation techniques and solid-phase peptide synthesis has proven 
to be very useful for the synthesis of proteins up to 200 amino acids in length.[50] The assembly 
of larger proteins, however, requires the development of a multistep ligation procedure which 
can be rather technically difficult. The combination of chemical ligation and biosynthetic 
methods therefore is an attractive strategy to construct proteins of, in principle, unlimited size 
and of designed composition.  
 
 
2.4.1. Expressed protein ligation 
  
 Some proteins undergo a process named splicing, in which two protein domains 
(exteins) are ligated with the concomitant elimination of the protein fragment (intein) between 
them (Figure 8). The intein itself is the catalyst of the splicing reaction and so far over 100 
different inteins have been identified from diverse organisms.[51-52] 
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Figure 8. Mechanism of intein-mediated protein splicing.  
 
Elucidations of the protein splicing mechanism have directed the design of engineered 
inteins that perform single splice-and-junction cleavage under specific conditions.[53] These 
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inteins, when fused to a particular protein either at its C or N terminus, may lead to the 
generation of a reactive C-terminal thioester or an N-terminal cysteine, respectively. In the 
case of the thioester formation (Figure 9), the strategy utilizes a mutation of the C-extein that 
prevents the splicing reaction to proceed after the initial acyl transfer reaction. The resulting 
thioester then becomes susceptible to undergo transthioesterification with added thiol 
reagents to release the intein and the thioester tagged protein. The C-terminus thioester in 
turn can be further modified by means of the native chemical ligation. The isolation of the 
protein-intein fusion complex after the expression step is facilitated by inclusion of an affinity 
tag (usually a chitin binding domain) in the intein fragment that permits immobilization of the 
fusion protein on a solid support before thiol-induced cleavage. 
 
  
 
Protein expression in bacteria
N
H
HS
O
O
N
H
O
H2N O
protein intein
Cys mutated to Ala
CBD
  N
H
HS
O
O
N
H
O
H2N O
protein intein
Purification of the fusion
 protein by immobilization
 in chitin beads
Thiol-induced
 protein cleavage
  
 
S
H
H2N
O
O
N
H
O
H2N O
protein intein
R-SH
 SR
O
protein
 intein
H2N
HS
O
thioester tagged protein
native chemical ligation
 N
H
O
protein
SH
O
synthetic peptide fragment or 
Cys derivatized molecule
 
 
 
 
 
 
Figure 9. Principles of Expressed Protein Ligation. CBD = chitin binding domain. 
 
 This approach, known as expressed protein ligation (EPL), has found widespread 
applications since its introduction in 1998.[54] By allowing the controlled assembly of synthetic 
peptides and recombinant polypeptides, expressed protein ligation permits unnatural amino 
acids, biochemical probes, and biophysical probes to be specifically incorporated into 
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semisynthetic proteins.[2,55-57] Nevertheless, EPL (like NCL) is still limited mainly by the 
requirement of a Cys residue. 
 
 
2.4.2. Unnatural amino acid site-mutagenesis and chemical ligations 
  
 As discussed before, suppressor tRNA techniques allow the use of the ribosomal 
machinery to insert a non-natural amino acid into proteins. Rather than just introduce the 
desired end-product amino acid, some recent approaches have instead demonstrated the 
incorporation of unique amino acid side chain featuring an orthogonal chemical functionality 
that can be further bioconjugated without interfering with other groups found inside the 
protein molecules. Using this approach, Schultz and co-workers have developed a method for 
the labeling of proteins in cells via hydrazone ligation using a ketone-modified protein.[58] The 
same group has reported recently a genetically-encoded incorporation of azide and acetylene 
tyrosine analogs into proteins that could be modified with dyes by copper(I)-catalysed click 
chemistry.[59] Furthermore, Bertozzi and co-workers demonstrated the modification of 
azidohomoalanine-labeled protein through Staudinger ligation with a phosphine reagent 
bearing an antigenic FLAG peptide (Figure 10). [60]  
 
NH2
O
R
O
N3
N
H
NNH2NH
CO2Me
PPh2
O
H
N
P(O)Ph2
N
N
N
Cu(I)
 
 
Figure 10. Combination of tRNA suppression technique and chemoselective bioconjugation 
for labeling of proteins. 
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2.5. Application of the chemical ligation methods for preparation 
of protein microarrays 
 
 Chemical ligation reactions can also be rationalized to be a valuable tool for the 
development of functional protein microarrays, an emerging branch of the proteomics field[61] 
that offers the possibility to simultaneously study a variety of proteins interactions in a 
microscale experiment. [62-66] By using a minute amount of sample, these miniaturized assays 
can be used for the high throughput analysis of interactions between proteins with other 
proteins, peptides, small molecules, oligosacharides or oligonucleotides. Nevertheless, the 
challenges when dealing with proteins microarrays are numerous and complex (in comparison 
with the established technology of DNA chips), requiring special manipulation and strategies 
to ensure appropriate spot uniformity, stable immobilization and preservation of desired 
protein activity in a microarray. Most of these aspects are dictated by the nature of the capture 
strategy in which the microarray is based. The development of appropriate capture agents is 
currently the most challenging bottleneck in protein microarray research.[67] 
 Glass slides have emerged to be a suitable surface to perform protein/peptide 
microarrays. They are inexpensive and possess great mechanical stability, low intrinsic 
fluorescence and a relatively homogeneous chemical surface. When used with appropriate 
bioconjugate chemistry, glass surfaces are capable of immobilizing biomolecules at very high 
densities. The surface of the glass slide is usually derivatized under specific conditions to 
generate functionalized layers. Immobilization of polypeptides is then subsequently carried out 
either by non-covalent or covalent linkage. Examples of non-covalent binding include: the 
interaction of antigens and antibody spotted surface; the binding of carbohydrates and 
nitrocellulose coated surfaces; the fixation of membrane proteins into lipidated surfaces.[64] 
Because the immobilized protein can adopt a variety of unpredictable orientations upon 
binding to the surface, these methods may lead to insufficient exposure of functional domains 
of a particular protein, rendering weak signals in further interactions with other analytes. The 
incorporation of recombinant affinity tags into specific sites of the protein molecule addresses 
the orientation issue (for instance, recombinant His-tagged proteins that binds to Ni-NTA-
coated slides[68]). However the interactions of the tags, like the other approaches of non-
covalent immobilization, are often reversible and may not be stable over the course of 
subsequent assays, resulting in graduate depletion of the protein from the microarray surface. 
More robust arrays are therefore obtained by covalent immobilization of the protein onto the 
glass surface. The first methods based on the covalent binding relied on the reaction of 
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chemical groups found within proteins (e.g. amines or thiols) with surfaces containing reactive 
groups (e.g. active esters, aldehydes, maleimides) using standard bioconjugation methods.[69] 
Here again the protein is attached to the surface in random orientations, which can often 
result in weaker signals because an unnecessary fraction of the biomolecules are immobilized 
with improper orientation, thus obstructing their binding with ligands.   
  Based on these facts, an attractive protein immobilization approach seems to involve 
the covalent binding of a protein onto a support surface via two unique and mutually reactive 
groups of small size, one present in a specific position of the protein and the other coated on 
the glass surface (Figure 11). Such type of linkage can be then fulfilled by chemical ligation 
strategies. While a number of research groups have demonstrated the use of chemical ligations 
to fix peptides, carbohydrates and other small biomolecules on glass surfaces (via aldehyde-
mediated ligation,[70] native chemical ligation, [71] Staudinger ligation[72-73] and click chemistry[74]), 
only a few reports have shown a direct immobilization of an entire protein onto glass slides 
through chemoselective reaction. Coleman and co-workers have recently described the use of 
EPL for the creation of microarrays of proteins by covalent attachment of thioester tagged 
proteins onto a modified glass surface containing an N-terminal Cys poly(ethylene glycol) 
linker.[75] A reversed approach was developed by Yao´s group where proteins possessing a N-
terminal Cys residue were immobilized on thioester functionalized glass surfaces. [76] EPL have 
been also employed to site-directed the immobilization of biotinylated proteins onto 
streptavidin coated surfaces[77] and of protein-nucleic acid conjugates onto DNA array 
containing capture oligonucleotides.[78]
 
 
 
 
 
 
 
 
 
 
 
 
mutually reactive 
groups
functionalized glass surface Robust protein microarray of 
uniformily oriented attached 
proteins 
Site-specific
covalent
immobilization
Screening for protein 
interactions
Figure 11. Principles of a protein microarray based on chemical ligation immobilization. 
 22
Theoritical Background 
2.6. Other orthogonal methods for polypeptide and protein 
ligation 
 
 Thioester-, azide- and aldehyde-based orthogonal reactions have showed their practical 
value for the study of protein function. However the spectrum of application of these 
techniques is not unlimited. To broaden the applicability of the chemical approach for protein 
functionalization, the development of new bioorthogonal chemical linkages is required. In this 
scenario, Diels-Alder reactions appear to be an attracting alternative to perform covalent 
modifications with biomolecules. 
 
 
2.6.1. Diels-Alder reactions in aqueous media 
 
Named after the German chemists Otto Diels and Kurt Alder, who won the Nobel 
Prize in 1950 for their pioneering work on [4π + 2π] cycloadditions, the Diels-Alder (DA) 
reaction is one of the most important reactions in modern organic synthesis, featuring the 
formation in one step of two new carbon-carbon bonds in a chemoselective manner. 
Generally this reaction involves cycloaddition of a 1,3-conjugated double bond (diene) and an 
olefin equipped with electron-attracting groups (dienophile) to form a six-membered 
carbocycle (Figure 12).  
Due to the hydrophobic nature of the reactants, organic solvents are the medium of 
choice for most synthetic Diels-Alder reaction procedures. However, since Breslow´s work in 
early 1980s,[79] many studies have shown that the Diels-Alder reaction often proceeds faster 
and with higher selectivity in water than in organic medium.[80-83] The origin for the water rate 
acceleration effect, although lacking complete understanding, seems to relay mainly on two 
effects: enforced hydrophobic interactions and activation of the dienophile by hydrogen 
bonding with water molecules.  
Hydrophobic interactions between nonpolar parts of molecules in water are important 
non-covalent forces found in various biological systems. For instance, they participate in 
protein folding processes and enzyme-substrate interactions as well as play a crucial role in the 
aggregation of phospholipids and other lipidated compounds in biological cell membranes. In 
the context of the Diels-Alder reactions, the interaction between diene and dienophile is also 
benefited from the hydrophobic effect. When these two nonpolar entities react to form the 
cycloproduct molecule, the nonpolar surface area that is exposed to water is reduced during 
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the activation process (Figure 13). Therefore some of the water molecules that were before 
part of the hydration shell surrounding the reactants are now released to the bulky aqueous 
environment providing an additional driving force for the reaction.[84] The hydrophobic effect 
also explains why the preference for the formation of endo-cycloadduct is enhanced in water. 
The endo transition state is more compact than the extended exo transition state, thus allowing 
more water molecules to be removed from the hydration shells to the aqueous media, favoring 
the cycloaddition process. 
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Figure 12. Principles of Diels-Alder cycloadditions. 
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Figure 13. Schematic representation of the hydrophobic hydration shells surrounding starting 
materials and activated complex of a Diels–Alder reaction. The regions marked in red indicate 
parts of the hydration shell that are released into bulk solution upon reaction.[84] 
 
 Hydrogen bonding between water and the activating group of the dienophile 
(frequently a carbonyl group) is likely to be also responsible for the rate acceleration.[80-83] 
Similarly to the way Lewis acids activate Diels-Alder reactions in organic solvents, the water 
molecules coordinate with the carbonyl group to form an activated dienophile that is more 
electrophilic and thus more reactive towards cycloaddition with dienes (Figure 14). 
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Figure 14. Hydrogen bond activation of the dienophile during Diels-Alder reactions in water. 
 
 
2.6.2. Diels-Alder reactions as biotechnological tools 
 
The ability to perform Diels-Alder cycloadditions in aqueous medium enables this 
highly chemoselective reaction to be regarded as a strong candidate to promote covalent 
modification of biomolecules, bringing up the opportunity to launch such versatile classical 
organic reactions into the biotechnological area. In fact, in the last few years, this idea has 
been explored by Sebesta and co-workers for the bioconjugation of nucleic acids. In a proof-
of-concept approach, they demonstrated that synthetic oligonucleotides conjugated with a 
diene moiety could be targeted with dienophile derivatized fluorophores and biotinylated 
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probes under aqueous conditions.[85] They also performed a few experiments to show that this 
method could be used to immobilize such oligonucleotides on surfaces.[86-87] 
Pozsgay et al. also utilized the Diels-Alder reaction for the synthesis of a glyconjugate 
vaccine against gram-negative bacterium Neisseria meningitidis A.[88-89]  Furthermore, Mrksich et 
al. have recently described in successive reports the development of biochips microarrays 
prepared by the Diels-Alder immobilization of monosaccharides[90]  and small peptides[91-93] to 
self-assembled monolayers on gold-coated glass surfaces. 
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The massive number of applications in which chemical ligations have been used in the 
last few years reflects the importance of these technologies for the present and future of 
biology research. There is still a strong requirement for the development of other new 
chemical ligation approaches in order to expand the number of chemical tools for the creation 
of tailor-made proteins. A possibility to broaden this field is to find new suitable chemical 
reactions that can be carried out under physiological conditions and are orthogonal with 
respect to the functionalities present in polypeptides and proteins. Unfortunately these 
requirements are difficult to be fulfilled by most of the organic chemical reactions.  
Nonetheless, Diels-Alder cyloadditions can be considered as a promising alternative reaction 
to perform such kind of orthogonal linkages with biomolecules.   
In light of these facts, this work is focused on the development of a novel chemical 
ligation method based on the Diels-Alder cycloadditions for the covalent modification of 
polypeptides and proteins. The first goal is to find suitable dienes and dienophile functions 
that could be easily incorporated into the peptide chain and could effectively and selectively 
undergo cycloaddition under mild aqueous conditions. To address these issues, a variety of 
diene- or dienophile-derived peptides are synthesized and the Diels-Alder ligation between 
these unprotected peptide segments is investigated in aqueous medium (Scheme 1).  
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Scheme 1. Diels-Alder ligation of peptides. 
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The next step is to investigate if the established Diels-Alder ligation method could also 
be applied for the covalent modification of entire proteins. The proposal is to equip a given 
protein with a diene unit that could later on be functionalized by Diels-Alder reactions with 
different dienophile probes. Examples of such type of protein derivatization are demonstrated 
herewith for the labeling of model proteins with fluorescent probes and for the protein 
immobilization on glass surfaces (Scheme 2). 
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Scheme 2. Functionalization of proteins by Diels-Alder reactions. 
 
 30
Results and Discussion 
 
 
 
 
 
 
 
 
 
  4. RESULTS AND DISCUSSION   
 
 
 
 
 
 
 
 
 
 
 31
Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 32
Results and Discussion 
 
 
4.1. Peptide Ligation by Diels-Alder Reaction 
 
 
4.1.1. First step: the choice of diene and dienophile  
 
In order to exploit the Diels-Alder cycloaddition as a chemical reaction for peptide and 
protein modification two important requirements ought to be fulfilled:  
• diene and dienophile functions should strongly react with each other under 
physiological conditions without need of catalysts or additional reagents; 
• diene and dienophile groups are to be stable in aqueous medium and inert with 
respect to the range of functionalities found in proteins and biomolecules. 
Based on these facts, hexadiene and maleimide were chosen as scaffolds for the first 
investigations of Diels-Alder ligation.  Previous studies have shown that the acyclic hexadiene 
moiety is stable under aqueous environment and can undergo cycloaddition with reactive 
dienophiles.[94] Maleimido-compounds, on the other side, are among the most reactive 
dienophiles and yet extremely stabile under physiological conditions.[13] The effectiveness of 
the two selected functionalities in Diels-Alder cycloaddition was verified by reacting trans,trans-
2,4-hexadienol 1 and maleimide in aqueous solution as illustrated in Scheme 3. 
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1 2
 
 
Scheme 3. Diels-Alder reaction between hexadienol and maleimide in aqueous solution and 
directions for peptide functionalization. 
 
 For the study of Diels-Alder peptide ligation, a set of diene- and dienophile-derived 
peptide segments was prepared: diene-peptides were constructed by C-terminal modification 
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with commercially available precursor 1, whereas the dienophile handle was incorporated at 
the N-terminus (Scheme 3).  
 
 
 
4.1.2. Preparation of the N-terminal dienophile peptides  
 
The N-terminal maleimido-peptides were assembled by Fmoc/tBu solid-phase strategy 
using Wang resin.[16] N-maleoyl-glycine was employed for introduction of the maleimide group 
in the last step of peptide sequencing. This compound was prepared by reaction of maleimide 
with methyl chloroformate and N-methylmorpholine in ethyl acetate, followed by conversion 
of N-methoxycarbonylmaleimide 3 with glycine in basic aqueous medium into N-
maleoylglycine 4 (Scheme 4).[95] 
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Scheme 4. Synthesis of the building block N-maleoyl-glycine. 
 
 As revealed in Scheme 5, attachment of Fmoc-glycine, the first amino acid of the 
peptide sequence, was accomplished by DMAP catalyzed esterification of the hydroxyl-
functionalized resin with diisopropylcarbodiimide (DIC) in DMF, giving quantitative resin 
loading as indicated by UV Fmoc-determination. The peptide chain was assembled by 
elongation cycles including Fmoc-protecting group removal with 20% piperidine in DMF 
followed by coupling of the next Fmoc-amino acid via HBTU/HOBt/DIPEA activation 
using standard procedures (4eq Fmoc-amino acid, 4eq HBTU, 4eq HOBt, 8eq DIPEA in 
DMF). Each residue coupling was monitored by Kaiser test. N-maleoyl-glycine 4 was coupled 
in the last cycle using DIC/HOBt activation in absence of base. Because the maleimide 
moiety is stable under acidic conditions,[95] side chain deprotection and cleavage were achieved 
trouble-free by treatment of the resin with TFA and scavengers, affording N-maleoyl peptides 
5a-d in 53-62% overall yield after lyophilization (Table 1). The identity of the four synthesized 
dienophile-peptides was confirmed by mass spectroscopy and NMR experiments (all products 
featured typical singlet signal at 6.8-7.0 ppm corresponding to the maleimido olefinic protons).  
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Scheme 5. Solid-phase synthesis of the N-maleoyl-peptides 5a-5d. TIS: triisopropylsilane. 
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Table 1. Results for the synthesis of N-maleoyl-peptides 5.  
ESI-MS for [M+H]+
Maleimide 
Peptide  
sequence 
Overall yield 
(%) found calculated 
5a YTG 62 477.0 477.1 
5b TQFHG 60 726.3 726.3 
5c SEWIG 53 728.1 728.3 
5d AKTSAESYSG 59 1137.5 1137.5 
 
 
 
4.1.3. Preparation of the C-terminal diene peptides 
 
For the synthesis of the diene-derived peptides in solution or solid phase, one should 
be concerned about the incompatibility of the diene functionality with acidic solid-phase 
cleavage conditions and protecting groups like tert-butoxycarbonyl (Boc), tert-butyl (tBu) and 
benzyloxycarbonyl (Z). Base- or mild acid-labile protecting groups must then be applied.  
The first template of a diene-modified peptide was prepared in solution as shown in 
Scheme 6.  
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Scheme 6. Solution synthesis of tripeptide hexadienyl ester 9. 
 
The synthesis began with the preparation of protected dipeptide 6 using the 
DIC/HOBt activation method. After piperidine-mediated Fmoc-deprotection, the next amino 
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acid was coupled by the EDC/HOBt activation method to give tripeptide 7 in 67% yield over 
three steps (Scheme 6). Afterwards, the C-terminal tert-butyl protecting group was removed by 
acidolysis with TFA in DCM and the resulting free carboxylic acid was submitted to 
esterification with hexadienol 1 promoted by 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide.HCl (EDC) and DIPEA in DCM, to generate the Fmoc-peptide hexadienyl ester 
8 in 71% yield. At last, 8 was converted into Val-Ala-Gly-hexadienyl ester 9 after removal of 
the Fmoc-group with 20% piperidine in DMF in 73% yield.  
 For the preparation of longer diene-peptide sequences, a solid-/solution-phase mixed 
approach was initially applied (Scheme 7). Fmoc-protected pentapeptides 10 and 11 were 
obtained by solid-phase synthesis following the Fmoc/tBu methodology and using Wang resin 
as polymeric support. The fully protected peptides were then treated with hexadienol and 
coupling reagents using a similar esterification procedure as described above for the synthesis 
of hexadienyl ester 9, but the reaction yielded very low amount of the desired peptide 
hexadienyl esters 12 and 13. 
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Scheme 7. Attempts for the solution-phase esterification of fully protected pentapeptides. 
 
Better results for the production of longer diene peptide segments were achieved by 
carrying out the complete synthesis on solid-phase using the sulfonamide-based safety-catch 
resin strategy. Initially introduced by Kenner et al,[96] the sulfonamide linker resin has been 
widely applied in SPPS for the preparation of carboxylic acid peptide derivatives. In this 
approach the linkage between the C-terminal residue and the resin linker is highly stable to the 
conditions of SPPS, but can be finally activated after peptide assembly by a mild chemical 
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reaction, resulting in an N-alkyl-N-acylsulfonamide which can then be cleaved by nucleophiles 
and provide compounds possessing a variety of carboxyl group modifications: 
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Scheme 8. Safety-catch strategy for C-terminus derivatization using sulfonamide linker resin. 
 
The diene-modified peptides were built on the sulfamylbutyryl linker resin (a 
modification of Kenner´s linker developed by Ellman and co-workers[97]) using Fmoc, trityl 
(Trt), 4-methyltrityl (Mtt) or tert-butylthiol (StBu) for protecting N-terminal and reactive side-
chain groups of the amino acid residues during peptide chain growing and activation/cleavage 
steps (Scheme 9). Due to the poor nucleophilicity of the sulfonamide function, attachment of 
the first amino acid onto this resin is often a demanding process, giving low loading and 
possible racemization.[98] For this reason, simple glycine was selected as the C-terminal amino 
acid for all diene-peptide sequences. Still quantitative loading of Fmoc-glycine was only 
achieved using a large excess of amino acid and coupling reagents over extended time (Table 
2). 
 
Table 2. Loading of Fmoc-glycine onto sulfamylbutyryl resin. 
Conditions Loading 
4eq Fmoc-Gly-OH, 4eq PyBOP, 8eq DIPEA, -20°C to rt, overnight 65% 
4eq Fmoc-Gly-OH, 4eq PyBOP, 8eq DIPEA, -20°C to rt, overnight (2x) 81% 
4eq Fmoc-Gly-OH, 4eq DIC, 4eq N-methylimidazole, rt, 26h 40% 
8eq Fmoc-Gly-OH, 8eq DIC, 8eq N-methylimidazole, rt, 2x 18h 100% 
 
 
Once the peptide chain synthesis was complete via the HBTU/HOBt activation 
protocol (in the same way as described for assembly of compounds 5), the fully protected 
peptidyl sulfonamide was activated by alkylation with iodoacetonitrile and DIPEA in NMP for 
18-24h (Scheme 9). The resulting N-cyanomethyl activated support was treated with a 
nucleophilic combination of hexadienol 1 and DMAP in dry THF for 1 day to release the 
protected peptide hexadienyl esters 14. Figure 15 depicts a typical HPLC analysis of the 
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cleavage mixture. The crude cleavage products were purified by reversed-phase HPLC to 
eliminate excess of hexadienol and DMAP. When necessary, further trityl deprotection was 
obtained by combining the peptide with 1% trifluoroacetic acid (TFA):5% triisopropylsilane 
(TIS) in dichloromethane for 2h at room temperature (only for peptide 14c). Hexadienyl ester 
peptides 14a-h were isolated in 10-43 % overall yield after HPLC purification (Table 3). In 
general the only by-product observed after cleavage from the resin was the non-esterified 
peptide found in smaller amounts (approximately 15% in comparison to the ester formation). 
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Scheme 9. Solid-phase synthesis of the protected peptide hexadienyl esters using the 
sulfonamide safety-catch linker resin. 
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Figure 15. HPLC analysis of the cleavage mixture for the synthesis of peptide 14a. 
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Table 3. Overall yield for the solid-phase synthesis of dienyl protected peptides 14 after 
HPLC purification. 
MS [M+H]+Diene Peptide  sequence Isolated 
yield (%) found calculated
14a Fmoc-KFmocPFLG 43 1085.3a 1085.5 
14b Fmoc-PCStBuSMG 20 572.3a 572.3 
14c Fmoc-KFmocLGFAG 33 1116.2 1116.5 
14d Fmoc-KFmocLGKMttAG 32 1353.4a 1353.7 
    14e Fmoc-KFmocCStBuGVFG 22 1222.2a 1222.5 
14f Fmoc-KFmocFPIGLFG 1424.7b 1424.7 
14g Fmoc-KFmocFPIGLGFG } 16c 1481.7b 1481.7 
14h Fmoc-KFmocFPIKMttLGKMttAG 10 2135.3b 2134.2 
 
a MS measured by ESI-MS. b MS measured by MALDI-TOF. c During peptide chain assembly 
of 14g one glycine residue coupling was not complete resulting in the formation of two 
products 14f and 14g in 12% and 4% yield, respectively.  
 
Fmoc protecting groups were removed from compounds 14 with 20% piperidine in 
DCM or DMF (Scheme 10) to give, after HPLC purification and lyophilization, unprotected 
peptides 15a-h in high purity (Table 4). Deprotection of the StBu group was accomplished by 
reduction of the disulfide bond of peptide 14e with dithiothreitol (DTT) in ammonium 
bicarbonate medium for 2h, affording unprotected diene 16 (Scheme 10).  
Surprisingly, in the case of compounds 15d and 15h, the Mtt group, which is known to 
be a very acid sensitive protecting group for amines,[99] could not be removed after treatment 
with 1%TFA/5% triethylsilane (or TIS) in DCM. While increasing the scavenger amount (up 
to 10%) seemed not to be relevant, the increment of TFA amount to 5% promoted partial 
removal of the Mtt group of peptide 15h. However the extra acid addition resulted in 
considerable decomposition of the diene moiety. Therefore peptidyl diene 17 was isolated in 
poor yield (Scheme 10). No further conditions were investigated for optimal removal of this 
protecting group; for that reason peptide 15d was subsequently employed having the Mtt-
group at the lysine side-chain. 
The synthesized peptides were characterized by mass spectroscopy and 1H NMR 
analysis. The presence of the dienyl group at the C-terminus was validated for all peptide 
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hexadienyl esters by detection of characteristic olefin signals at 5.6, 5.8, 6.0 and 6.2 ppm and 
of the terminal methyl group at 1.7 ppm during proton-NMR experiments (Figure 19). 
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Scheme 10. Removal of the protecting groups of the dienyl peptides. 
 
 
Table 4. Isolation yields after removal of the protecting groups. 
ESI-MS [M+H]+Diene Peptide  sequence Overall isolation 
yield (%) found calculated
15a KPFLG 72 641.4a 641.4 
15b PCStBuSMG 51 662.2a 662.3 
15c KLGFAG 83 671.4a 671.4 
15d KLGKMttAG 73 909.6b 909.6 
15e KCStBuGVFG 80 778.8c 778.4 
15f KFPIGLFG 91 958.7a 958.6 
15g KFPIGLGFG 92 1015.7a 1015.6 
15h KFPIKMttLGKMttAG 71 1651.6a 1651.0 
16 KCGVFG 72 691.0c 690.4 
17 KFPIKLGKAG 16 1138.9a 1138.7 
 
MS measured by: a ESI-MS; b FAB-MS; c MALDI-TOF.  
 41
Results and Discussion 
 
H
N
O
N
H
O H
N
O
O
O
N
H
H
NH2N
O
O
NH2
H2N
N
H2N
O
H
N
O
N
H
O H
N
O
O
O
HN
O
H
N
O
N
H
O H
N
O
O
O
S
OH
S
H
N
S
H
N
O
N
H
O H
N
O
O
O
N
H
H
NH2N
O
O
NH2
HN
H
N
O
N
H
O H
N
O
O
O
N
H
H
NH2N
O
SHO
NH2
H2N
HN
O
N
O
H
N N
H
H
N
O
O
O
N
H
H
N O
O
O
O
NH2
H2N
HN
O
N
O
N
H
H
N N
H
O
O
O H
N
O
H2N
H
N O
O
O
N
H
O
H2N
HN
O
N
O
H
N N
H
H
N N
H
H
N
O
O
O
O
O
N
H
H
N O
NH2
O
O
O
NH2
H2N
15a
15b
15c
15d
15f
15g
16
17  
 
Figure 16. Overview of the final peptide hexadienyl esters structures. 
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4.1.4. Peptide Ligation via Diels-Alder Reaction 
 
The Diels-Alder ligations of the diene and dienophile peptide segments to give the 
cycloadduct 18 (Scheme 11) were performed in aqueous solution at room temperature (Table 
5). Diene and dienophile were mixed in equal amounts in most cases (usually at 10mM 
concentration) and allowed to react overnight. Eventually, methanol or DMF was added to 
help peptide solubilization in water.  
O
O N
O
O
+
O
O
N
O
O
aqueous media
6, 15 or 17 5
18
 C-peptide
 C-peptide
 N-peptide 
 N-peptide
 
Scheme 11. Diels-Alder ligation of dienyl and maleoyl-peptides. 
 
Table 5. Diels-Alder ligation of dienyl and maleoyl-peptides. 
Entry 
Cyclo-
product 
Diene 
Malei-
mide 
Solvent Time 
Ligation 
efficiencya
1 18a 6 5ab H2O:MeOH (10:3) 20h ~100% 
2 18b 15a 5a H2O:MeOH (4:1) 24h 93% 
3 18c 15d 5b H2O:MeOH (20:1) 24h 95% 
4 18d 15d 5c H2O:DMF (4:1) 47h 84% 
5 18e 15b 5ac H2O:MeOH (3:2) 24h ~100% 
6 18f 15f 5d H2O 48h 93% 
7 18g 15g 5d H2O 48h 92% 
8 18h 17 5d H2O 48h 87% 
 
a Based on the consumption of diene-peptide by analytical HPLC. Dienophile was added in 
excess: b 1.2 eq; c 2.4 eq. 
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A typical time course diagram for the Diels-Alder ligation of peptides 15 and 5 is given 
in Figure 17. After overnight reaction (ca 18h), ligation products were formed in 70-100% 
yield as revealed by HPLC analysis (except for entry 4, Table 5: at 18h, 52%). In some cases, 
consumption of the starting materials was mostly completed only after longer reaction time 
(entries 4, 6, 7, 8, Table 5). The use of DMF as co-solvent seems to slow down the rate of 
cycloaddition (entry 3 vs 4, Table 5). The utilization of an excess of the dienophile over the 
diene content considerably shortened the coupling time and led to total conversion of the 
hexadienyl peptide to the new cycloadduct (entries 1 and 5, Table 5). 
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Figure 17. A. The time course for the ligation of peptides 15f and 5d followed by HPLC 
traces (entry 6, Table 5). a = maleimido-peptide 5d. b = cycloadduct 18f. c = diene-peptide 
15g. B. Plot of ligation efficiency versus time for reaction of peptide 15h and 5d. 
 
All ligation products were isolated by HPLC purification and identified by mass 
spectroscopy (Figure 18).  Most of the losses in yield (in comparison with the observed 
ligation efficiency) arose simply from HPLC recoveries (Table 6). The new ligated 
cycloadducts were clearly characterized by analysis of their 1H NMR spectra: the most striking 
feature was the replacement of the typical diene four-vinyl-proton multiplets at 5.6-6.1 ppm 
and of the sharp maleimido-olefin singlet peak at ca 6.9 ppm by a broadened two-proton 
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signal at 5.7 ppm (Figure 19). In addition, new peaks appeared at 2.5, 2.7, 3.1 and 3.3 ppm 
which were attributed to the protons connected to the novel C-C bonds (H3, H4, H5 and H6 
in Figure 19). Also the terminal methyl doublet of the diene group at 1.7 ppm was shifted to 
1.4 ppm for all cycloadducts. 
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Figure 18. ESI-MS spectrum of ligated cycloproducts: A. 18f: 2096.0 [M+H]+ (calculated 
2096.0); B. 18g: 2153.0 [M+H]+ (calculated 2153.1). 
 
 
Table 6. Recoveries from ligated peptides after HPLC purification. 
MS [M+H]+Cyclo 
product Sequence 
Yield 
(%) found calculated
18a VAG-cyclo-GYTG 87 802.4a 802.4 
18b KPFLG-cyclo-GYTG 60 1117.6a 1117.6 
18c KLGK(Mtt)AG-cyclo-GTQFHG 74 1634.6/1378.7a,c 1634.7/1378.7
18d KLGK(Mtt)AG-cyclo-GSEWIG 64 1636.6/1380.8a,d 1636.7/1380.7
18e PCStBuSMG-cyclo-GYTG 32 1138.4a 1138.4 
18f KFPIGLFG-cyclo-GAKTSAESYSG 69 2096.0a 2096.0 
18g KFPIGLGFG-cyclo-GAKTSAESYSG 67 2153.0a 2153.1 
18h KFPIKLGKAG-cyclo-GAKTSAESYSG 50 2277b 2276 
 
Found mass peak for the cycloadducts measured by: a ESI-MS or b MALDI-TOF. The Mtt 
group was partially detached during reaction course and purification step, giving two final 
products: c 18c (with Mtt, 43%) and 18c´ (without Mtt, 31%); d 18d (with Mtt, 40%) and 18d´ 
(without Mtt, 24%). 
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Figure 19. Comparison of the H-NMR spectra of peptidyl diene 9, dienophile 5a and 
cycloproduct 18a. 
 
These results revealed that the Diels-Alder ligation is chemoselective and compatible 
with reactive amino acids as lysine, histidine and tryptophan. Also no nucleophilic addition of 
the N-terminal amino group to the dienophile α,β-unsaturated double bond was observed 
under these conditions. However, due to the rather electrophilic nature of the maleimido 
moiety, we recognized the potentially troublesome reaction which can take place between this 
structure and the highly nucleophilic sulfhydryl group of cysteines. Michael addition to 
maleimide double bond by the mercaptan group of cysteines is a well established linkage 
method applied for bioconjugation of peptides and proteins.[13] Indeed, when peptide 16, 
which possesses a free cysteine residue, was mixed with maleimido-peptide 5b, the formation 
of product 19 resulting from both nucleophilic addition and cycloaddition reactions was 
detected (Scheme 12). To avoid this side-reaction, protection of the cysteine side-chain during 
Diels-Alder ligation is necessary, as illustrated for the combination of peptides 15b and 5a 
(entry 5, Table 5), where the sulfhydryl moiety is temporarily blocked by disulfide formation 
with a StBu group.  
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Scheme 12. Diels-Alder ligation involving peptides holding blocked and free cysteine 
residues. 
 
 
 
4.1.5. Stereochemistry of the Diels-Alder ligation  
 
The Diels-Alder reaction between an acyclic diene like 1 and maleimide normally gives 
the endo adduct as described earlier (Figure 20).[100-101]   
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Figure 20. Structure of the endo and exo adducts (and the pair of enantiomers of each 
conformation) which can result from the cycloaddition between maleimide and diene 1. The 
endo conformation is the favored one. 
 
 47
Results and Discussion 
 
To check if the cycloaddition of peptidyl hexadienes and maleimides would also 
exhibit the expected selectivity, the proton NMR spectra of a set of peptide-like simple 
cycloadducts 20-22 and of the smallest ligation products 18a and 18b were examined. 
Spectroscopic and chromatographic analysis of the other ligation adducts did not permit a 
conclusive determination of the stereoselectivety.  
The synthesis of the small cycloadducts is outlined in Scheme 13.  
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Scheme 13. Preparation of Diels-Alder adducts 20, 21 and 22. The cycloaddition yielded a 
pair of the endo-enantiomers.  
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Conversion of hexadienol 1 via CDI activation to an intermediate imidazolyl 
carbamate that in turn reacts with glycine methylester in basic media afforded 2,4-hexadienyl-
(methoxycarbonyl)-methylcarbamate 23, which is then transformed into N-glycyl-2,4-
hexadienyl carbamate 24 by saponification. This compound was further combined with 2-
(maleimido)-ethanamine (see page 62 for synthesis of this building block) in H2O:MeOH (4:1) 
producing the Diels-Alder adduct 20 (Scheme 13A). Cycloadduct 21 and 22 were obtained 
from reaction of glycine- and triglycine-hexadienyl ester 26 and 27, respectively, with 3-
maleimidopropionic acid in aqueous solution (Scheme 13B and 13C). Dienyl esters 26 and 27 
were synthesized from esterification of precursors Fmoc-glycine and Fmoc-triglycine 28, 
respectively. 
As pointed out in Table 7, compounds 20, 21 and 22 showed clear chemical shifts for 
all protons belonging to the cyclohexene framework. Moreover the measured coupling 
constants are in good concordance with literature values (compounds 29 and 30),[100] indicating 
the formation of the endo product (≥ 98% based on NMR) as expected. Additional NOE 
experiments supported the proposed stereochemistry (Figure 21).  
 
Table 7. 1H-NMR data from compounds 20, 21, 22, 18a and 18b in CD3OD (experimental) 
and from 29 and 30 (literature).[101]
Cycloadduct: 20 21 22 18a 18b 29 30 
Configuration 
(ratio) 
endo 
 
endo 
 
endo 
 
endo I/endo II 
(95:5) 
endo I/endo II 
(50:50) 
endo 
 
endo 
 
Chemical shift δ(ppm)        
H1 + H2 5.8 5.7 5.7 5.7 5.7   
H3 2.7 2.7 2.7 2.7 2.7   
H4 3.4 3.3 3.3 3.4/3.5 3.4/3.5   
H5 3.2 3.1 3.1 3.2/3.1 3.2/3.1   
H6 2.5 2.5 2.5 2.5 2.5   
Me 1.4 1.4 1.4 1.4 1.39/1.40   
Coupling constant J(Hz)        
J(H5,H6) 7.0 6.9 7.0 7.2/ma 7.2/7.3 6.9 6.6 
J(H4,H5) 8.4 8.4 8.4 8.5/ma 8.4/8.5 8.4 8.4 
J(H3,H4) 6.2 6.2 6.2 6.2/ma 6.2/6.3 6.0 - 
 
a The observed multiplet signal was too weak for an appropriate J constant determination.  
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Figure 21. NOE signals enhancements observed for compounds 20, 21 and 18a in CD3OD 
(experimental) and for 29 and 30 (literature).[100]  The NOE spectrum of 18a did not give 
strong signals for all proton-proton interactions. Thus the mentioned peak was observed but, 
due to its weakness (~1%), not quantified. 
 
 
The Diels-Alder ligation process to give the peptides 18a and 18b led to the formation 
of the expected endo-products (Figure 22) as confirmed by comparison of their NMR values 
with the ones found for the model cycloadducts 20-22 (Table 7). Surprisingly, the cycloadduct 
18a was obtained as a single endo-stereoisomer (95%) whereas the cycloadduct 18b was 
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obtained as a mixture of the two endo-isomers (50:50). These results suggest that a certain 
hydrogen bond pattern between the two reacting polypeptide chains may fix the diene and 
dienophile groups in a specific position that favors the endo-attack of only one of the faces. 
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Figure 22. Structure of cycloproducts 18a and 18b and endo enantiomeric ratio. 
 
 
 
4.1.6. Other diene and dienophile functionalities  
 
In further experiments, the Diels-Alder peptide ligation was investigated using 
different dienophile building blocks. So far only maleimide and benzoquinone have been 
utilized as dienophiles for Diels-Alder assisted biomolecule modifications. [85-93] In order to 
determine the influence of dienophile double bond activation on the rate of cycloaddition, the 
N-terminal acryloyl peptide 31 was prepared by solid-phase synthesis following the same 
procedure as described for the synthesis of 5, but replacing the maleoyl-glycine part for N-
acryloylglycine 32 (Scheme 14). This acrylamide was obtained from reaction of glycine methyl 
ester with acryloyl chloride and subsequent C-terminal deprotection by saponification. The N-
acryloylpeptide 31 was then combined with dienyl-peptide 15d in aqueous solution; however 
no cycloadduct was formed even after prolongated reaction time. Consequently the presence 
of two activating groups in the dienophile structure seems to be necessary for effective Diels-
Alder ligation to occur.  
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Scheme 14. Reactions involving N-acryloylpeptides. 
 
Diverse other diene groups can also be regarded as reaction partners for the Diels-
Alder ligation (Figure 23). Previous studies demonstrated comparable Diels-Alder reaction 
rate for biomolecules equipped with a hexadiene having acyclic 34 or cyclic configuration 35, 
as well as enclosing internal 36 or terminal 34 diene moieties.[85,89] Likewise, application of 
anthracene 37 has been reported for construction of RNA conjugates.[102] Peptides 
incorporated with a cyclopentadiene moiety (38) presumably undergo rather faster 
cycloaddition, and this scaffold has been successfully employed for the preparation of peptide 
chips as described by Mrksich et al.[91-93] 
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R OR
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Figure 23. Structure of various dienes which undergo Diels-Alder with biomolecules. 
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Due to the great reactivity of cyclopentadiene towards cycloaddition, we were 
interested in exploring the peptide ligation using this diene group. For this purpose, the 
precursor cyclopentadienylethylamine 39 was synthesized from sodium cyclopentadienide as 
indicated in Scheme 15.  At room temperature, the substituted cyclopentadiene underwent 
hydrogen migration and a mixture of rearranged compounds 39a and 39b was found.[103]  
Amine 39 was then coupled to the C-terminus of Fmoc-alanine and the resulting amide was 
deprotected with piperidine to generate the cyclopentadienyl modified peptide 40. Afterwards 
the cyclopentadiene 40 was combined with maleoyl-glycine in aqueous media to give 
cycloadduct 41 within 2h. 
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Scheme 15. Reactions with cyclopentadienyl-peptide. 
 
Attempts to modify longer peptide sequences with the cyclopentadienyl precursor 
either by solution- or solid-phase synthesis proved to be a difficult task. The mayor problem 
was the facile dimerization of the cyclopentadienyl moiety under reaction conditions and 
peptide purification steps (HPLC). The Diels-Alder cycloaddition of cyclopentadiene to itself 
is actually accelerated in aqueous media[104] and, even though this group has the advantage of 
being quite more reactive, its instability is a considerable drawback for the utilization of this 
functionality for the Diels-Alder ligation. Nevertheless, for some particular applications where 
an excess of the diene-component is used over the amount of the dienophile during a ligation 
reaction, the level of dimerization may not be prejudicial for the efficiency of the Diels-Alder 
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ligation process and therefore the cyclopentadienyl group may be successfully applied. This is 
the case for the immobilization of biomolecules on glass slides, where a dienyl-derived 
substrate is spotted on a dienophile-functionalized surface.[92,93] This issue will be further 
discussed in Section 4.3. 
A peptide possessing a furane group at the C-terminus has also been synthesized 
(Scheme 16). This functionality however was less reactive towards Diels-Alder cycloaddition 
using similar conditions applied for the acyclic diene/maleimide ligation system. 
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Scheme 16. Reactions with furane-peptide. 
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4.2. Protein Ligation by Diels-Alder Reaction 
 
 
The stability of the hexadiene function in aqueous solutions and its compatibility with 
all functional groups present in coded amino acids opens up the opportunity to combine the 
Diels-Alder ligation method with other conjugation techniques to generate tailor-made 
proteins. In such a combined strategy the protein of interest is initially functionalized with a 
diene unit and then the resulting protein-derived diene can be further functionalized by Diels-
Alder reactions with different dienophiles under very mild conditions. If the protein possesses 
reactive cysteine residues, the ligation conditions may be manipulated to avoid unspecific 
reactions between the dienophile unit and the mercapto group by temporary blocking of the 
sulfhydryl groups.  
Three different approaches were explored for the incorporation of the diene 
functionality into proteins: 
 Method 1: Labeling of a protein-ligand complex 
 Method 2: Selective bioconjugation using a heterobifunctional cross-linker 
 Method 3: Site-specific functionalization using Expressed Protein Ligation 
 
 
4.2.1. Labeling of a protein-ligand complex 
 
The scope of the Diels-Alder reaction for protein ligation employing the 1,3-
hexadiene/maleimide method was initially investigated employing the biotin-binding 
tetrameric proteins streptavidin and avidin as model systems. These proteins were chosen as 
first model because they contain no free cysteines in their structure. Streptavidin has no 
cysteine at all in its sequence[105] and the cysteine residues found in avidin form disulfide bonds 
and are not reactive[106] (Figure 24). Both proteins have been applied extensively as probes in 
immunoassays and labeling of antibodies, enzymes and other molecules of interest.[13] Even 
though they bind biotin similarly, their primary structure differs considerably. Streptavidin is a 
55 KDa protein isolated from bacteria Streptomyces avidinii, avidin is a 66 KDa glycoprotein 
found in egg white and tissues of birds, reptiles and amphibians.  
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                              Streptavidin                                                     Avidin 
 
Streptavidin subunit sequence (127 AA):  
AEAGITGTWYNQLGSTFIVTAGADGALTGTYESAVGNAESRYVLTGRYDSAPATDGSGTA 
LGWTVAWKNNYRNAHSATTWSGQYVGGAEARINTQWLLTSGTTEANAWKSTLVGHDTFTK 
VKPSAAS 
 
Avidin subunit sequence (128 AA): 
ARKCSLTGKWTNDLGSNMTIGAVNSRGEFTGTYTTAVTATSNEIKESPLHGTENTINKRT 
QPTFGFTVNWKFSESTTVFTGQCFIDRNGKEVLKTMWLLRSSVNDIGDDWKATRVGINIF 
TRLRTQKE 
 
 
Figure 24. Structure details for streptavidin[105] and avidin.[106] The pictures show the proteins 
in complex with biotin. 
 
In this first protein ligation study, the high affinity of streptavidin and avidin for biotin 
- which is the strongest known noncovalent biological interaction (Kd ~ 10-15 M) – was 
exploited for the preparation of a stable protein-diene complex. To this end, biotinylated 
hexadienyl-compound 44 was synthesized via EDC/HOBt-assisted coupling of biotin-6-
amino-caproic acid and dienyl tripeptide 9 (Scheme 17). The biotinylated diene was then 
bound to streptavidin and avidin. A 5-fold excess of 6 over the biotin specific binding activity 
of the proteins was used to ensure occupation of all biotin-binding sites. Excess of this 
compound was posterior removed by diafiltration with a centrifugal membrane device to 
ensure that all diene-peptide present in the solution was linked to the protein.  
 Diels-Alder ligation using this protein-diene complex was performed applying the 
fluorescently labeled peptide 46 and maleimido-peptide 5d. The first compound was 
synthesized in solid phase by the same method as for 5d but utilizing maleimido-propionic 
acid for the insertion of the dienophile moiety (Scheme 18). The fluorescent dansyl group was 
introduced as a building block connected to the lysine residue as Fmoc-Lys(Dansyl)-OH 47.  
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Scheme 17. Synthesis of the biotinylated peptide hexadienyl ester and complexation with 
streptavidin and avidin.  
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Scheme 18. Synthesis of the fluorescent labeled maleimido-peptide 46. 
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The protein-hexadiene complex 45 at a concentration of 3.5 mg/mL (ca. 65µM of 
45a) or 8 mg/mL (ca. 120µM of 45b) was treated with maleimido-peptides 46 and 5d (50-fold 
dienophile relative to the estimated diene content) in water at room temperature during 1 day 
(Scheme 19). Subsequently unligated dienophile was removed by membrane 
ultracentrifugation. As control experiment, streptavidin/avidin was incubated with the same 
amount of dienophile and submitted to same procedure.  
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Scheme 19. Diels-Alder ligation with protein-diene complexes 45a and 45b. Only one binding 
site of the tetrameric protein is shown. 
 
Concerning the case where the protein ligation was performed with labeled dienophile 
46, reaction vials (ligation and control) were scanned for fluorescence at 302nm. As shown in 
Figure 25A, only the solution involving the combination of streptavidin-diene complex and 
dienophile became fluorescent. The Diels-Alder ligation product was also detected by carrying 
out the reaction with the avidin complex 45b and different amounts of dienophile 46 (Figure 
25B). Further analyses were performed for all ligation reactions where the solution of complex 
48 was heated until boiling in the presence of isopropanol in order to denature the protein, 
break the complex and release the biotinylated cycloadduct, whose mass was confirmed by 
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MALDI-TOF (Figure 26). Without denaturation of the protein, the ligation product could not 
be easily detected by mass spectrometry. 
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combined with the maleimide 46 (lane 3, Figure 27A and 27B), thus the observed fluorescence 
of the complexes 48a and 48b was attributed to the Diels-Alder reaction which took place 
between the hexadiene group of the biotinylated compound and the dansyl-labeled 
maleimido-peptide.  
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Figure 27. Analysis of the Diels-Alder ligation involving streptavidin and avidin complexes. 
A. Basic native PAGE of the Diels-Alder model using streptavidin. B. Acidic native PAGE of 
the Diels-Alder model using avidin. 
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4.2.2. Selective bioconjugation mediated by Diels-Alder Ligation 
 
To introduce the Diels-Alder ligation as a method for protein bioconjugation, the 
heterobifunctional cross-linker 49, which encloses a 1,3-hexadiene functionality and an amine-
reactive part, was devised. Heterobifunctional conjugation reagents are used to cross-link 
proteins and other molecules in a two-step procedure (Scheme 20).[13] They contain one 
reactive group that displays extended stability in aqueous environments (in our case, the diene 
group), therefore allowing purification of an activated intermediate before adding the second 
molecule to be conjugate. The result is the ability to direct the cross-linking reaction to 
selected parts of target molecules and better control over the conjugation process. 
 
most reactive 
group 
aqueous stable 
reactive group 
+ 
protein heterobifunctional cross-linker 
molecule to be 
conjugated 
 
 
O
OO
ON
O
O 49
amine  
reactive part
dienophile 
reactive part
target 
conjugate 
intermediate  
conjugate 
Scheme 20. Bioconjugation strategy using a heterobifunctional cross-linker. 
 
The cross-linker 49 was easily prepared in two steps from esterification of pimelic acid 
and trans,trans-2,4-hexadien-1-ol 1 followed by transformation of the diene 50 into the N-
hydroxysuccimidyl ester 49. Both reactions were mediated by the DIC/DMAP coupling 
method (Scheme 21). The linker 49 was first attached to streptavidin protein molecules by 
acylation of superficial lysine residues through the NHS-moiety (Scheme 22). The molar ratio 
between the cross-linker and streptavidin (6:1) and reaction conditions (H2O, 2h, 25°C) were 
adjusted to provide low levels of protein modification. The diene-streptavidin conjugate 51 
was finally purified using diafiltration with four changes of water. MALDI-TOF 
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measurements of the conjugated protein indicated that on average each streptavidin subunit 
was conjugated with one diene-linker (Figure 29B).  
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Scheme 21. Synthesis of the diene cross-linker and preparation of the hexadienyl conjugated 
streptavidin.  
 
To illustrate the applicability of the DA conjugation the diene-modified protein was 
treated with three different fluorescent labeled maleimide probes 46, 52 and 53. Dansyl- (52) 
and fluorescein-maleimide (53) were synthesized from precursor 54[107] as shown in Scheme 
22. 
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Scheme 22. Synthesis of the maleimide fluorophores. 
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The conditions for the cycloaddition reactions were: 10µL diene-conjugated protein at 
5 mg/ml in water (ca. 100µM concentration) was incubated with 2.7µL of a 10mM stock 
solution of the maleimide-compound (30-fold relative to protein, approximately 6-fold relative 
to diene quantity) at 25°C for 24h (Scheme 23). After removal of unligated dienophile by 
passing the reaction mixture through a spin gel filtration column (DyeEx columns, Qiagen), 
the presence of the new fluorescent protein 56 at 302 nm was verified by SDS-PAGE for all 
three conjugation reactions (Figure 28). In addition, the mass of the expected ligation 
cycloadduct was confirmed by MALDI-TOF analysis (Figure 29). Control tests involving the 
combination of streptavidin and maleimido-molecules 46, 52 and 53 yielded no evidence of 
unspecific reactions of the dienophile with other functionalities of the protein (Figure 28).  
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Scheme 23. Diels-Alder conjugation of the diene-modified streptavidin with maleimide 
fluorophores.  
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Figure 28. SDS-PAGE analysis of the Diels-Alder bioconjugation. strep: streptavidin, DI: 
diene-streptavidin conjugate, DF: dienophile (maleimide probes), M: molecular weight marker 
(up to down): 97, 67, 43 and 30 KDa. 
 
Previous reports stated that the rate of the Diels-Alder bioconjugation employing 
nucleotides or carbohydrates is notably affected by the pH, proceeding much faster at pH 5.5-
5.7 or in ion-exchanged water.[85,89] The next step was then to inspect the selectivity of the 
cycloaddition at different pH values. Anticipately the possibility to carry out these reactions at 
pH above 7 was discarded since nucleophilic addition of the dienophile double bond by 
amino groups can take place under these conditions.[13] Although this side reaction is 
remarkably slow at neutral and slightly acidic pH, one should be concerned about its possible 
occurrence owing to the relatively elongated reaction time and dienophile excess in which the 
cycloaddition needs to be performed for furnishing efficient Diels-Alder bioconjugation. For 
this reason, the ligation between streptavidin-diene conjugate 51 and a larger excess of 
dansylated maleimide-peptide 46 (100-fold relative to 51, ca 25-fold relative to diene content) 
was investigated in sodium phosphate buffer in the pH range of 5.5 to 7.0 for 24h at 25°C. To 
verify any possible side-reaction, control experiments were carried out substituting the 
streptavidin-conjugate by pure streptavidin. As shown by SDS-PAGE analysis (Figure 30), the 
Diels-Alder cycloaddition is selective at pH 5.5 to 6.5, but not completely at pH 7.0. The 
observation of a fluorescent band for the reaction of streptavidin with 46 at this pH (lane 9, 
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Figure 30) indicated that the maleimido-compound binds unspecifically to the protein 
molecule under these conditions. 
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Figure 29. MALDI-TOF mass spectra for streptavidin and streptavidin conjugate subunits. 
Because the composition of native streptavidin subunits varies from 123 to 125 amino acids, a 
range of different mass peaks was found between 13115 and 14000 for the spectrum of 
streptavidin (A). The largest subunit peak, experimentally found at mass 13180 (± 6), was 
taken as reference for calculation of the expected protein conjugate mass. A. Streptavidin 
subunit: 1 = major peak 13180. B. Streptavidin-hexadiene conjugate 51: 2 = one diene linker 
conjugated 13407 (calc. 13402), 2´ = two dienes linkers conjugated 13630 (calc. 13624). C. 
Streptavidin-cycloproduct 56a: 3 = one cycloproduct conjugated 14307 (calc. 14306), 3´ = two 
cycloproducts conjugated 15432 (calc. 15432). D. Streptavidin-cycloproduct 56b: 4 = one 
cycloproduct conjugated 13779 (calc. 13775), 4´ = two cycloproducts conjugated 14374 (calc. 
14370). E. Streptavidin-cycloproduct 56c: 5 = one cycloproduct conjugated 13900 (calc. 
13900),  5´ = two cycloproducts conjugated 14623 (calc. 14620).  
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Figure 30. SDS-PAGE analysis for the Diels-Alder bioconjugation at pH 5.5 to 7.0. The 
observed protein bands represent streptavidin subunits as the tetrameric protein complex was 
denatured upon heating of the sample at 80°C for 3 minutes with denaturating loading buffer 
prior gel loading.  
 
 The last results revealed that the ligation between the diene derived protein and the 
dienophile compounds was an effective and selective reaction in pure water or under slightly 
acidic conditions. Subsequently it was also important to determine the consequences of the 
Diels-Alder labeling process for the proteins biological activity. Since the model protein 
employed here combines stoichiometrically with biotin, it was possible to use two standard 
spectrophotometric biotin-streptavidin complex assays to measure the biotin binding capacity 
of the new modified streptavidin proteins and then estimate any loss of activity.[108] In the first 
assay, the complex formation between streptavidin and biotin is monitored at 233nm. A red 
shift in absorption of the tryptophan residues of streptavidin that occurs upon complexation 
with biotin is responsible for the absorption change (Figure 31A). The second assay makes use 
of the dye 4´-hydroxyazobenzene-2-carboxylic acid (HABA) which also binds noncovalently 
streptavidin at the same site as biotin but with lower affinity (106 M-1), forming a colorful 
complex that absorbs at 500 nm. The addition of biotin to a HABA-streptavidin complex 
results in displacement of HABA from the binding site by biotin and consequent decay on the 
absorbance of the complex at 500 nm (Figure 31B).  
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A. Direct measurement of streptavidin-biotin complexation 
 
0
10
20
30
40
50
60
70
80
0 2 4 6 8 10 12 14 16 18
µl biotin 0.1 mg/mL
A
bs
or
ba
nc
e 
(A
-A
0)
saturation 
point
streptavidin
streptavidin
conjugate 
56b
c
  
 
+ 
streptavidin 
complex formation at 233 nm 
biotin 
 
B. Indirect measurement of streptavidin-biotin complexation 
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Figure 31. Assays for the determination of biotin binding capacity of streptavidin. Solutions 
of wild-type streptavidin and conjugate 56b were assayed at concentration of 0.1 mg/mL.  A. 
In this assay, the streptavidin sample was titrated with a biotin solution and the absorbance 
was recorded at 233nm. The amount of biotin at the inflection point indicates the biotin 
binding capacity. Because the biotin binding of both proteins is saturated with the same 
amount of biotin, they have the same activity (1mg protein binds 14µg biotin). B. In this 
assay, a solution containing a streptavidin-HABA complex was titrated with a solution of 
biotin and the absorbance was recorded at 500nm. If the protein samples show the same 
differential absorbance (A-A0) at 500nm after the titration over the saturated point, then they 
have the same biotin binding activity. 
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In both titrimeric assays, wild-type streptavidin and streptavidin conjugate 56b 
displayed similar biotin binding capacity (determined as 14 µg biotin per milligram protein, in 
concordance with the value given by the commercial supplier), indicating that the protein 
remained fully functional after the Diels-Alder conjugation. 
 
 
 
4.2.3. Site-specific labeling of Rab proteins by combination of Expressed 
Protein Ligation and Diels-Alder Ligation. 
 
The Expressed Protein Ligation method is a suitable tool to equip a given protein with 
the diene functionality at a specific position.[2] For instance, the hexadiene group can be 
specifically located at the C-terminus of the protein by reaction of a thioester tagged 
recombinant protein with a particular linker enclosing a hexadienyl ester at one extremity and 
a cysteine amino acid at the other (Scheme 24). The EPL process generates a nucleophilic 
cysteine residue at the ligation site which should be temporary protected (along with other 
accessible cysteine side chains present in the protein) to avoid undesired modification of the 
mercapto group in the subsequent reaction with maleimido-probes. After the Diels-Alder 
ligation process, the masked cysteines can be transformed back into the free thiol form. 
 
 
 
Scheme 24. Combination of EPL and Diels-Alder ligation. 
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This approach was successfully implemented employing the Rab7 protein as a 
representative biologically relevant example (Figure 32). The Rab proteins are small GTP-
binding proteins that mediate intracellular vesicular traffic.[109] Their function is important in 
the control of protein distribution after translation and processing, exocytosis, and 
endocytosis. Many aspects of the multi-step processes involving the Rab proteins are only 
partially understood, including, for instance, the timing of the cellular event and the 
localization of the proteins involved. Therefore, differently and site-specific labeled Rab 
proteins are considered versatile probes for the study of such biological events.[110-114]  
 
 
 
 
Rab7 (207 AA):  
MTSRKKVLLKVIILGDSGVGKTSLMNQYVNKKFSNQYKATIGADFLTKEVMVDDRLVTMQ 
IWDTAGQERFQSLGVAFYRGADCCVLVFDVTAPNTFKTLDSWRDEFLIQASPRDPENFPF 
VVLGNKIDLENRQVATKRAQAWCYSKNNIPYFETSAKEAINVEQAFQTIARNALKQETEV 
ELYNEFPEPIKLDKNERAKASAESCSC 
 
Figure 32. Structural details for Rab7 protein complexed with GNP and magnesium ion. 
Cysteine residues are marked in red. 
 
 
 Before implementing the proposed methodology for the labeling of Rab proteins, it 
was crucial to find an appropriate cysteine blocking agent that could efficiently bind to the 
mercapto groups of the protein and render them inert toward further reactions with 
maleimides. Ellmann´s reagent, 5,5´-dithio-bis-nitrobenzoic acid (DTNB), is a suitable reagent 
for this purpose.[115] It readily reacts with cysteines to form stable disulfide bonds and can later 
be cleaved by addition of reducing reagents to regenerate the free sulfhydryl groups (Scheme 
25). 
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Scheme 25. Protection/deprotection of cysteine residues with the Ellman´s reagent. In both 
reactions, the chromogenic  TNB anion (5-thio-2-nitrobenzoic acid) is released (absorbance at 
412nm).[13] 
 
To prove the efficiency of Ellmann´s reagent to mask the cysteine residues of Rab 
proteins, several control experiments were performed in which wild-type Rab7 was treated 
with dansylated maleimide 46 with or without prior DTNB protection. Rab7 has five Cys 
residues in its structure: three of them are located on the protein surface and can potentially be 
labeled by maleimides while the other two are buried in the core of the molecule and are not 
easily accessible as long as the protein remains folded.[114] Without blocking the Cys residues 
with the DTNB reagent, the protein was multi-labeled after overnight incubation with 46 at 
pH 6 as indicated by SDS gel electrophoresis analysis (Figure 33A). However, if the three Cys 
residues located on the protein surface are impeded to react by TNB disulfide formation 
blockage, no significant binding of the maleimide and Rab7wt was observed and the protein 
remained unlabeled. The other two Cys residues were mostly not reached by the Ellmann´s 
reagent as well as by the maleimide compound. These results were confirmed by ESI-MS 
measurements (Figure 33B). 
Initial functionalization of Rab7 to generate the hexadienyl protein was achieved by 
means of expressed protein ligation. To this end, recombinant truncated Rab7 thioester from 
Canis familiaris (Rab7∆C3-MESNA thioester) was prepared by members of the research group 
of Dr. Kirill Alexandrov at Department of Physical Biochemistry at MPI Dortmund.[110] The 
method uses a genetically engineered intein and a chitin binding domain (CBD) as fusion 
partners to express and purify the desired Rab thioester (Section 2.6.1) and has been 
successfully applied for the semi-synthesis of fluorescent labeled and lipidated Rab proteins by 
the groups of Dr. Kirill Alexandrov and Prof. Dr. Herbert Waldmann.[110-114] 
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Figure 33. A. SDS-PAGE analysis of control reactions involving Rab7 wild type and 
maleimide 46 with or without prior cysteine DTNB protection. Labeled Rab7 appeared as a 
fluorescent protein band at ca 24-26 KDa. Key: M: molecular weight marker (up to down): 30, 
20 KDa. B. ESI-MS for Rab7wt (experimental mass: 23721), TNB protected Rab7 (expected 
mass for Rab7 + 2TNB: 23415), and the product from the reaction of protected Rab7wt with 
maleimide 46 (20h, 25°C) followed by treatment with DTT (expected mass: 23721 (Rab7wt), 
23918 (Rab7wt + 1TNB)). 
 
 
For the dienyl linker construction, three different cysteinyl hexadiene linkers 57, 58 
and 59 were synthesized (Scheme 26). Two of them have a peptide-like structure while the 
other embodies an alkyl chain. The reductively cleavable StBu group was chosen as the 
protecting group of the N-terminal cysteine to prevent oxidative reactions.[111] The 
deproctection of the cysteine is carried out in situ during protein ligation by using an excess of 
thiol agent. The synthesis of the linker 57 began with the assembly of Fmoc-protected 
compound 60 on solid phase using 2-chloro-trityl resin, followed by esterification of the 
resulting carboxylic peptide 60 with hexadienol 1 and final removal of the Fmoc protecting 
group (Section 4.1.3). Peptidyl hexadienyl ester 58 was synthesized on solid phase using the 
safety-catch resin strategy as described before (Section 4.1.3). The synthesis of the linker 59 
started from the carbamate precursor 61, which was prepared by reaction of hexadienol 1 and 
CDI and subsequent combination with 1,6-diamino-hexane in DMF. After that, the amino 
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group of 61 was coupled to Fmoc-Cys(StBu)-OH by the EDC activation method followed by 
Fmoc-deprotection to give the unprotected cystenyl compound 59. 
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Scheme 26. Synthesis of the cysteinyl hexadiene linkers. 
 
 
For the construction of the C-terminal hexadienyl Rab7 protein, recombinant 
truncated Rab7 thioester (Rab7∆C3-thioester) was ligated with peptide hexadienyl ester under 
reducing conditions (MESNA) overnight at 16°C (Scheme 27).[111] An excess of 20 equivalents 
of the dienyl compound was used to ensure complete conversion. The ligation was carried out 
in the presence of guanosine 5´-diphosphate (GDP) and magnesium chloride to assure protein 
stabilization. Small amount of the detergent CHAPS were also included to increase protein 
and peptide solubilization under ligation conditions. While the ligation of dienes 57 and 58 
was straightforward, the linker 59 could not be efficiently ligated to the protein because of its 
insolubility in the ligation buffer.  
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Scheme 27. Semi-synthesis of C-terminal Rab7 hexadienyl esters by EPL. 
 
The ligation process generates a nucleophilic cysteine side chain and the truncated Rab 
proteins 62a-b embody three further cysteines (Figure 34). The accessible cysteine side chains 
were protected as disulfide by treatment with Ellmann`s reagent immediately after the ligation 
reaction, without intermediate purification, to yield masked protein esters 63a and 63b 
(Scheme 28).  
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Figure 34. Position of the cysteine residues in the Rab7 hexadienyl ester protein.[114] 
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Protein hexadienyl ester was then dialyzed against DA buffer (5mM Na-Pi pH 6.0, 
20mM NaCl, 0.2mM MgCl2, 20µM GDP) to remove all small molecules (MESNA, Ellmann´s 
reagent, dienyl peptide) and prepare the protein solution for the following ligation step. As 
determined by ESI-MS measurements (Figure 36), the two accessible cysteine residues of the 
truncated Rab7 protein 63 were in fact masked by the disulfide groups. 
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Scheme 28. Masking of the accessible cysteine residues of the Rab7 hexadienyl esters by 
treatment with DTNB. 
 
 Next the protected hexadienyl Rab7 protein 63 was subjected to Diels-Alder reaction 
with peptide-derived dienophile 46 and dansyl derivative 52 (Scheme 29). The cycloaddition 
ligation was carried out in buffer pH 6.0 at a protein concentration of approximately 40µM 
and at room temperature. A variety of other conditions were investigated for this ligation step 
as demonstrated in Figure 35. The coupling reactions were terminated by addition of excess 
dithiothreitol which traps the dienophile and simultaneously converts the disulfides into 
unmasked thiols. Because of the release of the chromogenic TNB group into solution, the 
ligation solution became yellowish at this point.  
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Scheme 29. Diels-Alder ligation of the masked Rab7 hexadienyl esters and maleimide 
compounds. 
 
 
The extent of the three-step ligation process was followed by SDS-PAGE (Figure 35) 
and all intermediates and final products were identified by ESI-MS mass spectrometry (Figure 
36). Based on gel quantification and LC spectra analyses, it appears that ca. 50% of the Rab7 
hexadienyl ester 63 underwent cycloaddition with the maleimide probes after 20-24h 
incubation. Increasing the amount of added maleimide to 100-fold improves considerably the 
ligation efficiency to almost complete conversion after 24h reaction (Figure 35C). Undesired 
multiple labeling of Rab7 was not detected at significant levels. 
 The Diels-Alder conjugation of the hexadienyl Rab protein with the dansylated labeled 
dienophile rendered this protein insoluble in the reaction solution. The aggregation formation 
could not be avoided even when the ligation was carried out in the presence of cosolvent 
(glycerol) or detergents (CHAPS, Triton X-100 or Tween-20), or at lower protein 
concentration (10-20µM). This behavior was also formerly observed during the semisynthesis 
of lipidaded Rab proteins.[111-113] 
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Figure 35. SDS-PAGE analysis of the Diels-Alder ligation between protected Rab7 
hexadienyl ester 63 and maleimide probes 46 and 52. Diels-Alder labeled Rab7 appeared as a 
unique fluorescent protein band at ca 24 KDa. Key: Rab7hxd: Rab7 hexadienyl ester. M: 
molecular weight marker (up to down): 43, 30, 20, 14 KDa (in A, B, D) and 94, 67, 43, 30, 20, 
14 KDa (in C). 
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Figure 36. ESI-MS spectra of the Rab7∆C3-thioester (A and F), Rab7 hexadienyl esters 62a 
(B) and 62b (G), masked Rab7 hexadienyl esters 63a (C) and 63b (H), and Diels-Alder 
modified Rab7 proteins 64a (D), 64b (E), 64c (I) and 64d (J). Key: * The ESI-MS spectrum of 
the hexadienyl esters showed a typical fragmentation peak of [M-80]+ corresponding to the 
lost of the hexadienyl group during ionization. 
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 The purification of the Rab protein 64 (Figure 37) was performed following the 
procedure described for the isolation of semisynthetic prenylated Rab proteins.[111] After 
incubation of the Rab hexadienyl ester 63 with the maleimide, the resulting protein precipitate 
was separated by centrifugation and washed with methanol in order to remove the excess of 
unligated dienophile. The resulting pellet was dissolved in buffer containing 6M guanidinium 
chloride and DTT and then refolded by a 25-fold dilution with renaturation buffer. 
Subsequently, REP-1 protein, a natural chaperone for Rab proteins,[114] was added and the 
formed complex was further purified by dialysis and concentrated by ultracentrifugation. 
Biochemical activity assays which will provide a measure of the functional activity of the 
fluorescent Rab7 64 are currently being performed at Kirill Alexandrov´s group at MPI 
Dortmund. 
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Figure 37. Purifcation of the ligation product (64a) resulting from the combination of the 
masked Rab7 hexadienyl ester 63a with maleimide 46 (50-fold). After 24h incubation of 
protein and dienophile, the formed precipitate was separated from the supernadant (lane 5) by 
centrifugation. The pellet was washed twice with methanol (resulting washings: lanes 6 and 7), 
dissolved in denaturation buffer, refolded in renaturating buffer and complexed with REP-1 
(lane 3). Other lanes: Rab7 MESNA thioester (lane 1), Rab hexadienyl ester 63a (lane 2),  
REP-1 (lane 4), molecular weight marker (lane M). 
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4.3. Immobilization of proteins on glass surfaces by Diels-Alder 
ligation 
 
 
 An attractive application of the developed Diels-Alder ligation method would be for 
the fabrication of protein biochips, enabling a robust and chemoselective covalent 
immobilization of proteins onto surfaces. Whereas the Diels-Alder reaction has been 
successfully employed for the surface attachment of small biomolecules in microarrays,[86,87,90-93] 
the challenge of immobilizing complex macromolecules such as proteins by this method still 
remains. Our initial efforts were focused on the use of avidin as a model protein in order to 
investigate the scope of the Diels-Alder reaction for immobilizing proteins on the surface of 
glass slides.  For this aim, dienyl-avidin conjugates were prepared and spotted onto maleimide-
functionalized glass slides. The level of immobilized protein was detected after binding with a 
fluorescently labeled biotin (Scheme 30). 
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Scheme 30. Immobilization of avidin protein by Diels-Alder ligation. 
 
Three different types of diene conjugates were designed to assist the Diels-Alder 
protein immobilization (Scheme 31). One encloses the 2,4-hexadienyl group, the diene 
functionality that has been extensively studied in previous investigations. The other two 
conjugates possess an anthracene or a cyclopentadienyl moiety. These functions are expected 
to also display high cycloaddition reaction rates in aqueous media.[79,82] Nevertheless these 
functionalities are presumably more unstable under aqueous solutions than the acyclic diene, 
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being gradually desactivated by dimerization. Therefore, the relation between reactivity and 
stability of the dienyl conjugates are two important issues to be investigated for the 
immobilization of proteins by Diels-Alder ligation. For this purpose, the dienyl bifunctional 
linkers 65, 66 and 67 were synthesized by Dr. José Palomo (Department of Chemical Biology, 
MPI Dortmund). As depicted in Scheme 31, avidin was bioconjugated with each linker 
employing essentially the same procedure as described previously (Section 4.2.2). On average, 
each avidin subunit was acylated with one dienyl linker as indicated by their mass spectrum 
(Figure 38). Conjugates 68, 69 and 70 were kept at -80°C until use (within one week). 
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Scheme 31. Preparation of the dienyl avidin conjugates.  
 
 
Dendrimer-activated glass slides were employed as support for the protein microarray 
and were kindly provided by Chimera Biotec GmbH (Dortmund).[116] The surface of these 
glass slides is modified with an intermediate layer of fourth generation polyamidoamine 
(PAMAM) starburst dendrimers, containing a large number of primary amino groups in the 
outer layer (Scheme 32). The presence of the dendrimeric interface leads to amplification of 
the signal intensity as well as to improvement of the physical-chemical stability and 
homogeneity of the biochips.[117,118] The functionalization of the dendrimeric slides with 
maleimido groups was performed by Maja Köhn (Department of Chemical Biology, MPI 
Dortmund) as indicated in Scheme 32. 
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Figure 38. MALDI-TOF mass spectra for avidin and avidin conjugate subunits. Because the 
composition of the avidin subunits is variable, a range of different mass peaks were found 
between 14527 and 16126 for the spectrum of avidin. The two subunit peaks, experimentally 
found at mass 14527 and 15950 (± 10) Da (A), were taken as reference for calculation of the 
expected protein conjugate mass. B: expected mass 14947 and 16370. C: expected mass 14838 
and 16261. D: expected mass: 14906 and 16329. 
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Scheme 32. Functionalization of dendrimer-modified glass surfaces with maleimido groups. 
MIC-OSu: Maleimido caproic acid-N-succinimidylester. 
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 For the detection of the immobilized avidin molecules in the microarray experiment, 
the Cy5 derivatized biotin 71 was synthesized by acylation of the biotin derivative 72 with Cy5 
mediated by the EDC/HOBt activation reagent in DMF (Scheme 33). 
 
N+N
S
O
O
OH
O
S
O
O
HO
O
H
N
O
S
NHHN
O
O N
H
O
H
N
O
S
NHHN
O
O NH2
Cy5-OH, EDC, 
HOBt, DMF, 21h
58%
Biotin-Cy5
72
71  
 
Scheme 33. Synthesis of the Cy5 labeled biotin.  
 
 
 The avidin array was prepared as demonstrated in Scheme 34. In the first experiments, 
the protein solutions were spotted manually on the maleimido-derivatized slide using an 
Eppendorf pipette (0.5-10µL capacity). After incubation of the spotted slide inside a saturated 
wet chamber at room temperature, the excess of protein solution was removed by rinsing the 
glass surface with water.  The slide was then treated with a 10nM solution of biotin-Cy5 71 for 
30 minutes and subsequently washed extensively with water and buffer containing detergent. 
The degree of protein immobilization was evaluated by screening the slide for fluorescence.  
The avidin conjugate solutions were initially spotted at different concentrations onto 
maleimido-modified slides and incubated overnight (Figure 39A). As a negative control, a 
solution of wild type avidin was also spotted at the same concentration on the same slide. As 
shown in Figure 39A, the intensity of the fluorescence signal is consistently influenced by the 
protein concentration for all three dienyl conjugates. The level of protein immobilization is 
also dependent on the incubation time (Figure 39A vs 39B).  
In all cases, the cyclopentadienyl conjugate displayed higher reactivity as expected, 
giving a signal-to-noise ratio of 8.3 at the conditions indicated in Figure 40. The level of 
immobilization of the other dienyl conjugates has also showed significant ratio values of 4.4 
for the anthracene 68 and 3.4 for the hexadiene 69. These conjugates were stable enough for 
efficient protein immobilization within one week of use (longer times were not investigated). 
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Scheme 34. Immobilization of the dienyl-avidin conjugates on the maleimido-derivatized 
glass slides and interaction with biotinylated Cy5. * Washing buffer: 10mM sodium phosphate 
pH 7.5 + 0.05% Tween-20. 
  
As indicated in Figure 39C, it was important to wash the spotted slide surface with a 
buffer containing detergent in order to lower the level of unspecific binding of the biotin-Cy5. 
To avoid unspecific binding of avidin to the maleimido-coated surface, it was essential to 
prevent the spots to be dried out during protein incubation as illustrated in Figure 39D.  
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Figure 39. Fluorescence image of the avidin arrays after binding with biotin-Cy5. 5µL of the 
avidin solutions (in water) were spotted at the concentration shown. The biotin-Cy5 solution 
was added over each protein spot (25µL for each spot) or added throughout the entire glass 
slide surface (1mL). Slides were incubated with avidin solutions inside a humidity chamber (A, 
B and C) or not (D). After binding of biotin-Cy5, the slides were washed only with water (first 
slide in C) or with: water, 10mM sodium phosphate pH 5 buffer containing 0.05% Tween-20 
and again water (A, B, D and second slide in C). 
 
These first results have shown that the Diels-Alder reaction can potentially be applied 
for the preparation of protein arrays. However, many parameters are still to be investigated. 
The first issue to be optimized is the level of unspecific binding that still needs to be 
diminished in order to ensure the chemoselectivity of the protein immobilization. Moreover 
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the protein samples should be spotted at pico-scale volume using a spotting robot, for a more 
realistic model of a protein array.  These issues are currently being addressed. Once the 
conditions for an effective chemoselective immobilization are established, the Diels-Alder 
reaction will be exploited for the site-specific immobilization of proteins in combination with 
the method described in Section 4.2.3. Future applications of this approach are intended for 
the preparation of Rab protein microarrays. 
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Figure 40. Fluorescence intensity of the proteins immobilized on the glass slide af
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Summary 
 
Diels-Alder Ligation of Peptides and Proteins 
 
Over the last years, chemical ligation methods have been shown to be valuable tools 
for the study of protein function, opening up opportunities to selectively tailor a target protein 
with a range of natural and unnatural modifications for subsequent biochemical and biological 
investigations. In order to expand the spectrum of application of these methods, there is still a 
strong demand for the development of new chemical ligation approaches, providing 
alternatives to the already established techniques. The chemistry required must be compatible 
with the functional groups found in proteins and proceed chemoselectively under mild 
aqueous conditions. The Diels-Alder reaction is such a highly chemoselective transformation 
and it often proceeds faster and with higher selectivity in water than in organic medium. 
This work demonstrated that the Diels-Alder reaction is a suitable tool for chemical 
ligation reactions involving peptides and entire functional proteins. At first, several peptides 
composed of up to ten amino acid residues were synthesized by solid-phase synthesis and 
equipped with a diene group (trans,trans-2,4-hexadienyl) at the C-terminus or a dienophile 
group (maleimide) at the N-terminus (Scheme 35). The hexadienyl ester peptides were 
synthesized using the safety-catch strategy on sulfonamide resin, representing an advantageous 
example of application of this strategy to the preparation of peptide esters.  
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Scheme 35. Synthesis and Diels-Alder ligation of the hexadienyl- and maleimido-peptides. 
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Diene- and dienophile-peptides were mixed in water at room temperature and the 
desired cycloaddition proceeded smoothly with 84-100% ligation efficiency after 20-48h 
reaction (Scheme 35). The Diels-Alder ligation process was fully compatible with the 
nucleophilic side chains incorporated into the amino acids lysine, histidine and tyrosine. 
However, free cysteine SH-groups underwent conjugate addition to the maleimide group and, 
therefore, they had to be protected during the course of the Diels-Alder ligation. 
Spectroscopic analysis of small peptidyl cycloadducts demonstrated that the Diels-Alder 
ligation of peptide-derivatized hexadiene and maleimides is endo-selective and may proceed 
with a high degree of stereoselectivity depending on the amino acid sequence. 
The stability of the hexadiene function in aqueous solutions and its compatibility with 
all functional groups present in proteins was explored for combination of the Diels-Alder 
ligation method with other conjugation techniques to generate tailor-made proteins. In this 
strategy a particular protein was initially functionalized with a diene unit and then the resulting 
protein-derived diene was further modified by Diels-Alder reactions with different dienophiles 
under very mild conditions. Three different approaches were employed to incorporate the 
diene function into proteins (Scheme 36). 
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Scheme 36. Strategies for Diels-Alder ligation of proteins. 
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In the first protein ligation model involving the labeling of a protein-ligand complex, 
streptavidin and avidin were chosen as model proteins because they do not embody reactive 
cysteine residues in their structure. A biotinylated hexadienyl ester 44 was synthesized and 
combined with streptavidin or avidin to form a stable protein-diene complex, which in turn 
was labeled with maleimido-derivatized peptides by means of the Diels-Alder cycloaddition. In 
the second approach, the Diels-Alder ligation was employed for the bioconjugation of 
streptavidin with fluorescent probes. To this end, streptavidin was acylated with the 
bifunctional linker 49 at lysine side chains to covalently introduce the hexadienyl unit into the 
protein molecule under controlled conditions. Subsequently the diene conjugate was 
combined with dansyl- or fluorescein-derivatized maleimides in aqueous solution for 24h at 
25°C to yield fluorescent protein with high efficiency. Further investigations using this model 
showed that the Diels-Alder ligation is only chemoselective under slightly acidic conditions 
being better performed at pH 5.5 to 6.5 or in pure water.  
Having established that the cycloaddition between the hexadiene and maleimide 
partners proceeded efficiently under the above mentioned conditions, the proposed Diels-
Alder ligation was successfully implemented for the site-specific labeling of Rab7 proteins. 
Initial functionalization of Rab7 with the hexadiene unit was achieved by means of expressed 
protein ligation. To this end, recombinant truncated Rab7 thioester was ligated with a cysteinyl 
peptide hexadienyl ester under reducing conditions. The ligation process generated a 
nucleophilic cysteine side chain and the Rab protein embodies one further accessible cysteine. 
To avoid undesired modification of these mercapto groups in the subsequent reaction with 
the maleimide, the exposed cysteine side chains were protected as disulfide by treatment with 
Ellmann`s reagent immediately after the ligation reaction (Scheme 36). The masked hexadienyl 
protein was purified and subjected to Diels-Alder ligation with two different dansylated 
dienophile-derived compounds at pH 6. The coupling reactions were terminated by addition 
of excess dithiothreitol which traps the dienophile and simultaneously converts the disulfides 
into unmasked thiols. As indicated by mass spectrometry and gel electrophoresis analysis, the 
hexadienyl protein was converted into the desired fluorescently labeled cycloaddduct protein 
after incubation with the maleimide probes (100-fold) during 24h at room temperature. 
Unspecific multiple labeling of Rab7 could not be detected.  
The applicability of the Diels-Alder ligation for the construction of protein 
microarrays was demonstrated for the immobilization of dienyl conjugated proteins onto 
maleimide-coated glass slides. As a simple model system, avidin was conjugated with a 
hexadiene, a cyclopentadiene or an anthracene unit under controlled conditions and spotted 
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onto the dienophile-functionalizated surface. The level of immobilized protein was detected 
after binding with fluorescently labeled biotin 71 (biotin-Cy5). Using avidin concentrations of 
1 to 50µM, the first model arrays showed considerable signal-to-noise ratio when the protein 
incubation was performed under saturated humidity atmosphere conditions (spots not dried). 
In conclusion this work has shown that the Diels-Alder ligation offers a new 
opportunity for the site-selective functionalization of proteins and peptides. The reaction 
partners of the Diels-Alder ligation, diene and dienophile, can be viewed as two entities which 
simply bind together when held in sufficiently proximity (driven by hydrophobic interactions) 
without need of any extra reagent or catalyst. The Diels-Alder coupling involving the 
maleimide segment should be carried out at slightly acidic conditions and in absence of 
reactive mercaptan moieties or other groups of similar nucleophilicity. If the protein possesses 
reactive cysteine residues in its structure, the ligation conditions must be manipulated to 
prevent unspecific reactions by carrying out a simple temporary blocking of the sulfhydryl 
groups. Although the Diels-Alder reaction leads to a non-traceless ligation site, the final 
cycloadduct skeleton cycloadduct is relatively small and should not significantly alter the 
protein structure. The 2,4-hexadiene moiety is stable under physiological conditions and can 
be easily incorporated chemically into biomolecules from the commercially available precursor 
trans,trans-2,4-hexadienol. Maleimide derivatives and probes are abundantly available from 
commercial suppliers. Other potent diene functions, such as cyclopentadiene, may also be 
appropriate employed for some particular applications, although their instability should be 
considered. 
Combining the results herein described and the previous outcomes from the 
bioconjugation of oligonucleotides and saccharides, the Diels-Alder [4+2] cycloaddition has 
proven to be a feasible method to promote covalent biomolecule modification and a 
complementary alternative for the in vitro assembly of semisynthetic proteins and biopolymers. 
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Zusammenfassung 
 
Diels-Alder Ligation von Peptiden und Proteinen 
 
In den letzten Jahren wurde gezeigt, dass Methoden der chemischen Ligation wertvolle 
Hilfsmittel sind, um Proteinfunktion zu studieren, indem sie Möglichkeiten eröffnen, selektiv 
ein Zielprotein mit einer Reichweite von natürlichen und unnatürlichen Modifikationen für 
darauf folgende biochemische und biologische Untersuchungen maß zu schneidern. Um das 
Spektrum der Anwendungen dieser Methoden zu erweitern, gibt es immer noch einen starken 
Bedarf für die Entwicklung neuer Ansätze der chemischen Ligation, als Alternativen zu den 
bereits etablierten Techniken. Die Chemie muss mit den in Proteinen vorkommenden 
funktionellen Gruppen kompatibel sein und chemoselektiv unter milden wässrigen 
Bedingungen verlaufen. Die Diels-Alder Reaktion ist solch eine hoch chemoselektive 
Transformation und verläuft in wässrigem Medium oft schneller und mit höherer Selektivität 
als im organischen Medium. 
Diese Arbeit zeigte, dass die Diels-Alder Reaktion ein geeignetes Hilfsmittel für 
chemische Ligations-Reaktionen ist, die Peptide und gesamte funktionelle Proteine einschließt. 
Um zunächst die Tauglichkeit der Diels-Alder Cycloaddition für Peptid-Ligation zu 
untersuchen, wurden unterschiedliche Peptide bestehend aus bis zu zehn Aminosäuren an der 
festen Phase synthetisiert und mit einer Dien-Gruppe (trans,trans-2,4-hexadienyl) am C-
Terminus oder einer Dienophil-Gruppe (maleinimid) am N-Terminus ausgestattet (Schema 
37). Die Hexadienylester-Peptide wurden mit der safety-catch Strategie an Sulfonamid-Harz 
synthetisiert, was bis heute eines der sehr wenigen Beispiele der Anwendung dieser Strategie 
zur Darstellung von Peptidestern repräsentiert. 
Die Dien- und Dienophil-Peptide wurden in Wasser bei Raumtemperatur gemischt 
und die erwünschte Cycloaddition verlief reibungslos mit 84-100% Ligations-Effizienz 
innerhalb 20-48 Stunden (Schema 37). Der Diels-Alder Ligations-Prozess war vollständig 
kompatibel mit den nucleophilen Seitenketten der Aminosäuren Lysin, Histidin, Tyrosin, usw. 
Die freien Cystein-SH-Gruppen unterlagen jedoch der konjugierten Addition an die 
Maleinimid-Gruppe, weshalb sie während des Verlaufs der Diels-Alder Reaktion geschützt 
werden mussten. Die spektroskopische Analyse kleiner Peptidyl-Cycloprodukte zeigte, dass 
die Diels-Alder Reaktion von Peptid-derivatisiertem Hexadien und Maleinimid mit einem 
hohen Grad an endo-Stereoselektivität verläuft.  
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Schema 37. Synthese und Diels-Alder Ligation der Hexadienyl- und Maleinimido-Peptide 
 
Die Stabilität der Hexadien-Einheit in wässriger Lösung und ihre Kompatibilität mit 
allen in Proteinen vorkommenden funktionellen Gruppen wurden dahingehend erforscht, die 
Diels-Alder Ligationsmethode mit anderen Konjugationstechniken zur Generierung 
maßgeschneiderter Proteine zu kombinieren. In dieser Strategie wurde ein bestimmtes Protein 
zunächst mit einer Dien-Einheit funktionalisiert und dann das resultierende Protein-
abgeleitete Dien durch Diels-Alder Reaktion mit unterschiedlichen Dienophilen unter sehr 
milden Bedingungen weiter modifiziert.  
Drei unterschiedliche Ansätze wurden verwendet, um Proteine mit der Dien-Funktion 
auszustatten (Schema 38). Das erste Protein Ligations-Modell umfasst das Labeling eines 
Protein-Liganden Komplexes durch eine Diels-Alder Reaktion. Zur Vereinfachung wurden 
Streptavidin und Avidin als Modell-Proteine gewählt, da sie keine reaktiven Cystein-
Seitenketten in ihrer Struktur enthalten. Ein biotinylierter Hexadienylester 44 wurde 
synthetisiert und mit Streptavidin oder Avidin kombiniert, um einen stabilen Protein-Dien 
Komplex zu formen, der wiederum mit Maleinimido-derivatisierten Peptiden durch Diels-
Alder Reaktion gelabelt wurde. Im zweiten Ansatz wurde die Diels-Alder Reaktion für die 
Biokonjugation von Streptavidin mit Fluoreszenz-Sonden eingesetzt. Zunächst wurde 
Streptavidin an Lysin-Seitenketten mit dem bifunktionellen Linker 49 acyliert, um die 
Hexadienyl-Einheit kovalent in das Protein unter kontrollierten Bedingungen einzuführen. 
Anschließend wurde das Dien-Konjugat mit Dansyl- oder Fluorescein-derivatisierten 
Maleinimiden in wässriger Lösung für 24 h bei 25 °C kombiniert, um das fluoreszente Protein 
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in hoher Effizienz zu erhalten. Weitere Untersuchungen mittels dieses Modells zeigten, dass 
die Diels-Alder Reaktion nur unter schwach sauren Bedingungen, am besten bei pH 5.5 bis 6.5 
oder in reinem Wasser, chemoselektiv verläuft. 
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Schema 38. Strategien der Diels-Alder Ligation von Proteinen 
 
Einmal etabliert, dass die Cycloaddition zwischen den Hexadien- und Maleinimid-
Partnern unter den oben genannten Bedingungen effizient verläuft, wurde die vorgeschlagene 
Diels-Alder Ligation erfolgreich für das Site-spezifische Labeling von Rab7 Proteinen als ein 
repräsentatives biologisch relevantes Beispiel zur Anwendung gebracht. Die anfängliche 
Funktionalisierung von Rab7 mit der Hexadien-Einheit wurde durch Expressed-Protein-
Ligation erreicht. Zu diesem Zweck wurde ein rekombinanter, verkürzter Rab7-Thioester mit 
einem Cysteinyl-Peptid Hexadienylester unter reduzierenden Bedingungen ligiert. Der 
Ligations-Prozess generiert eine nucleophile Cystein-Seitenkette und das Rab-Protein enthält 
ein weiteres zugängliches Cystein. Um ungewünschte Modifikationen dieser Mercaptogruppen 
in den folgenden Reaktionen mit dem Maleinimid zu verhindern, wurden die zugänglichen 
Cystein-Seitenketten als Disulfid durch Behandlung mit Ellman's Reagenz direkt nach der 
Ligations-Reaktion geschützt, um den geschützten Proteinester zu erhalten (Schema 38). 
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Dieses modifizierte Protein wurde aufgereinigt und der Diels-Alder Ligation mit zwei 
unterschiedlichen dansylierten Dienophil-abgeleiteten Verbindungen bei pH 6 unterworfen. 
Die Kupplungs-Reaktionen wurden durch Zugabe von Überschuss Dithiothreitol, welches das 
Dienophil abfängt, beendet und simultan die Disulfide in unmaskierte Thiole überführt. Wie 
durch Massenspektrometrie und Gel-Elektrophorese angedeutet, wurde das meiste 
Hexadienyl-Protein in das gewünschte fluoreszenz-markierte Cycloaddukt-Protein nach 
Inkubation mit der Maleinimid-Sonde (100fach) während 24 h bei Raumtemperatur 
umgesetzt. Unspezifisches mehrfaches Labeling von Rab7 konnte nicht detektiert werden. 
Die Anwendbarkeit der Ligation via Diels-Alder Reaktion für den Aufbau von Protein-
Microarrays wurde für die Immobilisierung von mit Dienyl-Einheiten verbundenen Proteinen 
auf Maleimid-bedeckten Glass-Trägern demonstriert. Als ein einfaches Modell-Beispiel wurde 
Avidin mit einer Hexadien-, Cylopentadien- oder Anthraceneinheit unter kontrollierten 
Bedingung verbunden uns auf die mit der Dienophil-funktionalisierten Oberfläche platziert. 
Die Menge an immobilisiertem Protein wurde nach der Umsetzung mit Biotin-Cy5, einem 
fluoreszenzmarkiertem Ligand, detektiert. Unter Verwendung von Avidin-Konzentrationen 
von eins bis 50 µM zeigten die ersten Modellversuche ein ansehnliches Signal-Rausch-
Verhältnis, wenn die Einwirkung des Proteins in einer mit Feuchtigkeit gesättigten 
Atmosphäre stattfand. 
Zusammenfassend hat diese Arbeit gezeigt, dass die Diels-Alder Ligation eine neue 
Möglichkeit für die Site-spezifische Funktionalisierung von Proteinen und Peptiden darstellt. 
Die Reaktionspartner der Diels-Alder Ligation, Dien und Dienophil, können als zwei 
Einheiten betrachtet werden, die sich einfach ohne Bedarf irgendwelcher zusätzlicher 
Reagenzien oder Katalysatoren miteinander vereinigen, wenn sie in ausreichende Nähe 
gebracht werden (getrieben durch hydrophobe Wechselwirkungen). Die Diels-Alder 
Kupplung mit dem Maleinimid-Segment sollte unter leicht sauren Bedingungen in 
Abwesenheit reaktiver Mercaptan-Einheiten oder anderer Gruppen ähnlicher Nucleophilie 
durchgeführt werden. Wenn das Protein reaktive Cystein-Seitenketten in seiner Struktur 
besitzt, können die Ligationsbedingungen durch einfaches temporäres Schützen der 
Sulfhydryl-Gruppen durch Disulfid-Bildung mit Ellman's Reagens variiert werden, um 
unspezifische Reaktionen zu verhindern. Obwohl die Diels-Alder Ligation zu einer nicht 
spurlosen Ligationsstelle führt, ist das endgültige Cycloaddukt-Grundgerüst relativ klein und 
sollte die Proteinstruktur nicht signifikant verändern. Die 2,4-Hexadien Einheit ist in 
physiologischem Medium stabil und kann mittels des kommerziell erhältlichen Precursor 
trans,trans-2,4-Hexadienol einfach über chemische Synthese in Biomoleküle eingeführt werden. 
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Maleinimid-Derivate und -Sonden sind in einer Vielzahl von kommerziellen Anbietern 
verfügbar. Andere wirksame Dien-Funktionen, so wie Cyclopentadien, können auch für einige 
spezielle Anwendungen geeignet eingesetzt werden, obwohl ihre Instabilität berücksichtigt 
werden sollte.  
In Kombination der hier beschriebenen Ergebnisse mit vorherigen Resultaten der 
Biokonjugation von Oligonucleotiden und Sacchariden wurde gezeigt, dass die Diels-Alder 
[4+2]-Cycloaddition eine brauchare Methode ist, um kovalente Biomolekül-Modifikationen 
durchzuführen und eine komplementäre Alternative für die in vitro-Assemblierung von 
artifiziellen Proteinen und Biopolymeren darstellt. 
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Resumo 
 
Ligação Diels-Alder de Peptídeos e Proteínas 
 
Chemical ligations são poderosos métodos químicos que vêm sido amplamente aplicados 
ao longo dos últimos anos para o estudo das funções de proteínas, abrindo novos caminhos 
para modular seletivamente suas estruturas de modo a facilitar subsequentes investigações 
bioquímicas ou biológicas. Contudo ainda existe uma forte necessidade em desenvolver novos 
tipos de ligações, de modo a abranger o espectro de aplicações destes métodos e fornecer 
alternativas para as técnicas já existentes. As reações envolvidas nestes processos devem ser 
compatíveis com os grupos funcionais presentes em proteínas e proceder 
quimiosseletivamente em condições suaves e aquosas. As reações de Diels-Alder enquadram-
se neste tipo de transformações seletivas e procedem, em geral, mais rapidamente e com maior 
seletividade em água do que em meio orgânico. 
Este estudo demonstrou que as reações de Diels-Alder podem ser adequadamente 
empregadas para a ligação de peptídeos e de proteínas inteiramente funcionais. Para investigar 
primeiramente a eficácia destas reações em conectar cadeias de aminoácidos, vários peptídeos 
compostos de até dez aminoácidos foram sintetizados em fase sólida e funcionalizados com 
um grupo dieno (trans,trans-2,4-hexadienila) na posição C-terminal ou com um grupo dienófilo 
(maleimida) na N-terminal (Esquema 39).  
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Esquema 39. Síntese e ligação Diels-Alder dos peptídeos de hexadienila  e maleimida. 
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Os ésteres de hexadienila peptídicos foram sintetizados utilizando a estratégia de safety-
catch em resina sulfonamida, representando um dos poucos exemplos de aplicação desta 
metodologia para a preparação de ésteres. 
Peptídeos contendo as porções de dieno e de dienófilo foram combinados em água à 
temperatura ambiente e a esperada ligação por cicloadição ocorreu com eficiência de 84-100% 
depois de 20-48h de reação (Esquema 39). A reação de Diels-Alder mostrou ser totalmente 
compatível com as cadeias laterias de aminoácidos tais como lisina, histidina e tirosina. 
Contudo, os grupos –SH livres de resíduos de cisteínas sofreram adição conjugada com o 
grupo maleimida e, por isso, devem ser protegidos durante o curso da ligação de Diels-Alder. 
As análises espectroscópicas dos cicloprodutos de peptídeos mais simples demonstraram que 
a ligação de Diels-Alder é endo-seletiva e pode proceder com alto nível de esterosseletividade. 
A estabilidade da função hexadieno em soluções aquosa e a sua compatibilidade com 
todos grupos funcionais encontrados em proteínas foram exploradas para a combinação da 
ligação Diels-Alder com outras técnicas de conjugação visando a produção de proteínas 
modificadas. Nesta estratégia, uma dada proteína é inicialmente funcionalizada com um grupo 
dieno e logo o derivado resultante é modificado com diferentes dienófilos sob condições 
suaves. Como ilustrado no Esquema 40, três procedimentos distintos foram empregados para 
incorporar a função dieno em proteínas. 
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Esquema 40. Estratégias de ligação Diels-Alder de proteínas. 
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O primeiro modelo de ligação de proteína envolveu a marcação de um complexo 
proteína-ligante através da reação de Diels-Alder. Por razões de simplicidade, estreptavidina e 
avidina foram escolhidas como proteínas modelo pois estas não contêm resíduos reativos de 
cisteína em suas estruturas. O éster de hexadienila biotinilado 44 foi sintetizado e combinado 
com streptavidina ou avidina para formar um complexo estável de proteína-dieno, que foi 
então marcado por meios da ligação Diels-Alder. No segundo método, a ligação Diels-Alder 
foi utilizada para a bioconjugação de streptavidina com grupos fluorescentes. Inicialmente, a 
streptavidina foi acilada com um conector bifuncional para introduzir covalentemente a 
unidade hexadieno na molécula de proteína sob condições controladas. Em seguida, o 
conjugado de dieno foi combinado com compostos de maleimida (incorporados com os 
grupos fluorescentes dansila ou fluoresceína) em solução aquosa a 25°C por 24h, produzindo 
uma proteína fluorescente com alta eficiência. Investigações adicionais deste modelo 
mostraram que a ligação Diels-Alder somente é quimiosseletiva sob condições ligeiramente 
ácidas sendo melhor conduzida em pH 5.5 a 6.5 ou em água pura. 
 Visto que a cicloadição entre os parceiros hexadieno e maleimida procedeu 
eficientemente sob as condições mencionadas, a ligação Diels-Alder foi implementada para a 
marcação sítio-específica de proteínas Rab7 como um exemplo biologicamente relevante de 
aplicação deste método. A funcionalização inicial da proteína Rab7 com o grupo hexadieno foi 
adquirida por meio do método EPL (expressed protein ligation). Para esse fim, um tioéster 
recombinante de Rab7 foi ligado, sob condições redutivas, com um peptídeo de éster de 
hexadienila que possui uma cisteína N-terminal. O processo de ligação gera um resíduo de 
cisteína e a proteína Rab7 incorpora uma outra cisteína que também é acessível a reações com 
o solvente. Para evitar a modificação indesejada desses grupos tióis em reações subsequentes 
com maleimidas, as cadeias laterais das cisteínas livres foram protegidas através da formação 
de dissulfeto pelo tratamento com o reagente de Ellmann imediatamente após a reação de 
ligação. A resultante proteína de hexadienila mascarada foi purificada e submetida à ligação 
Diels-Alder em solução tamponada a pH 6.0 com dois diferentes dienófilos marcados com o 
grupo fluorescente dansila. As reações de acoplamento foram terminadas pela adição de 
excesso de ditiotreitol que captura o dienófilo e simultaneamente desbloqueia os grupos tióis. 
Baseado em análises de espectrometria de massa e eletroforese em gel, comprovou-se que a 
maioria da proteína de hexadienila foi convertida no cicloproduto fluorescente desejado 
depois de sua incubação com os reagentes fluoróforos de maleimida durante 24h à 
temperatura ambiente. Marcação múltipla não-específica da proteína Rab7 não foi detectada.  
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 A aplicabilidade da ligação Diels-Alder para a construção de microarrays de proteínas foi 
demonstrada para a imobilização de proteínas conjugadas de dienila sobre placas de vidro 
funcionalizadas com grupos dienófilo. Em um modelo simples, a avidina foi conjugada com 
um grupo hexadienila, um ciclopendienila ou um antraceno sob condições controladas e então 
fixada sobre um superfície vítrea modificada com grupos maleimida. O nível de proteína 
imobilizada foi detectado após complexação da avidina com um composto de biotina marcada 
com o fluoróforo Cy5. Usando concentrações de avidina entre 1 e 50µM, níveis significantes 
de imobilização seletiva dos conjugados de dienila foram obtidos quando a incubação da 
proteína foi realizada sob condições saturadas de humidade. 
 Em conclusão este estudo mostrou que a ligação de Diels-Alder oferece uma nova 
oportunidade para a funcionalização sítio-seletiva de proteínas e peptídeos. Os parceiros desta 
ligação, dieno e dienófilo, podem ser vistos como duas entidades que se combinam facilmente 
quando colocados em suficiente proximidade (dirigida por interações hidrofóbicas) sem 
precisar de nenhuma adição extra de reagentes ou catalisadores. O acoplamento de Diels-
Alder envolvendo o segmento maleimida deve ser conduzido em meio ligeiramente ácido e na 
ausência de grupos mercaptanos reativos ou de qualquer outro grupo de igual nucleofilicidade. 
Caso a proteína possua resíduos reativos de cisteína, as condições da ligação podem ser 
manipuladas para prevenir reações não-específicas através de um simples bloqueio temporário 
dos grupos tióis através da formação de dissulfetos com reagente de Ellmann.  
Apesar da reação de Diels-Alder gerar um grupo não-natural na molécula de proteína, 
o esqueleto do cicloproduto final é relativamente pequeno e não deve alterar significamente a 
sua estrutura. A função 2,4-hexadieno é estável em meio fisiológico e pode ser facilmente 
incorporada em proteínas a partir do precursor trans,trans-2,4-hexadienol. Os derivados de 
maleimida são abundantemente disponíveis comercialmente. Outras funções dieno como o 
ciclopentadieno e antraceno podem também ser apropriadamente empregadas para algumas 
aplicações, embora suas instabilidades em meio aquoso devem ser levadas em consideração. 
Combinando os resultados aqui descritos com aqueles envolvendo a bioconjugação de 
oligonucleotídeos e sacarídeos reportados anteriormente, a cicloadição de Diels-Alder provou 
em ser um método adequado para ser empregado em modificações covalentes de 
biomoléculas e uma alternativa complementar para a construção in vitro de proteínas e outros 
biopolímeros artificiais. 
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6.1. Materials, instruments and general methods for purification 
and analyses 
 
Reagents 
The reagents were purchased from Acros Chimica, Advanced Chemtech, Aldrich, Avocado, 
Bachem, Fluka, J.T. Baker, Merck, Novabiochem, Riedel de Haen, Roth, Senn Chemicals or 
Sigma. All solvents, when not purchased with necessary purity or dryness, were distilled using 
standard methods. Deionized water (Millipore Q-plus System) was used for all experiments. 
 
Silica gel flash liquid chromatography 
Purifications were performed using silica gel from J. T. Baker or Merck (particle size 40-60µm) 
under approximately 0.5 bar pressure. 
 
Preparative reversed-phase high performance liquid chromatography (prep 
HPLC) 
Purification of the compounds was performed on an Agilent preparative HPLC 1100 Series 
system using Nucleodur C18 Gravity column (Macherey-Nagel) and detection at 215 and 
254nm. Linear gradients of solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA in 
water) were used at 25mL/min flow rate.  
 
Nuclear magnetic resonance spectroscopy (NMR) 
1H- and 13C-NMR spectra were recorded using a Varian Mercury 400 spectrometer (400MHz 
(1H) and 100.6MHz (13C)). Chemical shifts are expressed in parts per million (ppm) from 
internal trimethylsilane standard. Coupling constants (J) are given in Hertz (Hz) and the 
following notations indicate the multiplicity of the signals: s (singlet), d (doublet), t (triplet), dd 
(doublet of doublet), ddd (doublet of doublet of doublet), m (multiplet), br (broad signal). 
 
Mass spectrometry (MALDI-TOF, ESI-MS and FAB-HR/LR) 
Matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) measurements were 
carried out with Voyager-DE Pro Biospectrometry Workstation from PerSeptive Biosystems 
using α-cyano-hydroxycinnammic acid (unless otherwise stated) as matrix. Electrospray mass 
spectrometric analyses (ESI-MS) were performed on a Finnigan LCQ spectrometer. Fast atom 
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bombardment (FAB) mass spectra were recorded on a Finnigan MAT MS 70 spectrometer, 
using m-nitrobenzylalcohol as matrix. Calculated masses were obtained using the program 
ChemDraw Ultra (CambridgeSoft Corporation).  
 
Reversed-phase liquid chromatography – electronspray ionization mass 
spectrometry (LC-MS) 
LC-MS measurements were carried out on a Hewlett Packard HPLC 1100/Finnigan LCQ 
mass spectrometer system using Nucleodur C18 Gravity, Nucleosyl 100-5 C18 Nautilus 
(Macherey-Nagel) or Jupiter C4 (Phenomenex) columns and detection at 215 and 254nm. 
Linear gradients of solvent B (0.1% formic acid in acetonitrile) in solvent A (0.1% formic acid 
in water) were used at 1mL/min flow rate.  
Method A: C18 Nautilus, gradient (time/solvent B): 0min/0%B → 3min/0%B → 
23min/70%B. 
Method B: C18 Gravity, gradient (time/solvent B): 0min/10%B → 15min/90%B. 
Method C: C4 Jupiter, gradient (time/solvent B): 0min/20%B → 35min/50%B. 
 
Analytical reversed-phase high performance liquid chromatography (an. HPLC) 
Analyses were performed on a Hewlett Packard HPLC 1100 system using Nucleodur C18 
Gravity and Nucleosyl 100-5 C18 Nautilus columns (Macherey-Nagel) and detection at 215 
and 254nm. Linear gradients of solvent B (0.1% TFA in acetonitrile) in solvent A (0.1% TFA 
in water) were used at 1mL/min flow rate.  
Method A: C18 Nautilus, gradient (time/solvent B): 0min/0%B → 3min/0%B → 
23min/70%B. 
Method B: C18 Gravity, gradient (time/solvent B): 0min/10%B → 15min/90%B. 
 
Thin layer chromatography (TLC) 
TLC was carried out on Merck precoated silica gel plates (60F-254) using ultraviolet light 
irradiation at 254nm or the following solutions as developing agents:  
Staining solution A: 25g molibdatophosphoric acid and 10g cerium (IV) sulfate in 60mL 
concentrated sulfuric acid and 940mL water. 
Staining solution B (for detection of free amino groups): 300mg ninhydrin in 100mL ethanol and 
3mL acetic acid. 
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Gas chromatography – mass spectrometry (GC-MS) 
Spectra were obtained from a Hewlett Packard 6890 GC system coupled to a Hewlett Packard 
5973 Mass Selective Detector. A HP 5TA capillary column (0.33µm x 25m x 0.2mm) and 
helium flow rate of 2mL/min were used. 
Method A: temperature gradient: 0min (100°C) → 1min (100°C) → 6min (300°C) → 12min 
(300°C). 
Method B: temperature gradient: 0min (50°C) → 2min (50°C) → 8min (300°C) → 12min 
(300°C). 
 
Optical rotation 
Optical rotations were measured in a Schmidt + Haensch Polartronic HH8 polarimeter at 589 
nm. Concentrations are given in g/100mL solvent. 
 
Ultraviolet Spectroscopy 
UV measurements were achieved by using a Cary 50 UV/VIS spectrophotometer from 
Varian. 
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6.2. Chemical methods 
 
6.2.1. General procedure for the peptide synthesis on solid support  
 
Resins and reactors  
Peptides were synthesized manually using glass synthesizers or plastic syringes. Resins were 
purchased from Novabiochem: Wang resin loading 1.2 mmol/g (200-400 mesh, 1% DVD), 4-
sulfamylbutyryl AM resin loading 1.1 mmol/g (200-400 mesh, 1% DVD) and 2-chlorotrityl 
chloride resin loading 1.6 mmol/g (100-200 mesh, 1% DVD).  
 
Peptides  
 
Table 8. Fmoc-amino acid building blocks used for each solid-phase method. 
Fmoc-amino acid 
Wang  
resin 
Sulfon
amide 
resin 
2-Cl-
trityl 
resin 
Fmoc-amino acid 
Wang  
resin 
Sulfon 
amide 
resin 
Fmoc-Ala-OH x   Fmoc-Lys(Fmoc)-OH  x 
Fmoc-β-Ala-OH   x Fmoc-Lys(Mtt)-OH  x 
Fmoc-Cys(StBu)-OH  x x Fmoc-Met-OH  x 
Fmoc-Gln(Trt)-OH x   Fmoc-Phe-OH x x 
Fmoc-Glu(Boc)-OH x   Fmoc-Pro-OH  x 
Fmoc-Gly-OH x x x Fmoc-Ser(tBu)-OH x  
Fmoc-His(Trt)-OH x   Fmoc-Ser(Trt)-OH  x 
Fmoc-Ile-OH x x  Fmoc-Thr(tBu)-OH x  
Fmoc-Leu-OH x x  Fmoc-Trp(Boc)-OH x  
Fmoc-Lys(Boc)-OH x   Fmoc-Tyr(tBu)-OH x  
Fmoc-Lys(Dansyl)-OH (46) x   Fmoc-Val-OH  x 
 
 
Semi-quantitative estimation of first amino acid loading on resin 
Approximately 1 mg of resin was placed into a 10 mm UV cuvette and treated with 3mL of a 
20% piperidine in DMF solution during 5 minutes. A reference sample containing only the 
piperidine solution (3mL) was also prepared. Using UV spectrophotometer, the absorbance 
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(Abs) of the samples at 290nm was measured and the Fmoc amino acid loading estimated 
using the equation: (Abssample – Absref)/(1.65 x mg of resin). 
 
Peptide chain assembly: 
1) Removal of Fmoc protection group. The Fmoc-protected peptidyl resin was treated with 
a 20% piperidine in DMF solution (10mL/g resin) for 10 minutes. The resin was drained and 
treatment procedure repeated 1x. Finally, the resin was washed 5 times with DMF. 
2) Coupling using HBTU/HOBt activation. The Fmoc amino acid to be coupled (4 
equivalents relative to resin loading) was dissolved in dry DMF (approximately 10mL/g resin), 
followed by addition of HOBt (4 equivalents) and HBTU (4 equivalents). DIPEA (8 
equivalents) was lastly included and the resulting solution was added immediately to the 
peptidyl resin. The mixture was shook at room temperature until the Kaiser test was negative 
(generally after 1-3h; occasionally some couplings were allowed to react overnight or 
repeated). Resin was filtered and washed with DMF (5 or more times). 
 
Kaiser test (ninhydrin test) for detection of primary amines 
Some beads of resin were removed, washed with DMF, and treated with 2 drops of each of 
the three Kaiser test solutions A (5g in 100mL ethanol), B (2mL of KCN 1mM and 98mL 
pyridine) and C (80g phenol in 20mL ethanol). The mixture was heated to circa 120°C using a 
heating gun. If the beads became blue, free amino groups are present on resin, and thus 
indicated incomplete coupling. The test could not be used for peptides having Mtt groups in 
the side chain. 
 
 
6.2.2. Preparation of the N-maleoyl-peptides  
 
6.2.2.1. Synthesis of the peptide building blocks used for the SPPS 
 
N-(methoxycarbonyl)-maleimide (3) 
N
O
O
OMe
O
 
Maleimide (4.0g, 41mmol) and N-methylmorpholine (4.5mL, 41mmol) were dissolved in 
EtOAc (200mL) and cooled to 0°C. After 30 minutes methyl choroformate (3.2mL, 41mmol) 
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was added and the reaction turned violet. After 1 hour at 0°C, the precipitate was filtered off 
and washed with EtOAc. Filtrate and washings were washed 3x with water, dried over Na2SO4 
and concentrated in vacuum. The product was crystallized from EtOAc/petroleum ether. 
Yield: 3.92g (25mmol, 62%) light violet crystals 
TLC: Rf = 0.58 (EtOAc) 
C6H5NO4 (155.11) 
1H-NMR (D2O, 400MHz):  δ = 3.65 (3H, s, OCH3), 6.23 (1H, d, J = 12.0 Hz, CH=CH) and 
6.50 (1H, d, J = 12.0Hz, CH=CH) ppm. 
13C-NMR (D2O, 100MHz): δ = 53.6 (OCH3), 129.0 (CH=CH), 133.2 (CH=CH), 153.4 (C=O 
methoxy) and 169.0 (C=O imide) ppm. 
GC-MS (Method B): tr = 5.12min; m/z 155 [M]+, 125/124 [M-OMe]+
 
N-maleoylglycine (4) 
N
O
O
O
OH
 
Glycine (375mg, 5mmol) was dissolved in NaHCO3 saturated solution, cooled to 0°C in an 
ice-bath and N-methoxycarbonylmaleimide 3 (775mg, 5mmol) was added. After 10 minutes, 
the solution was diluted by adding 100mL water and stirred at room temperature for 40 
minutes. The pH was brought to 6-7 by dropping concentrated H2SO4 and the solution was 
freeze-dried by lyophilization. 30mL water was added and the pH acidified to 2 by adding 
concentrated H2SO4. The product was extracted 4x 30mL EtOAc, washed with brine, dried 
over MgSO4 and concentrated in vacuum. The crude product (~ 600mg) was dissolved in 
CHCl3/5% acetic acid (10mL) passed through a column of silica gel (20g) and eluted with the 
same solvent. The fractions containing the desired product were collected, the eluate 
evaporated and residual acetic acid removed by co-evaporation with water. 
Yield: 410mg (2.6mmol, 53%) colorless solid 
TLC: Rf = 0.39 (CHCl3/MeOH, 1:1) 
C6H5NO4 (155.11) 
1H-NMR (DMSO-d6, 400 MHz):  δ = 4.12 (2H, s, α-CH2), 7.10 (2H, s, CH=CH) ppm. 
13C-NMR (DMSO-d6, 100 MHz): δ = 39.4 (α-CH2 Gly), 135.6 (CH=CH), 169.4 (CO2H) and 
170.9 (C=O imide) ppm. 
GC-MS (Method B): tr= 5.58 min; m/z: 155 [M] +, 110/111 [M-CO2]+/+H 
ESI-MS: 154.1 [M-H]- (calculated: 154.1) 
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Fmoc-Lys(Dansyl)-OH (47) 
H
N
O
OH
HN
S
O
O
N
O
O
 
 
Fmoc-Lys(Boc)-OH (500mg, 1.1mmol) was treated with 10mL TFA:DCM (1:1) for 80 
minutes at room temperature. Excess of TFA was removed by coevaporation with toluene 
and the peptide was dried under reduced pressure (colorless oil, Fmoc-Lys-OH.TFA). The 
side-chain unprotected peptide was dissolved in 35mL MeOH:H2O (5:2), followed by addition 
of NaHCO3 (270mg, 3.2mmol) and dansyl chloride (432mg, 1.6mmol). The reaction mixture 
was stirred for 19h at room temperature. The pH was adjusted to 2 by adding HCl 1M and the 
product was extracted 3x with DCM, washed with brine, dried over Na2SO4 and concentrated 
in vacuum. Purification was performed by flash silica gel chromatography, eluting first with 
DCM, followed by DCM:MeOH (10:1). Product showed characteristic dansyl-fluorescence. 
Yield: 336mg (0.56mol, 52%) light yellow oil (fluorescent) 
TLC: Rf = 0.10 (DCM:MeOH (10:1)) 
C33H35N3O6S (601.71) 
1H-NMR (CD3OD, 400 MHz): δ = 1.07-1.34 (4H, m, γ-CH2 + δ-CH2), 1.35-1.70 (2H, m, β-
CH2), 2.77-2.84 (2H, m, ε-CH2), 2.79 (6H, s, 2x CH3 Dan), 3.95 (1H, dd, J = 4.5, 9.2 Hz, α-
CH), 4.20 (1H, t, J = 6.7 Hz, CH Fmoc), 4.33 (2H, d, J = 6.0 Hz, CH2 Fmoc), 7.06 (1H, d, J = 
7.1 Hz, Ar Dan), 7.10-7.21 (2H, m, Ar Dan), 7.27 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.40 (2H, t, J = 
7.4 Hz, Ar Fmoc), 7.50 (2H, d, J = 7.0 Hz, Ar Fmoc), 7.64 (2H, d, J = 7.5 Hz, Ar Fmoc), 8.17 
(1H, d, J = 7.2 Hz, Ar Dan), 8.34 (1H, d, J = 8.7 Hz, Ar Dan) and 8.51 (1H, d, J = 8.5 Hz, Ar 
Dan) ppm. 
13C-NMR (CD3OD, 100 MHz): δ = 22.4, 29.1, 31.8, 42.8, 45.6, 47.3, 54.0, 67.2, 115.5, 119.3, 
120.0, 123.5, 125.4, 127.1, 127.8, 128.5, 129.6, 129.8, 130.0, 130.5, 135.1, 141.4, 143.9, 144.1, 
152.0, 156.8 and 174.8  ppm. 
MALDI-TOF: m/z 600.4 [M-H]+ (calc. 600.2),  624.4 [M+Na]+ (calc. 624.2). 
[ ]20Dα : - 5.5 (c= 0.4, CHCl3) 
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6.2.2.2. Solid-phase synthesis of the N-maleoyl-peptides using Wang resin 
 
Loading of Fmoc-glycine to Wang resin 
4 equivalents of Fmoc-glycine, 0.1 equivalent of DMAP and 4 equivalents DIC were dissolved 
in DMF (10mL/g resin) and directly added to Wang resin (pre-swelled in DMF). The mixture 
was agitated overnight. The resin was washed with DMF (3x), DCM (3x) and MeOH (3x) and 
finally dried under high vacuum. Quantitative loading of Fmoc-glycine was obtained as 
indicated by UV measurements (0.9mmol Fmoc-glycine/g resin). 
 
Peptide chain assembly 
The general procedure was employed (Section 6.2.1). 
 
Coupling of the N-maleoyl-amino acid.  
4 equivalents of N-maleoyl-glycine 4 (or N-maleoyl-β-alanine), of HOBt and of DIC were 
dissolved in DCM:DMF (1:1, 10mL/g resin) and added to resin. The mixture was agitated at 
room temperature and the coupling efficiency monitored by Kaiser test. The resin was washed 
with 5x DMF. 
 
Peptide cleavage from Wang resin  
The cleavage cocktail normally used was TFA:TIS:water (95:2.5:2.5). For peptide sequences 
longer than 10 amino acids, the amount of scavengers was increased. The peptidyl resin was 
treated with the cleavage cocktail (10mL/g resin) for 2-3h with gentle swirling. The resin was 
filtered off and washed with small portions of TFA. The filtrates were combined and the 
volume reduced to ca. 30% under reduced pressure. Ice-cooled diethylether was dropwise 
added to this solution (10-fold in volume) to promote peptide precipitation. The solid was 
separated by filtration, washed several times with diethylether, finally dissolved in a mixture of 
MeOH:water and freeze-dried. The desired peptides were obtained mostly in satisfactory 
purity. In a few cases, though, HPLC purification was required. 
 
N-maleoyl-Gly-Tyr-Thr-Gly-OH (5a) 
 
N
O
O
H
N
O
N
H
O
OH
O
H
N
O
OH
OH  
Starting from 301mg Fmoc-glycine loaded Wang resin (0.31mmol).  
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Yield: 91mg colorless solid (0.19mmol, 62%) 
C21H24N4O9 (476.44) 
1H-NMR (D2O, 400 MHz): δ = 0.99 (3H, d, J = 6.4 Hz, CH3 Thr), 2.81-2.90 (2H, m, β-CH2 
Tyr), 3.77 (2H, s, α-CH2 Gly), 4.02-4.07 (1H, m, α-CH Thr), 4.10 (2H, d, J = 2.8 Hz, α-CH2 
Gly), 4.17 (1H, d, J = 4.0 Hz, β-CH Thr), 4.50 (1H, t, J = 7.8 Hz, α-CH Tyr), 6.66 (2H, d, J = 
8.4 Hz, Ar Tyr), 6.75 (2H, s, CH=CH) and 6.97 (2H, d, J = 8.4 Hz, Ar Tyr) ppm. 
 13C-NMR (D2O, 100 MHz): δ = 18.8, 36.4, 39.9, 41.4, 55.7, 58.9, 67.2, 115.7, 127.8, 130.7, 
134.7, 154.5, 169.0, 171.7, 171.9, 172.7 and 173.2 ppm. 
LC-MS (Method A): tr = 13.9 min; m/z 477.0 [M+H]+ (calc. 477.1), 499.0 [M+Na]+ (calc. 
499.1). 
FAB-HRMS: m/z 499.1458 [M+Na]+ (calc. 499.1441). 
[ ]20Dα : +16.2  (c = 0.4, DMF) 
 
N-maleoyl-Gly-Thr-Gln-Phe-His-Gly-OH (5b) 
N
H
N
N
H
H
N
N
H
H
N
OH
O
O
O
O
O
O
N
HN
OH2N
OH
O
O
 
Starting from 276mg Fmoc-glycine loaded Wang resin (0.32mmol).  
Yield: 140mg colorless solid (0.19mmol, 60%) 
C32H39N9O11 (725.71) 
1H-NMR (DMSO-d6, 400 MHz): δ = 1.00 (3H, d, J = 6.2 Hz, CH3 Thr), 1.61-1.68 (1H, m, β-
CH2 Gln), 1.80-1.88 (1H, m, β-CH2 Gln), 1.99-2.11 (2H, m, γ-CH2 Gln), 2.78 (1H, dd, J = 13.6, 
9.4 Hz, β-CH2), 2.83-3.01 (2H, m, 2x 1H β-CH2), 3.11 (1H, dd, J = 15.2, 5.4 Hz, β-CH2), 3.68-
3.84 (2H, m, α-CH2 Gly), 3.91-3.98 (1H, m, β-CH Thr), 4.14-4.30 (4H, m, α-CH2 Gly + 2x α-
CH), 4.43 (1H, dd, J = 8.8, 5.4 Hz, α-CH), 4.62 (1H, dd, J = 7.7, 6.0 Hz, α-CH), 6.82 (1H, br 
s, CH His), 7.08 (2H, s, CH=CH), 7.16-7.26 (5H, m, Ar Phe), 7.35 (1H, br s, CH His), 8.02 
(1H, d, J = 7.6 Hz, CONH), 8.07 (1H, d, J = 7.5 Hz, CONH), 8.14 (1H, t, J = 5.8 Hz, 
CONH), 8.20 (1H, d, J = 8.1 Hz, CONH), 8.35 (1H, d, J = 8.5 Hz, CONH) and 8.95 (1H, s) 
ppm. 
LC-MS (Method A): 12.2 min; m/z 726.3 [M+H]+ (calc. 726.3). 
MALDI-TOF: m/z 726.9 [M+H]+ (calc. 726.3), 748.9 [M+Na]+ (calc. 748.3) and 764.9 
[M+K]+ (calc. 764.3). 
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[ ]20Dα : - 20.2 (c = 1.0, DMF) 
 
N-maleoyl-Gly-Ser-Glu-Trp-Ile-Gly-OH (5c) 
O
N
O
O
H
N
N
H
H
N
N
H
H
N
OH
O
O
O
O
O
OH
OHO
NH
 
Starting from 350mg Fmoc-glycine loaded Wang resin (0.40mmol).  
Yield: 152mg colorless solid (0.21mmol, 53%) 
C33H41N7O12 (727.72) 
1H-NMR (CDCl3, 400 MHz): δ = 0.80 (3H, t, J = 7.4 Hz, CH3 Ile), 0.84 (3H, d, J = 6.8 Hz, 
CH3 Ile), 1.00-1.13 (1H, m, CH2 Ile), 1.38-1.47 (1H, m, CH2 Ile), 1.65-1.75 (2H, m, β-CH2 Glu), 
1.83-1.92 (1H, m, β-CH Ile), 2.19 (2H, t, J = 8.0 Hz, γ-CH2 Glu), 2.89 (1H, dd, J = 14.8, 8.6 
Hz, β-CH2 Trp), 3.11 (1H, dd, J = 14.8, 5.4 Hz, β-CH2 Trp), 3.49-3.59 (2H, m, β-CH2 Ser), 
3.65-3.80 (2H, m, α-CH2 Gly), 4.12 (d, 2H, J = 5.5 Hz, α-CH2 Gly), 4.17-4.28 (2H, m, 2x α-
CH), 4.34 (1H, dd, J = 7.7, 5.9 Hz, α-CH), 4.59 (1H, dd, J = 8.1, 5.7 Hz, α-CH), 6.96 (1H, t, J 
= 8.0 Hz, Ar Trp), 7.04 (1H, t, J = 8.0 Hz, Ar Trp), 7.07 (s, 2H, CH=CH), 7.11 (1H, d, J = 2.3 
Hz, Ar Trp), 7.30 (1H, d, J = 8.0 Hz, Ar Trp), 7.56 (1H, d, J = 7.8 Hz, Ar Trp), 7.86 (1H, d, J = 
8.9 Hz, CONH), 8.02 (1H, d, J = 8.0 Hz, CONH), 8.10-8.12 (2H, m, 2x CONH), 8.33 (1H, d, 
J = 7.8 Hz, CONH) and 10.76 (1H, d, J = 2.0 Hz, NH Trp) ppm. 
LC-MS (Method A): tr = 16.9 min; m/z 728.1 [M+H]+ (calc. 728.3). 
MALDI-TOF: m/z 750.8 [M+Na]+ (calc. 750.3) and 766.8 [M+K]+ (calc. 766.3). 
[ ]20Dα : - 24.5 (c = 0.7, DMF) 
 
N-maleoyl-Gly-Ala-Lys-Thr-Ser-Ala-Glu-Ser-Tyr-Ser-Gly-OH (5d) 
 
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
O
O
O
O
NH2
O
OH
O
OH
O
O
O OH
O
OH
O
OH
O
OH
O
OH
O
 
 
Starting from 285mg Fmoc-glycine loaded Wang resin (0.29mmol).  
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HPLC purification: gradient (time/solvent B): 0min (5%B) → 3min (5%B) → 15min (30%B), 
retention time: 10.1min. 
Yield: 196mg colorless solid (0.17mmol, 59%) 
C47H68N12O21 (1137.11) 
1H-NMR (D2O, 400 MHz): δ = 1.05 (3H, d, J = 6.4 Hz, CH3 Thr), 1.20-1.37 (2H, m, γ-CH2 
Lys), 1.26 (6H, d, J = 7.2 Hz, 2x CH3 Ala), 1.47-1.57 (2H, m, δ-CH2 Lys), 1.58-1.78 (2H, m, β-
CH2 Lys), 1.79-1.97 (2H, m, β-CH2 Glu), 2.31 (2H, t, J = 7.5 Hz, γ-CH2 Glu), 2.82-2.92 (4H, m, 
ε-CH2 Lys + β-CH2 Tyr), 3.63-3.79 (6H, m, 3x β-CH2 Ser), 3.83 (2H, s, α-CH2 Gly), 4.10-4.33 
(11H, m, 8x α-CH + α-CH2 + β-CH Thr), 4.50 (1H, t, J = 7.5 Hz, α-CH Tyr), 6.67 (2H, d, J = 
8.5 Hz, Ar Tyr), 6.80 (2H, s, CH=CH) and 7.00 (2H, d, J = 8.5 Hz, Ar Tyr) ppm. 
LC-MS (Method A): tr = 11.4 min; m/z 1137.5 [M+H]+ (calc. 1137.5). 
MALDI-TOF: 1137.7 [M+H]+ (calc. 1137.5), 1159.7 [M+Na]+ (calc. 1159.5), 1175.6 [M+K]+ 
(calc. 1175.5). 
FAB-LRMS: 1136.45 [M]+ (calc. 1136.46). 
[ ]20Dα : - 7.7 (c = 0.3, DMF) 
 
N-maleoyl-βAla-Ser-Lys-Thr- Lys(Dansyl)-Gly-OH (46) 
 
H
N
O
N
H
O
OH
O
HN
S
O
O N
N
H
H
N
OH
O
NH2
O
N
H
HO
O
N
O
O
 
 
Starting from 147mg Fmoc-glycine loaded Wang resin (0.13mmol) 
Yield: 67mg of colorless solid (0.074mmol, 57%) 
C40H57N9O13S (904.0) 
1H-NMR (CD3OD, 400 MHz): δ = 1.16 (3H, d, J = 6.4 Hz, CH3 Thr), 1.22-1.43 (4H, m, 2x γ-
CH2 Lys), 1.47-1.73 (6H, m, 2x δ-CH2 Lys + β-CH2 Lys), 1.73-1.81 (1H, m, β-CH2 Lys), 1.94-
2.03 (1H, m, β-CH2 Lys), 2.54 (2H, t, J = 6.7 Hz, CH2 βAla), 2.84 (2H, t, J = 6.3 Hz, ε-CH2 
Lys), 2.94-3.00 (8H, m, ε-CH2 Lys + 2x CH3 Dan), 3.68-3.83 (4H, m, CH2 βAla + β-CH2 Ser), 
3.84-3.93 (2H, m, α-CH2 Gly), 4.13-4.19 (1H, m, β-CH Thr), 4.25 (1H, dd, J = 9.1, 4.8 Hz, α-
CH), 4.29-4.34 (2H, m, 2x α-CH), 4.43 (1H, dd, J = 9.7, 4.7 Hz, α-CH), 6.79 (2H, s, 
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CH=CH), 7.39 (1H, d, J = 7.6 Hz, Ar Dan), 7.59-7.64 (2H, m, Ar Dan), 8.20 (1H, d, J = 7.3 
Hz, Ar Dan), 8.42 (1H, d, J = 8.7 Hz, Ar Dan) and 8.53 (1H, d, J = 8.6 Hz, Ar Dan) ppm. 
MALDI-TOF: m/z 904.9 [M+H]+ (calc. 904.4), 926.9 [M+Na]+ (calc. 926.4), 942.9 [M+K]+ 
(calc. 943.3). 
ESI-MS: m/z 904.7 [M+H]+ (calc. 904.4) 
FAB-HRMS: m/z 904.3904 [M+H]+ (calc. 904.3875). 
[ ]20Dα : - 19.0 (c = 0.4, MeOH) 
 
 
6.2.3. Synthesis of the hexadienyl ester peptides in solution phase 
 
6.2.3.1. First hexadienyl esters peptide templates  
 
Fmoc-Ala-Gly-OtBu (6) 
 
H
N
N
H
O
O
O
O
O  
 
Fmoc-Ala-OH (3.79g, 12.2mmol) was dissolved in 25mL THF:DCM (3:2) and combined with 
a solution of H-Gly-OtBu (2.04g, 12.2mmol) in 10mL DCM. After addition of HOBt (2.09g, 
14.6mmol), the flask was cooled to 0°C and DIC (2.1mL, 13.4mmol) was added dropwise. 
After 1 hour, the reaction was allowed to warm to room temperature by stirring overnight. 
The resulting mixture was filtered to remove precipitated urea. The filtrate was washed 3x HCl 
1M, 3x 10% NaHCO3, 1x brine, dried over MgSO4 and concentrated in vacuum. The product 
was recrystallized from EtOAc. 
Yield: 4.2g colorless crystals (9.9mmol, 81%) 
TLC: Rf = 0.46 (cHex/EtOAc, 1:2) 
C24H28N2O5 (424.50) 
1H-NMR (CDCl3, 400 MHz): δ = 1.41 (3H, d, J = 7.0 Hz, CH3 Ala), 1.45 (9H, s, tBu), 3.95 
(2H, d, α-CH2 Gly), 4.18 (1H, t, J = 6.8 Hz, CH Fmoc), 4.30 (1H, m, α-CH Ala), 4.42 (2H, d, J 
= 5.5 Hz, CH2 Fmoc), 5.36 (1H, br s, NH), 6.45 (1H, br s, NH), 7.32 (2H, t, J = 7.4 Hz, Ar 
Fmoc), 7.42 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.60 (2H, d, J = 7.4 Hz, Ar Fmoc) and 7.78 (2H, d, J = 
7.5 Hz, Ar Fmoc) ppm.  
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13C-NMR (CDCl3, 100 MHz): δ = 19.1 (CH3 Ala), 28.4 (tBu), 42.5 (CH Fmoc), 47.5 (α-CH2 
Gly), 50.9 (α-CH Ala), 67.5 (tBu), 82.9 (CH2 Fmoc), 120.4 (Ar Fmoc), 125.4 (Ar Fmoc), 127.5 (Ar 
Fmoc), 128.1 (Ar Fmoc), 141.7 (Ar Fmoc), 144.1 (Ar Fmoc), 156.3 (C=O), 169.1 (C=O) and 172.5 
(C=O) ppm. 
 
Fmoc-Val-Ala-Gly-OtBu (7) 
 
 
H
N
N
H
O
O
OO
N
H
O
O
 
 
1) Fmoc deprotection: Fmoc-Ala-Gly-OtBu 6 (556mg, 1.31mmol) was treated with 5mL 
20% piperidine in DCM during 30 minutes. Piperidine was then removed by coevaporation 
with methanol (3x) and the product H-Ala-Gly-OtBu was purified by flash chromatography 
(DCM, DCM:MeOH (10:1)), affording 250mg colorless oil (1.23mmol, 94% yield). TLC: Rf = 
0.17 (DCM/MeOH, 10:1). 1H-NMR (CDCl3, 400 MHz): δ = 1.42 (3H, d, J = 7.0 Hz, CH3 
Ala), 1.46 (9H, s, C(CH3)3), 3.52 (1H, m, α-CH Ala), 3.85 (2H, m, α-CH2 Gly) and 7.68 (1H, 
br s, NH) ppm.  
2) Coupling: Fmoc-Val-OH (2.07g, 6.1mmol), H-Ala-Gly-OtBu (1.24g, 6.1mmol) and 
triethylamine (846µl, 6.1mmol) were dissolved in DCM (30mL) and cooled to 0°C. HOBt 
(1.87g, 12.2mmol) and EDC (1.64g, 8.5mmol) were added and the reaction mixture was 
allowed to warm up to room temperature by stirring overnight. After 19 hours, the precipitate 
was separated by filtration, washed with DCM and the product crystallized from methanol 
(2.0g product was isolated). As some amount of product remained dissolved in the filtrate, this 
was washed 2x HCl 1M, 2x NaHCO3 1M, 1x water, dried over Na2SO4 and concentrated in 
vacuum. Product was again recrystallised from methanol (0.8g isolated, 88% yield). 
Yield: 2.8g colorless solid (5.3mmol, 83% over two steps) 
TLC: Rf = 0.51 (EtOAc) 
C29H37N3O6 (523.62) 
1H-NMR (DMSO-d6, 400 MHz): δ = 0.84 (3H, d, J = 6.8 Hz, CH3 Val), 0.86 (3H, d, J = 6.9 
Hz, CH3 Val), 1.23 (3H, d, J = 7.0 Hz, CH3 Ala), 1.38 (9H, s, tBu), 1.99 (1H, m, β-CH Val), 
3.70 (2H, ddd, J = 44.4, 27.0, 5.5 Hz, α-CH2 Gly), 3.90 (1H, t, J = 6.8 Hz, CH Fmoc), 4.22 (2H, 
d, J = 5.5 Hz, CH2 Fmoc), 4.23 (2H, m, α-CH Val + α-CH Ala), 7.32 (2H, t, J = 7.4 Hz, Ar 
Fmoc), 7.41 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.45 (1H, CONH), 7.74 (2H, d, J = 7.4 Hz, Ar Fmoc), 
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7.88 (2H, d, J = 7.5 Hz, Ar Fmoc), 8.00 (1H, d, J = 7.5 Hz, CONH) and 8.24 (1H, t, J =  5.7 
Hz, CONH) ppm. 
13C-NMR (DMSO-d6, 100 MHz): δ = 18.5 (CH3 Val), 18.9 (CH3 Val), 19.6 (CH3 Ala), 28.0 
(C(CH3)3), 30.7 (β-CH Val), 37.0 (CH Fmoc), 47.0 (α-CH2 Gly), 48.2 (α-CH), 60.4 (α-CH), 
66.0 (C(CH3)3), 80.9 (CH2 Fmoc), 120.5 (Ar Fmoc), 125.7 (Ar Fmoc), 127.4 (Ar Fmoc), 128.0 (Ar 
Fmoc), 141.1 (Ar Fmoc), 144.1 (Ar Fmoc), 156.5 (C=O), 169.1 (C=O), 171.1 (C=O) and 172.8 
(C=O) ppm. 
ESI-MS: m/z 546.4 [M+Na]+ (calc. 546.3) 
[ ]20Dα :  - 24.8 (c = 1.3, MeOH) 
 
Fmoc-Val-Ala-Gly-hexadienylether (8) 
 
H
N
N
H
O
O
OO
N
H
O
O
 
 
1) tBu deprotection: Fmoc-Val-Ala-Gly-OtBu 7 (1.03g, 1.97mmol) was treated with 20mL 
TFA:DCM (1:1) for 1 hour at room temperature. Excess of TFA was removed by 
coevaporation with toluene and the peptide dried under reduced pressure (0.89g, colorless 
crystals, Fmoc-Val-Ala-Gly-OH).  
2) Esterification: Fmoc-Val-Ala-Gly-OH (445mg, 0.95mmol) was dissolved in 24mL 
DCM:DMF (1:1) and combined with a solution containing trans,trans-2,4-hexadien-1-ol (95mg, 
0.95mmol) and triethylamine (264µL, 1.90mmol) in 2mL DCM. After cooling the mixture to 
0°C, HOBt (292mg, 1.90mmol) and EDC (255mg, 1.33mmol) were added. Next, the cooling 
bath was removed and reaction was stirred overnight at room temperature. After 18h, DCM 
was added and reaction mixture washed 3x 5% NaHCO3, 1x water, dried over Na2SO4 and 
concentrated in high vacuum. 
Yield: 385mg colorless solid (0.70mmol, 71%) 
TLC: Rf = 0.60 (EtOAc) 
C31H37N3O6 (547.64) 
1H-NMR (DMSO-d6, 400 MHz): δ = 0.84 (3H, d, J = 6.8 Hz, CH3 Val), 0.86 (3H, d, J = 6.8 
Hz, CH3 Val), 1.22 (3H, d, J = 7.0 Hz, CH3 Ala), 1.72 (3H, d, J = 6.6 Hz, CH3 Hxd), 1.92-2.02 
(1H, m, β-CH Val), 3.78-3.93 (2H, ddd, J = 21.9, 17.4, 5.8 Hz, α-CH2 Gly + 1H, CH Fmoc), 
4.19-4.37 (4H, m, CH2 Fmoc + 2x α-CH), 4.55 (2H, d, J = 6.4 Hz, CH2 Hxd), 5.56-5.63 (1H, 
m, CH=CHCH3), 5.70-5.79 (1H, m, CH2CH=CH), 6.02-6.09 (1H, dd, J = 15.1, 10.5 Hz, 
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CH=CHCH3), 6.22-6.29 (1H, dd, J = 15.2, 10.4 Hz, CH2CH=CH), 7.32 (2H, t, J = 7.4 Hz, Ar 
Fmoc), 7.39-43 (2H, t, J = 7.4 Hz, Ar Fmoc + 1H, CONH), 7.74 (2H, t, J = 6.8 Hz, Ar Fmoc), 
7.88 (2H, d, J = 7.5 Hz, Ar Fmoc), 8.00 (1H, d, J = 7.5 Hz, CONH) and 8.32 (1H, t, J = 5.7 
Hz, CONH) ppm. 
LC-MS (Method B): tr = 9.9 min; m/z 548.0 [M+H]+ (calc. 548.3), 570.2 [M+Na]+ (calc. 
570.3). 
[ ]20Dα : - 22.8 (c = 1.0, MeOH) 
 
H-Val-Ala-Gly-OHxd (9) 
 
H
N
N
H
O
O
OO
H2N
 
 
152mg (0.29mmol) of the Fmoc-protected peptide hexadienyl ester 8 was treated with 20% 
piperidine in DMF (2.0mL) for 30 minutes at room temperature. After removal of piperidine 
was accomplished by coevaporation with methanol, the crude product was dried in vacuum 
and purified by HPLC and dried by lyophilization. 
HPLC purification: gradient of 0min (10%B) → 16min (50%B), retention time: 10.7min. 
Yield: 70mg colorless solid (0.21mmol, 73%) 
C16H27N3O4 (325.40) 
1H-NMR (CD3OD, 400 MHz): δ = 0.89 (3H, d, J = 6.8 Hz, CH3 Val), 0.95 (3H, d, J = 6.8 
Hz, CH3 Val), 1.36 (3H, d, J = 7.1 Hz, CH3 Ala), 1.72 (2H, d, J = 6.5 Hz, CH3 Hxd), 1.93-2.03 
(1H, m, β-CH Val), 3.16 (1H, d, J = 5.3 Hz, α-CH Val), 3.84-4.00 (2H, m, α-CH2 Gly), 4.42 
(1H, q, J = 7.1 Hz, α-CH Ala), 4.59 (2H, d, J = 6.5 Hz, CH2 Hxd), 5.59 (1H, ddd, J = 14.1, 
6.5, 6.5 Hz, CH=CHCH3), 5.70-5.79 (1H, m, CH2CH=CH), 6.04 (1H, dd, J = 15.0, 10.5 Hz, 
CH=CHCH3) and 6.25 (1H, dd, J = 15.0, 10.6 Hz, CH2CH=CH) ppm.  
13C-NMR (CD3OD, 100 MHz): δ = 16.2 (CH3 Val), 16.7 (CH3 Val), 16.9 (CH3 Ala), 18.3 
(CH3 Hxd), 31.8 (β-CH Val), 37.0 (α-CH2 Gly), 40.5 (α-CH), 59.9 (α-CH), 65.1 (CH2 Hxd), 
123.0 (CH=CHCH3), 130.3 (CH2CH=CH), 130.7 (CH2CH=CH), 134.8 (CH=CHCH3), 169.4 
(C=O), 173.8 (C=O) and 174.6 (C=O) ppm. 
LC-MS (Method B): tr = 1.5 min; m/z 326.1 [M+H]+ (calc. 326.2). 
MALDI-TOF: m/z 326.6 [M+H]+ (calc. 326.2), 364.5 [M+K]+ (calc. 364.2). 
[ ]20Dα : - 18.5 (c = 0.5, MeOH) 
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Fmoc-Lys(Fmoc)-Ala-Met-Phe-Gly-OH (10) 
 
OH
O
H
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Starting from 272mg Fmoc-glycine loaded Wang resin (0.31mmol). Due to the presence of a 
methionine residue, a different cleavage cocktail was used for this peptide: TFA: 
H2O:EDT:TIS (94.5:2.5:2.5:1.0), which was isolated following the general procedure described 
above (Section 6.2.2). 
Yield: 165mg colorless solid (0.17mmol, 55%) 
C55H60N6O10S (997.16) 
1H-NMR (DMSO-d6, 400 MHz): δ = 1.16 (3H, d, J = 7.0 Hz, CH3 Ala), 1.17-1.45 (4H, m, γ-
CH2 Lys + δ-CH2 Lys), 1.46-1.85 (4H, m, β-CH2 Lys + β-CH2 Met), 1.97 (3H, s, CH3 Met), 
2.26-2.37 (2H, m, γ-CH2 Met), 2.79 (1H, dd, J = 13.9, 9.5 Hz, β-CH2 Phe), 2.90-3.00 (2H, m, ε-
CH2 Lys), 3.03 (1H, dd, J = 13.9, 4.5 Hz, β-CH2 Phe), 3.71-3.83 (2H, m, α-CH2 Gly), 3.93-3.98 
(1H, m, α-CH), 4.17-4.36 (8H, m, 2x CH Fmoc + 2x α-CH + 2x CH2 Fmoc), 4.53-4.58 (1H, m, 
α-CH Phe), 7.12-7.23 (5H, m, Ar Phe), 7.25-7.33 (5H, m, Ar Fmoc + CONH), 7.41 (4H, t,  J = 
7.5 Hz, Ar Fmoc), 7.49 (1H, d, J = 8.1 Hz, CONH), 7.65-7.73 (4H, m, Ar Fmoc), 7.87-7.91 (6H, 
m, Ar Fmoc + 2x CONH), 8.03 (1H, d, J = 7.1 Hz, CONH) and 8.33 (1H, t, J =5.7 Hz, 
CONH) ppm. 
LC-MS (Method B): tr = 10.2 min; m/z 997.2 [M+H]+ (calc. 997.4). 
 
Fmoc-Cys(StBu)-Ala-Met-Phe-Gly-OH (11) 
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Starting from 272mg Fmoc-glycine loaded Wang resin (0.32 mmol). Due to the presence of a 
methionine residue, a different cleavage cocktail was used for this peptide: TFA: 
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H2O:phenol:TIS (88:5:5:2), which was isolated following the general procedure described 
above (Section 6.2.2). 
Yield: 106mg of a colorless solid (0.13mmol, 41%) 
C41H51N5O8S3 (838.07) 
1H-NMR (DMSO-d6, 400 MHz): δ = 1.17 (3H, d, J = 7.0 Hz, CH3 Ala), 1.29 (9H, s, tBu), 
1.68-1.83 (2H, dm, β-CH2 Met), 1.98 (3H, s, CH3 Met), 2.28-2.36 (2H, m, γ-CH2 Met), 2.79 (1H, 
dd, J = 14.0, 9.4 Hz, β-CH2 Phe), 2.93 (1H, dd, J = 12.9, 9.9 Hz, β-CH2 Phe), 3.02-3.08 (2H, m, 
β-CH2 Cys), 3.72-3.83 (2H, m, α-CH2 Gly), 4.20-4.33 (6H, m, CH Fmoc + 3x α-CH + CH2 
Fmoc), 4.52-4.58 (1H, m, α-CH), 7.14-7.23 (5H, m, Ar Phe), 7.32 (2H, t,  J = 7.4 Hz, Ar Fmoc), 
7.41 (2H, t,  J = 7.4 Hz, Ar Fmoc), 7.72 (3H, m, Ar Fmoc + 1H, NH), 7.89 (3H, m, Ar Fmoc + 
1H, NH), 8.16 (1H, d, J = 7.3 Hz, NH) and 8.34 (1H, t, J = 5.6 Hz, NH) ppm. 
LC-MS (Method B): tr = 10.0 min; m/z 838.2 [M+H]+ (calc. 838.3). 
 
Fmoc-Lys(Fmoc)-Ala-Met-Phe-Gly-OHxd (12) 
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Starting from 78mg Fmoc-Lys(Fmoc)-Ala-Met-Phe-Gly-OH 10 (0.078mmol). Esterification 
procedure similar to the one performed for compound 9. After overnight reaction, the 
mixture was directly submitted to reversed-phase HPLC purification (retention time: 18.4min). 
Fractions containing the desired product were combined and freeze-dried. 
Yield: 5mg colorless solid (0.004mmol, 5%) 
C61H68N6O10S (1077.29) 
1H-NMR (DMSO-d6, 400 MHz): δ = 1.16 (3H, d, J = 7.0 Hz, CH3 Ala), 1.20-1.44 (4H, m, γ-
CH2 Lys + δ-CH2 Lys), 1.45-1.85 (4H, m, β-CH2 Lys + β-CH2 Met), 1.71 (3H, d,  J = 6.3 Hz, 
CH3 Hxd), 1.97 (3H, s, CH3 Met), 2.26-2.38 (2H, m, γ-CH2 Met), 2.79 (1H, dd, J = 14.0, 9.5 
Hz, β-CH2 Phe), 2.91-3.00 (2H, m, ε-CH2 Lys), 3.03 (1H, dd, J = 13.9, 4.5 Hz, β-CH2 Phe), 
3.80-3.90 (2H, m, α-CH2 Gly), 3.91-3.98 (1H, m, α-CH), 4.17-4.29 (8H, m, 2x CH Fmoc + 2x 
α-CH + 2x CH2 Fmoc), 4.52-4.55 (1H, m, α-CH Phe), 4.57 (2H, d, J = 6.3 Hz, CH2 Hxd), 5.59 
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(1H, ddd, , J = 13.0, 6.3, 6.3 Hz, CH=CHCH3), 5.70-5.79 (1H, m, CH2CH=CH), 6.06 (1H, 
dd, J = 15.0, 10.8 Hz, CH=CHCH3), 6.27 (1H, dd, J = 15.2, 10.5 Hz, CH2CH=CH), 7.13-7.24 
(5H, m, Ar Phe), 7.25-7.33 (5H, m, Ar Fmoc + CONH), 7.41 (4H, t,  J = 7.4 Hz, Ar Fmoc), 7.49 
(1H, d, J = 8.0 Hz, CONH), 7.66-7.72 (4H, m, Ar Fmoc), 7.87-7.94 (6H, m, Ar Fmoc + 2x 
CONH), 8.03 (1H, d, J = 7.0 Hz, CONH) and 8.47 (1H, t, J = 5.6 Hz, CONH) ppm. 
ESI-MS: m/z 1077.2 [M+H]+ (calc. 1077.5) 
MALDI-TOF: m/z 1099.8 [M+Na]+ (calc. 1099.5), 1115.8 [M+K]+ (calc. 1115.4). 
 
 
6.2.3.2. Peptides used for investigation of the stereochemistry 
 
2,4-hexadienyl-(methoxycarbonyl)-methylcarbamate (23) 
 
ON
H
O
O
O  
 
1,1´-carbonyl-diimidazole (486mg, 3mmol) was added to a solution of trans,trans-2,4-hexadien-
1-ol (294mg, 3mmol) in dry DMF (5mL) and the reaction solution was stirred at room 
temperature for 3 hours. A mixture of glycine-methyl ester hydrochloride (502mg, 4mmol) 
and triethylamine (1.3mL, 10mmol) in 10mL dry DMF was slowly added to the reaction 
solution and the resulting mixture was agitated overnight. DMF was removed in high vacuum 
at 55°C, followed by dilution of crude product in EtOAc:MeOH (20:1). The organic solution 
was washed with 3x NaHCO3 5%, 1x water, 1x brine, dried over Na2SO4 and concentrated 
under reduced pressure. The product was purified by flash silica gel chromatography, eluting 
with cHex:EtOAc  (2:1). 
Yield: 217mg colorless oil (1 mmol, 34%) 
TLC: Rf = 0.37 (EtOAc) 
C10H15NO4 (213.23) 
1H-NMR (CDCl3, 400MHz):  δ = 1.74 (3H, d, J = 6.6 Hz, CH3), 3.74 (3H, s, OCH3), 3.95 
(2H, d, J = 5.5 Hz, α-CH2 Gly), 4.57 (2H, d, J = 6.5 Hz, CH2 Hxd), 5.26 (1H, br s, NH), 5.61 
(1H, ddd, , J = 13.7, 6.6, 6.6 Hz, CH=CHCH3), 5.68-5.77 (1H, m, CH2CH=CH), 6.03 (1H, 
dd, J = 15.0, 10.6 Hz, CH=CHCH3) and 6.22 (1H, dd, J = 15.1, 10.5 Hz, CH2CH=CH) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 18.3 (CH3), 42.8 (α-CH2 Gly), 52.5 (OCH3), 66.0 (CH2 
Hxd), 124.3 (CH2-CH=CH), 130.7 (CH2-CH=CH), 131.4 (CH=CH-CH3), 134.8 (CH2-
CH=CH), 156.5 (CONH) and 170.7 (COOMe) ppm. 
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GC-MS (Method B): tr = 6.39 min; m/z: 213 [M]+. 
FAB-HRMS: m/z 213.0970 [M]+ (calc. 213.1001). 
 
N-glycyl-2,4-hexadienyl carbamate (24) 
 
ON
H
O
HO
O  
 
Compound 23 (189mg, 0.88mmol) was dissolved in 5mL MeOH and treated with NaOH 4M 
(443µl, 1.77mmol) for 30 minutes at room temperature. Methanol was removed from the 
solution under reduced pressure and water was added to the resulting mixture. The aqueous 
phase was washed with EtOAc and later acidified to pH 4 by adding HCl 1M. The product 
was extracted with EtOAc (3x), the organic phase then washed with brine, dried over Na2SO4 
and concentrated/dried under vacuum. The resulting product showed satisfactory purity. 
Yield: 162 mg colorless solid (0.81 mmol, 92%) 
TLC: Rf = 0.16 (EtOAc) 
C9H13NO4 (199.20) 
1H-NMR (CDCl3, 400MHz):  δ = 1.75 (3H, d, J = 6.7 Hz, CH3), 4.01 (2H, d, J = 5.6 Hz, α-
CH2 Gly), 4.59 (2H, d, J = 6.5 Hz, CH2 Hxd), 5.31 (1H, br s, NH), 5.61 (1H, ddd, , J = 13.4, 
6.6, 6.6 Hz, CH=CHCH3), 5.70-5.79 (1H, m, CH2CH=CH), 6.04 (1H, dd, J = 15.0, 10.5 Hz, 
CH=CHCH3), 6.24 (1H, dd, J = 15.1, 10.5 Hz, CH2CH=CH) and 9.42 (1H, br s, COOH) 
ppm. 
13C-NMR (CDCl3, 100MHz): δ = 18.3 (CH3), 42.7 (α-CH2 Gly), 66.8 (CH2 Hxd), 124.0 (CH2-
CH=CH), 130.6 (CH2-CH=CH), 131.5 (CH=CH-CH3), 135.0 (CH2-CH=CH), 157.6 (CONH) 
and 174.6 (COOH) ppm. 
FAB-HRMS: m/z 200.0923 [M+H]+ (calc. 200.0910). 
 
Glycine-2,4-hexadienyl-1-ester (26) 
 
O
O
H2N  
 
1) Esterification: Fmoc-Gly-OH (6.89g, 23mmol) and trans,trans-2,4-hexadien-1-ol (2.27g, 
23mmol) were dissolved in THF (100mL) and the solution cooled to 0°C. DMAP (280mg, 
2.3mmol) and DIC (3.9mL, 25mmol) were added and the solution was allowed to warm up to 
room temperature and stirred overnight. After 13 hours, the reaction mixture was 
concentrated in vacuum, dissolved in DCM and NaHCO3 saturated solution was added. The 
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urea precipitate was filtered off and the filtrate transferred to a separation funnel. The organic 
phase was washed again with NaHCO3 saturated solution and brine, dried over MgSO4 and 
concentrate in vacuum. The product was roughly purified by flash chromatography (flash 
master, cyclohexane:EtOAc) to give a colorless oil (7.1g, Fmoc-glycine-hexadienylester (60%) 
+ hexadienol, determined by 1H-NMR (data not shown)). 
2) Fmoc deprotection: The Fmoc-glycine-hexadienylester (90mg, 60%, 0.14mmol) was 
treated with 20% piperidine in DCM (2.5mL) at room temperature for 30 minutes. Piperidine 
was removed by coevaporation with methanol and the product purified by flash 
chromatography (EtOAc, EtOAc:MeOH (95:5)) 
Yield: 15mg light yellow oil (0.10mmol, 34% over two steps) 
TLC: Rf = 0.42 (CHCl3/MeOH, 4:1) 
C8H13NO2 (155.19) 
1H-NMR (CDCl3, 400MHz):  δ = 1.66 (2H, br s, NH2), 1.74 (3H, d, J = 6.6 Hz, CH3), 3.41 
(2H, s, CH2 Gly), 4.60 (2H, d, J = 6.7Hz, CH2), 5.60 (1H, m, CH=CH-CH3), 5.75 (1H, m, 
CH2-CH=CH),  6.03 (1H, dd, J = 15.2, 10.4 Hz, CH=CH-CH3) and 6.24 (1H, dd, J = 15.2, 
10.4 Hz, CH2-CH=CH) ppm. 
13C-NMR (DMSO-d6, 100MHz): δ = 18.6 (CH3), 44.4 (CH2 Gly), 65.7 (CH2), 123.4 (CH=CH-
CH3), 130.4 (CH2-CH=CH), 131.8 (CH=CH-CH3), 135.5 (CH2-CH=CH) and 174.0 (C=O) 
ppm. 
ESI-MS: m/z 155.9 [M+H]+ (calc. 156.1) 
 
Fmoc-Gly-Gly-Gly-OH (28) 
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1) Loading on 2-Cl trityl resin: 2 equivalents of the Fmoc-Gly-OH and 4 equivalents of 
DIPEA were combined in DCM (10mL per gram resin) and added to the resin (378mg, 
0.60mmol, pre-swelled in DCM). After stirring the mixture for 4 hours, the resin was washed 
3x with DCM/MeOH/DIPEA (17:2:1), then 3x DCM, 2x DMF, 2x DCM and finally dried 
under reduced pressure. The loading was quantitative (determined by UV measurement). 
2) Peptide chain assembly: general procedure (section 6.2.1) 
3) Cleavage: The peptidyl resin was treated four times with a solution of 1% TFA in DCM 
(approximately 10mL/g resin) for 5-10 minutes. The filtrates were combined and a solution of 
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10% pyridine in methanol was added (1/2 volume from peptide solution). The solvent was 
partially removed under reduced pressure and the peptide was precipitated by adding water. 
The solid was removed by filtration, dissolved in a mixture of methanol/water and finally 
dried by lyophilization. 
Yield: 177mg colorless solid (0.43mmol, 72%) 
C21H21N3O6 (411.41) 
1H-NMR (CD3OD, 400 MHz): δ = 3.81 (2H, br s, α-CH2 Gly), 3.93 (4H, br s, 2x α-CH2 Gly), 
4.22 (1H, t, J = 6.8 Hz, CH Fmoc), 4.38 (2H, d, J = 6.8 Hz, CH2 Fmoc), 7.30 (2H, t, J = 7.5 Hz, 
Ar Fmoc), 7.39 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.66 (2H, d, J = 7.4 Hz, Ar Fmoc) and 7.78 (2H, d, 
J = 7.5 Hz, Ar Fmoc) ppm. 
MALDI-TOF: m/z 412.4 [M+H]+ (calc. 412.2), 434.4 [M+Na]+ (calc. 434.2), 450.4 [M+K]+ 
(calc. 450.1). 
 
H-Gly-Gly-Gly-OHxd (27) 
 
O
O
H
N
N
H
O
H2N
O
 
 
1) Esterification: Starting from 72mg Fmoc-Gly-Gly-Gly-OH 28 (0.17mmol). Similar 
procedure was carried out as for compound 9. Product was purified by silica gel flash 
chromatography eluting with ethyl acetate, to give 25mg colorless oil (0.051mmol, 30%). TLC: 
Rf = 0.18 (EtOAc). 1H-NMR (CDCl3, 400 MHz): δ = 1.74 (3H, d, J = 6.7 Hz, CH3 Hxd), 3.88 
(2H, br s, α-CH2 Gly), 3.98 (4H, br s, α-CH2 Gly), 4.19 (1H, t, J = 6.8 Hz, CH Fmoc), 4.40 (2H, 
d, J = 6.6 Hz, CH2 Fmoc), 4.57 (2H, d, J = 6.6 Hz, (CH2 Hxd), 5.53 (1H, ddd, , J = 14.0, 6.7, 
6.7 Hz, CH=CHCH3), 5.69-5.77 (1H, m, CH2CH=CH), 5.87 (1H, br s, CONH), 6.00 (1H, dd, 
J = 15.0, 10.6 Hz, CH=CHCH3), 6.20 (1H, dd, J = 15.3, 10.7 Hz, CH2CH=CH), 7.06 (1H, br 
s, CONH), 7.15 (1H, br s, CONH), 7.28 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.38 (2H, t, J = 7.3 Hz, 
Ar Fmoc), 7.57 (2H, d, J = 7.2 Hz, Ar Fmoc) and 7.74 (2H, d, J = 7.5 Hz, Ar Fmoc) ppm.  
2) Fmoc deprotection: Starting from 25mg Fmoc-Gly-Gly-Gly-O-hexadienyl ester 
(0.051mmol).  Procedure was performed similarly to the synthesis of compound 6.  
Yield: 10mg colorless oil (0.037mmol, 73% for last step) 
C12H19N3O4 (269.30) 
1H-NMR (CDCl3, 400 MHz): δ = 1.74 (3H, d, J = 6.7 Hz, CH3 Hxd), 3.74 (2H, s, α-CH2 Gly), 
3.97 (2H, s, α-CH2 Gly), 3.99 (2H, s, α-CH2 Gly), 4.62 (2H, d, J = 6.6 Hz, (CH2 Hxd), 5.61 
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(1H, ddd, , J = 13.9, 6.6, 6.6 Hz, CH=CHCH3), 5.74-5.81 (1H, m, CH2CH=CH), 6.06 (1H, 
dd, J = 15.0, 10.5 Hz, CH=CHCH3) and 6.27 (1H, dd, J = 15.3, 10.4 Hz, CH2CH=CH) ppm. 
MALDI-TOF: m/z 270.5 [M+H]+ (calc. 270.1), 292.5 [M+Na]+ (calc. 292.1), 308.5 [M+K]+ 
(calc. 308.1). 
 
 
6.2.4. Preparation of the C-terminal hexadienyl ester peptides in solid phase 
using safety-catch strategy 
 
6.2.4.1. Solid-phase synthesis on sulfonamide linker resin  
 
Optimized loading of Fmoc-glycine to sulfamylbutyryl resin.  
After swelling with DCM for 1h, the sulfamyl resin was treated overnight with a solution 
containing 7 equivalents of Fmoc-glycine, 7 equivalents N-methylimidazole and 7 equivalents 
DIC in DCM:DMF (4:3, 10mL/g resin). The resin was washed with DMF (3x), DCM (3x) and 
MeOH (3x) and finally dried under high vacuum. Estimation of amino acid attachment by UV 
measurements revealed a substitution level of 0.8 mmol Fmoc-glycine/g, conresponding to 
quantitative loading of the resin. 
 
Peptide chain assembly 
The general procedure was employed (Section 7.2.1). 
 
Peptide cleavage from sulfamylbutyryl resin 
1) Activation: The fully-protected peptidyl resin was swelled in DCM (1h) and washed 3 
times with NMP. Iodoacetonitrile (25 equivalents relative to resin loading) and DIPEA (10 
equivalents) were dissolved in NMP (4mL/mmol ICH2CN) and filtered through basic 
alumina. The resulting solution was added to resin and the syringe was shielded from light. 
The mixture was shaken at room temperature for 18-24h. The resin was washed with NMP 
(5x) and THF (3x) and directly used for cleavage. 
2) Cleavage: The activated resin was transferred to a round bottom flask and treated with a 
solution of trans,trans-2,4-hexadien-1-ol (20 equivalents) and DMAP (0.5 equivalent) in dry 
THF (10mL/g resin) during 1 day. The resin was removed by filtration and washed several 
times with THF. The filtrates were combined and THF was removed under reduced pressure. 
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The crude product was purified by reversed-phase HPLC (unless otherwise stated). Fractions 
containing the product (analysed by MALDI) were combined and dried by lyophilization. 
 
Fmoc-Lys(Fmoc)-Pro-Phe-Leu-Gly-OHxd (14a) 
Starting from 122mg Fmoc-Gly loaded sulfonamide resin (0.075mmol).  
HPLC purification: gradient (time/solvent B) of  0min (10%B) → 10min (60%B) → 25min 
(100%B), retention time: 23.5min. 
Yield: 35mg colorless solid (0.032mmol, 43%) 
C64H72N6O10 (1085.29) 
1H-NMR (CDCl3, 400 MHz): broad peaks: δ = 0.62-0.80 (6H, 2x CH3 Leu), 1.10-2.10 (16H, 
δ-CH2 Lys + γ-CH2 Lys + β-CH2 Leu + γ-CH Leu + CH3 Hxd + β-CH2 Lys + β-CH2 Pro + γ-
CH2 Pro), 2.9-3.2 (4H, β-CH2 Phe + ε-CH2 Lys), 3.45-3.70 (2H, ε-CH2 Pro), 3.75-3.90 (2H, α-
CH2 Gly), 4.00-4.55 (12H, α-CH Lys + α-CH Pro + α-CH Leu + α-CH Phe + CH2 Hxd + 2x 
CH2 Fmoc + 2x CH Fmoc), 5.36-5.49 (1H, CH=CHCH3), 5.60-5.68 (1H, CH2CH=CH), 5.82-
5.94 (1H, CH=CHCH3), 6.06-6.13 (1H, CH2CH=CH), 7.00-7.10 (5H, Ar Phe), 7.13-7.23 (4H, 
2x Ar Fmoc), 7.25-7.35 (4H, 2x Ar Fmoc), 7.40-7.55 (4H, 2x Ar Fmoc), 7.60-7.70 (4H, 2x Ar 
Fmoc) ppm and amide protons gave weak signals. 
LC-MS (Method B): tr = 11.6 min, m/z 1085.3 [M+H]+ (calc. 1085.5) 
 
Fmoc-Pro-Cys(StBu)-Ser-Met-Gly-OHxd (14b) 
Starting from 151mg Fmoc-Gly loaded sulfonamide resin (0.10mmol). Product was cleaved 
from the resin as Fmoc-Pro-Cys(StBu)-Ser(Trt)-Met-Gly-OHxd and purified by RP-HPLC. 
Resulting fractions containing product were combined and concentrated in vacuum. After 
evaporation of the solvent, partial Trt-deprotection was detected (MALDI and LC-MS). In 
order to achieve complete removal of the Trt group, the crude product (58mg) was further 
treated with 1mL DCM:TFA:TIS (100:1:5) for 2h at room temperature. Solvents were 
removed in vacuum and product was purified by RP-HPLC. 
HPLC purification: gradient (time/solvent B) of  0min (10%B) → 10min (60%B) → 25min 
(100%B), retention time: 14.5 min.  
Yield: 18mg colorless solid (0.02mmol, 20%) 
C43H57N5O9S3 (884.14) 
1H-NMR (CD3OD, 400 MHz): δ = 1.32 (9H, s, tBu), 1.73 (3H, d, J = 6.6 Hz, CH3 Hxd), 1.86-
2.00 (4H, m, γ-CH2 Pro + β-CH2 Pro), 2.06 (3H, s, CH3 Met), 2.09-2.38 (2H, m, β-CH2 Met), 
2.44-2.65 (2H, m, 2H, γ-CH2 Met), 3.3 (β-CH2 Cys peak overlapped with solvent peak), 3.41-
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3.70 (2H, m, ε-CH2 Pro), 3.78-3.88 (2H, m, β-CH2 Ser), 3.92 (2H, br s, α-CH2 Gly), 4.18-4.56 
(6H, m, CH Fmoc + CH2 Fmoc + 3x α-CH), 4.59 (2H, d, J = 6.5 Hz, CH2 Hxd), 4.62-4.66 (1H, 
m, α-CH Cys), 5.57-5.63 (1H, m, CH=CHCH3), 5.70-5.79 (1H, m, CH2CH=CH), 6.01-6.08 
(1H, dd, J = 15.0, 10.4 Hz, CH=CHCH3), 6.21-6.28 (1H, dd, J = 15.0, 10.3 Hz, CH2CH=CH), 
7.32 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.40 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.65 (2H, t, J = 7.4 Hz, Ar 
Fmoc), 7.80 (2H, d, J = 7.4 Hz, Ar Fmoc) ppm and weak amide peaks. 
LC-MS (Method B): tr = 7.3 min, m/z 884.4 [M+H]+ (calc. 884.3) 
MALDI-TOF: m/z 906.8 [M+Na]+ (calc. 906.3), 922.8 [M+K]+ (calc. 922.4) 
 
Fmoc-Lys(Fmoc)-Leu-Gly-Phe-Ala-Gly-OHxd (14c) 
Starting from 51mg Fmoc-Gly loaded sulfonamide resin (0.043mmol).  
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (50%B) → 17min 
(100%B), retention time: 14.3 min.  
Yield: 16mg colorless solid (0.014mmol, 33%) 
C64H73N7O11 (1116.3) 
1H-NMR (DMSO-d6, 400 MHz): δ = 0.81 (3H, d, J = 6.5 Hz, CH3 Leu), 0.82 (3H, d, J = 6.5 
Hz, CH3 Leu), 1.23 (3H, d, J = 7.1 Hz, CH3 Ala), 1.22-1.65 (9H, m, 3x CH2 Lys + β-CH2 Leu 
+ γ-CH Leu), 1.70 (3H, d, J = 6.6 Hz, CH3 Hxd), 2.71-2.77 (1H, m, β-CH2 Phe), 2.92-2.99 (2H, 
m, CH2 Lys), 2.99-3.05 (2H, m, β-CH2 Phe), 3.55-3.71 (2H, m, α-CH2 Gly), 3.77-3.91 (2H, m, 
α-CH2 Gly), 3.94-4.00 (1H, m, α-CH), 4.14-4.35 (8H, m, 2x CH Fmoc + 2x α-CH + 2x CH2 
Fmoc), 4.51-4.55 (1H, m, α-CH), 4.56 (2H, d, J = 6.2 Hz, CH2 Hxd), 5.60 (1H, ddd, J = 12.8, 
6.4, 6.4 Hz, CH=CHCH3), 5.69-5.78 (1H, m, CH2CH=CH), 6.04 (1H, dd, J = 14.9, 10.2 Hz, 
CH=CHCH3), 6.27 (1H, dd, J = 15.0, 10.3 Hz, CH2CH=CH), 7.13-7.26 (5H, m, Ar Phe), 7.31 
(4H, t, J = 7.4 Hz, Ar Fmoc), 7.40 (4H, t, J = 7.4 Hz, Ar Fmoc), 7.66-7.71 (4H, m, Ar Fmoc), 
7.84-7.86 (1H, m, NH), 7.87 (4H, d, J = 7.4 Hz, Ar Fmoc), 7.98 (1H, d, J = 8.2 Hz, NH), 8.05 
(1H, t, J = 5.3 Hz, NH), 8.13 (1H, t, J = 5.7 Hz, NH) and 8.19 (1H, d, J = 7.6 Hz, NH) ppm. 
LC-MS (Method B): tr = 11.0 min, m/z 1116.2 [M+H]+ (calc. 1116.5) 
MALDI-TOF: m/z 1155.1 [M+K]+ (calc. 1155.5) 
 
Fmoc-Lys(Fmoc)-Leu-Gly-Lys(Mtt)-Ala-Gly-OHxd (14d) 
Starting from 59mg Fmoc-Gly loaded sulfonamide resin (0.05mmol).  
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (50%B) → 17min 
(100%B), retention time: 12.7min. 
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Yield: 21mg colorless solid (0.016mmol, 32%) 
C81H92N8O11 (1353.64) 
LC-MS (Method B): tr = 9.6 min, m/z 1353.4 [M+H]+ (calc. 1353.7) 
MALDI-TOF: m/z 1392.2 [M+K]+ (calc. 1391.8), 1136.1 [(M-Mtt)+K]+ (calc. 1235.7) + Mtt 
peak. 
FAB-LRMS: m/z 1352.79 [M]+ (calc. 1352.69). 
 
Fmoc-Lys(Fmoc)-Cys(StBu)-Gly-Val-Phe-Gly-OHxd (14e) 
Starting from 164mg Fmoc-Gly loaded sulfonamide resin (0.056mmol).  
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (50%B) → 15min 
(100%B), retention time: 11.9min. 
Yield: 14mg colorless solid (0.012mmol, 22%) 
C67H79N7O11S2 (1222.52) 
1H-NMR (DMF-d7, 400 MHz): δ = 0.92 (3H, d, J = 6.8 Hz, CH3 Val), 0.94 (3H, d, J = 6.8 
Hz, CH3 Val), 1.46 (9H, s, tBu), 1.63-1.72 (4H, m, γ-CH2 Lys + δ-CH2 Lys), 1.88 (3H, d, J = 
6.6 Hz, CH3 Hxd), 1.90-2.10 (2H, m, β-CH2 Lys), 2.16-2.25 (1H, m, β-CH Val), 3.28-3.50 (6H, 
m, ε-CH2 Lys + β-CH2 Phe + β-CH2 Cys), 4.00-4.21 (4H, m, 2x α-CH2 Gly), 4.34-4.48 (8H, m, 
2x CH Fmoc + 2x α-CH + 2x CH2 Fmoc), 4.78 (2H, d, J = 6.4 Hz, CH2 Hxd), 4.85-4.90 (2H, 
m, 2x α-CH), 5.78-5.85 (1H, m, CH=CHCH3), 5.90-5.98 (1H, m, CH2CH=CH), 6.22-6.28 
(1H, dd, J = 15.0, 11.0 Hz, CH=CHCH3), 6.45-6.52 (1H, dd, J = 15.0, 10.4 Hz, CH2CH=CH), 
7.34 (1H, t, J = 7.2 Hz, Ar Phe), 7.41 (2H, t, J = 7.2 Hz, Ar Phe), 7.47 (2H, d, J = 7.0 Hz, Ar 
Phe), 7.50 (4H, t, J = 7.4 Hz, Ar Fmoc), 7.60 (4H, t, J = 7.4 Hz, Ar Fmoc), 7.84-7.97 (8H, m, Ar 
Fmoc + 4x CONH), 8.05 (4H, d, J = 7.4 Hz, Ar Fmoc), 8.35 (1H, t, J = 6.0 Hz, CONH), 8.49 
(1H, t, J = 5.8 Hz, CONH) and 8.66 (1H, d, J = 7.5 Hz, CONH) ppm. 
LC-MS (Method B): tr = 11.8 min, m/z 1222.2 [M]+ (calc. 1222.5), 1244.5 [M+Na]+ (calc. 
1244.5) 
FAB-LRMS: 1221.7 [M]+ (calc. 1221.5). 
[ ]20Dα : - 13.5 (c = 0.2, MeOH) 
 
Fmoc-Lys(Fmoc)-Phe-Pro-Ile-Gly-Leu-Phe-Gly-OHxd (14f) and  
Fmoc-Lys(Fmoc)-Phe-Pro-Ile-Gly-Leu-Gly-Phe-Gly-OHxd (14g) 
Starting from mg Fmoc-Gly loaded sulfonamide resin (0.09mmol). The coupling of the 
second glycine residue was incomplete, yielding a mixture of two peptides 14f and 14g. 
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HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (50%B) → 20min 
(100%B), retention time: 17.3min (14f) and 18.1min (14g). 
Yield: 16% overall yield: 5.4mg of 14f (0.010mmol, 4%) and 14.5mg of 14g (0.0037mmol, 
12%). 
 14f: C83H98N10O14 (1459.73) 
MALDI-TOF: m/z 1481.7 [M+Na]+ (calc. 1481.7), 1497.7 [M+K]+ (calc. 1497.7). 
 14g: C81H95N9O13 (1402.67) 
MALDI-TOF: m/z 1424.7 [M+Na]+ (calc. 1424.7), 1440.7 [M+K]+ (calc. 1440.7). 
 
Fmoc-Lys(Fmoc)-Phe-Pro-Ile-Lys(Mtt)-Leu-Gly-Lys(Mtt)-Ala-Gly-OHxd (14h) 
Starting from 59mg Fmoc-Gly loaded sulfonamide resin (0.05mmol).  
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (50%) → 20min 
(100%B), retention time: 14.5min. 
Yield: 9.6mg colorless solid (0.005mmol, 10%) 
C127H147N13O15 (2095.6) 
MALDI-TOF: m/z 2135.3 [M+K]+ (calc. 2134.2), 1877.3 [(M-Mtt)+K]+ (calc. 1877.1), 1621.2 
[(M-2Mtt)+K]+ (calc. 1621.0) + Mtt peak. 
 
 
6.2.4.2. Removal of the protecting groups of the C-terminal hexadienyl ester 
peptides 
 
 
General method for Fmoc deprotection of hexadienyl peptides  
5-30mg Fmoc-protected peptide 14 was treated with 0.5-2.0mL 20% piperidine in DMF or 
DCM for 40 minutes at room temperature. The reaction mixture was coevaporated with 
methanol to remove excess of piperidine. The product was purified by reversed-phase HPLC, 
fractions containing the product (evaluated by MALDI-TOF) were combined and dried by 
lyophilization. 
 
H-Lys-Pro-Phe-Leu-Gly-OHxd (15a) 
H2N
N
H2N
O
H
N
O
N
H
O
H
N
O
O
O
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33 mg of 14a (0.032mmol) were treated with 1.5mL 20% piperidine in DCM.  
HPLC purification: gradient (time/solvent B) of 0min (5%B) → 7min (5%B) → 15min 
(100%B), retention time: 12.1min. 
Yield: 15mg colorless solid (0.023mmol, 72%) 
C34H52N6O6 (640.81) 
1H-NMR (D2O, 400 MHz): ): δ = 0.91 (3H, d, J = 6.1 Hz, CH3 Leu), 0.94 (3H, d, J = 6.2 Hz, 
CH3 Leu), 1.46-1.82 (7H, m, δ-CH2 Lys + γ-CH2 Lys + β-CH2 Leu + γ-CH Leu), 1.74 (3H, J = 
6.7 Hz, CH3 Hxd), 1.84-2.23 (6H, m, β-CH2 Pro + γ-CH2 Pro + β-CH2 Lys), 2.90-3.00 (2H, m, 
ε-CH2 Lys), 3.02 (1H, dd, J = 13.9, 7.7 Hz, β-CH2 Phe), 3.13 (1H, dd, J = 13.9, 6.5 Hz, β-CH2 
Phe), 3.56-3.63 (1H, m ε-CH2 Pro), 3.67-3.73 (1H, m, ε-CH2 Pro), 3.81-3.96 (2H, α-CH2 Gly), 
4.25 (1H, t, J = 6.1 Hz, α-CH), 4.42 (1H, dd, J = 9.5, 5.5 Hz, α-CH), 4.50 (1H, t, J = 5.2 Hz, 
α-CH), 4.57 (1H, t, J = 6.6 Hz, α-CH), 4.61 (2H, d, J = 6.6 Hz, CH2 Hxd), 5.61 (1H, ddd, J = 
13.5, 6.5, 6.5 Hz, CH=CHCH3), 5.72-5.81 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 15.0, 10.4 
Hz, CH=CHCH3), 6.28 (1H, dd, J = 15.0, 10.4 Hz, CH2CH=CH) and 7.17-7.30 (5H, m, Ar 
Phe) ppm. 
LC-MS (Method B): tr = 5.1 min, m/z 641.4 [M+H]+ (calc. 641.4) 
MALDI-TOF: m/z 641.8 [M+H]+ (calc. 641.4), 679.8 [M+K]+ (calc. 679.5) 
FAB-HRMS: m/z 640.3945 [M]+ (calc. 640.3948). 
[ ]20Dα : - 27.9 (c = 0.3, MeOH) 
 
H-Pro-Cys(StBu)-Ser-Met-Gly-OHxd (15b) 
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6 mg of 14b (6.8µmol) were treated with 0.5mL 20% piperidine in DCM.  
HPLC purification: gradient (time/solvent B) of 0min (5%B) → 7min (5%B) → 15min 
(100%B), retention time: 11.3min. 
Yield: 2.3mg colorless solid (3.5µmol, 51%) 
C28H47N5O7S3 (661.90) 
1H-NMR (CD3OD, 400 MHz): δ = 1.35 (9H, s, tBu), 1.75 (3H, d, J = 6.6 Hz, CH3 Hxd), 1.90-
2.21 (6H, m, γ-CH2 Pro + β-CH2 Pro + β-CH2 Met), 2.09 (3H, s, CH3 Met), 2.38-2.64 (2H, m, 
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γ-CH2 Met), 3.02 (1H, dd, J = 13.7, 9.1 Hz, β-CH2 Cys), 3.23 (1H, dd, J = 13.6, 5.0 Hz, β-CH2 
Cys), 3.30-3.45 (2H, m, ε-CH2 Pro), 3.75 (1H, dd, J = 10.9, 5.9 Hz, β-CH2 Ser), 3.85 (1H, dd, J 
= 10.9, 5.4 Hz, β-CH2 Ser), 3.94 (2H, m, α-CH2 Gly), 4.31 (1H, dd, J = 8.4, 6.3 Hz, α-CH Pro), 
4.40 (1H, t, J = 5.7 Hz, α-CH Met), 4.56 (1H, dd, J = 9.0, 4.9 Hz, α-CH Ser), 4.62 (2H, d, J = 
6.7 Hz, CH2 Hxd), 4.69 (1H, dd, J = 9.0, 5.1 Hz, α-CH Cys), 5.61 (1H, ddd, J = 13.2, 6.5, 6.5 
Hz, CH=CHCH3), 5.73-5.81 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 15.0, 10.4 Hz, 
CH=CHCH3) and 6.27 (1H, dd, J = 15.1, 10.3 Hz, CH2CH=CH) ppm.  
ESI-MS: m/z 662.2 [M+H]+ (calc. 662.3), 684.3 [M+Na]+ (calc. 684.2) 
MALDI-TOF: m/z 662.8 [M+H]+ (calc. 662.3), 684.8 [M+Na]+ (calc. 684.2), 700.8 [M+K]+ 
(calc. 700.4) 
[ ]20Dα : - 17.1 (c = 0.1, MeOH) 
 
H-Lys-Leu-Gly-Phe-Ala-Gly-OHxd (15c) 
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7 mg of 14c (0.0063 mmol) were treated with 1.5mL 20% piperidine in DMF.  
HPLC purification: gradient (time/solvent B) of 0min (5%B) → 7min (5%B) → 15min 
(100%B), retention time:  9.4 min. 
Yield: 3.5 mg colorless solid (0.0052mmol, 83%) 
C34H53N7O7 (671.83) 
1H-NMR (CD3OD, 400 MHz): ): δ = 0.95 (3H, d, J = 6.5 Hz, CH3 Leul), 0.97 (3H, d, J = 6.5 
Hz, CH3 Leu), 1.38 (3H, d, J = 7.2 Hz, CH3 Ala), 1.45-1.91 (9H, m, 3x CH2 Lys + β-CH2 Leu 
+ γ-CH Leu), 1.74 (3H, d, J = 6.4 Hz, CH3 Hxd), 2.90-3.20 (4H, m, β-CH2 Phe + CH2 Lys), 
3.88-3.97 (4H, m, 2x α-CH2 Gly), 4.34-4.42 (2H, m, 2x α-CH), 4.58-4.61 (2H, m, 2x α-CH), 
4.62 (2H, d, J = 6.2 Hz, CH2 Hxd), 5.62 (1H, ddd, J = 13.6, 6.6, 6.6 Hz, CH=CHCH3), 5.72-
5.81 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 15.0, 10.5 Hz, CH=CHCH3), 6.28 (1H, dd, J = 
15.1, 10.3 Hz, CH2CH=CH) and 7.18-7.29 (5H, m, Ar Phe) ppm. 
HPLC (Method A): 16.8 min. 
ESI-MS: m/z 671.4 [M]+ (calc. 671.4) 
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MALDI-TOF: m/z 672.9 [M+H]+ (calc. 672.4), 694.9 [M+Na]+ (calc. 694.4), 710.9 [M+K]+ 
(calc. 710.4) 
[ ]20Dα : - 7.2 (c = 0.3, MeOH) 
 
H-Lys-Leu-Gly-Lys(Mtt)-Ala-Gly-OHxd (15d) 
H
N
O
N
H
O
H
N
O
O
O
N
H
H
N
H2N
O
O
NH2
HN
 
21 mg of 14d (15.5µmol) were treated with 1.5mL 20% piperidine in DMF. 
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (10%B) → 17min 
(100%B), retention time: 10.2min. 
Yield: 10.2 mg colorless solid (11.2µmol, 73%) 
C51H72N8O7 (909.17) 
1H-NMR (CD3OD, 400 MHz): δ = 0.94 (3H, d, J = 6.4 Hz, CH3 Leu), 0.96 (3H, d, J = 6.4 
Hz, CH3 Leu), 1.29-1.40 (2H, m, γ-CH2 Lys), 1.39 (3H, d, J = 7.2 Hz, CH3 Ala), 1.44-1.55 (2H, 
m, γ-CH2 Lys), 1.58-1.93 (11H, m, 2x δ-CH2 Lys + β-CH2 Leu + 2x β-CH2 Lys + γ-CH Leu), 
1.74 (3H, d, J = 6.6 Hz, CH3 Hxd), 2.38 (3H, s, CH3 Mtt), 2.85-2.99 (4H, m,  2x ε-CH2 Lys), 
3.77-3.96 (5H, m, 2x α-CH2 Gly + α-CH), 4.26-4.43 (3H, m, 3x α-CH), 4.58 (2H, d, J = 6.6 
Hz, CH2 Hxd), 5.59 (1H, ddd, J = 13.3, 6.6, 6.6 Hz, CH=CHCH3), 5.71-5.80 (1H, m, 
CH2CH=CH), 6.05 (1H, dd, J = 15.0, 10.4 Hz, CH=CHCH3), 6.28 (1H, dd, J = 15.0, 10.6 Hz, 
CH2CH=CH), 7.18 (2H, d, J = 8.4 Hz, Ar Mtt), 7.27-7.33 (6H, m, Ar Mtt)  and 7.43-749 (6H, 
m, Ar Mtt) ppm. 
HPLC (Method A): tr = 18.8 min 
MALDI-TOF: m/z 672.9 [M+H]+ (calc. 672.4), 694.9 [M+Na]+ (calc. 694.4), 710.9 [M+K]+ 
(calc. 710.5). 
FAB-HRMS: m/z 909.5684 [M+H]+ (calc. 909.5602). 
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H-Lys-Cys(StBu)-Gly-Val-Phe-Gly-OHxd (15e) 
 
H
N
O
N
H
O
H
N
O
O
O
N
H
H
N
H2N
O
S
O
NH2
S
 
 
11mg of 14e (9.0µmol) were treated with 1mL 20% piperidine in DMF for 40 minutes.  
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 3min (10%B) → 15min 
(100%B), retention time 9.6min. 
Yield: 5.6 mg colorless solid (7.2µmol, 80%) 
C37H59N7O7S2 (778.04) 
1H-NMR (CD3OD, 400 MHz): δ = 0.73 (3H, d, J = 6.8 Hz, CH3 Val), 0.82 (3H, d, J = 6.8 
Hz, CH3 Val), 1.34 (9H, s, tBu), 1.45-1.55 (2H, m, γ-CH2 Lys), 1.63-1.70 (2H, m, δ-CH2 Lys), 
1.74 (3H, d, J = 6.6 Hz, CH3 Hxd), 1.84-1.95 (2H, m, β-CH2 Lys), 2.01-2.10 (1H, m, β-CH 
Val), 2.94 (2H, t, J = 7.6 Hz, ε-CH2 Lys), 2.98-3.07 (2H, m, β-CH2 Phe), 3.20 (2H, dt, J = 13.9, 
6.4 Hz, β-CH2 Cys), 3.68 (1H, d, J = 16.1 Hz, α-CH Val), 3.94 (2H, s, α-CH2 Gly), 3.98 (1H, t, 
J = 6.4 Hz, α-CH Lys), 4.08 (2H, t, J = 8.2 Hz, α-CH2 Gly), 4.63 (2H, d, J = 6.6 Hz, CH2 
Hxd), 4.63-4.66 (2H, m, α-CH Cys + α-CH Phe), 5.58-5.65 (1H, m, CH=CHCH3), 5.72-5.82 
(1H, m, CH2CH=CH), 6.03-6.10 (1H, dd, J = 15.0, 10.4 Hz, CH=CHCH3), 6.25-6.32 (1H, dd, 
J = 15.1, 10.5 Hz, CH2CH=CH) and 7.18-7.30 (m, 5H, Ar Phe) ppm. 
MALDI-TOF: m/z 778.8 [M+H]+ (calc. 778.4), 800.8 [M+Na]+ (calc. 800.4), 816.7 [M+K]+ 
(calc. 816.5) 
[ ]20Dα : - 9.0 (c = 0.1, MeOH) 
 
H-Lys-Phe-Pro-Ile-Gly-Leu-Phe-Gly-OHxd (15f) 
 
H2N
HN
O
N
O
H
N
N
H
H
N
O
O
O
N
H
H
N
O
O
O
O
NH2  
 
14.5mg of 14f (10.3µmol) were treated with 1mL 20% piperidine in DMF.  
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HPLC purification: gradient (time/solvent B) of 0min (5%B) → 15min (50%B) → 17min 
(100%B), retention time 14.2min. 
Yield: 9.0mg colorless solid (9.4µmol, 91%) 
C51H75N9O9 (958.20) 
1H-NMR (CD3OD, 400 MHz): δ = 0.82 (3H, dd, J = 6.3, 4.3 Hz, CH3 Ile), 0.87 (3H, d, J = 
6.3 Hz, CH3 Ile), 0.91-1.00 (6H, 2x CH3 Leu), 1.21-1.71 (10H, m, CH2 Ile + δ-CH2 Lys + γ-CH2 
Lys + β-CH2 Leu + β-CH2 Lys),  1.74 (3H, J = 6.6 Hz, CH3 Hxd), 1.83-2.14 (6H, m, β-CH2 Pro 
+ γ-CH2 Pro + γ-CH Leu + β-CH Ile), 2.90-3.04 (4H, m, 2x 1H β-CH2 Phe + ε-CH2 Lys), 3.17-
3.26 (2H, m, 2x 1H β-CH2 Phe), 3.32-3.52 (1H, m, ε-CH2 Pro), 3.76-3.95 (6H, m, ε-CH2 Pro + 
2x α-CH2 Gly), 4.08 (1H, t, J = 7.0 Hz, α-CH Pro), 4.22-4.28 (2H, m, 2x α-CH), 4.53-4.67 
(2H, m, 2x α-CH), 4.62 (2H, d, J = 6.5 Hz, CH2 Hxd), 5.61 (1H, ddd, J = 13.6, 6.4, 6.4 Hz, 
CH=CHCH3), 5.72-5.81 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 15.0, 10.5 Hz, 
CH=CHCH3), 6.28 (1H, dd, J = 15.2, 10.5 Hz, CH2CH=CH) and 7.17-7.34 (5H, m, Ar Phe) 
ppm. 
HPLC (Method A): tr = 18.9 min 
ESI-MS: m/z 958.7 [M+H]+ (calc. 958.6) 
MALDI-TOF: m/z 958.9 [M+H]+ (calc. 958.6), 980.9 [M+Na]+ (calc. 980.6), 996.8 [M+K]+ 
(calc. 996.5). 
FAB-LRMS: m/z 958.75 [M]+ (calc. 958.58). 
[ ]20Dα : - 28.6 (c = 0.3, MeOH) 
 
H-Lys-Phe-Pro-Ile-Gly-Leu-Gly-Phe-Gly-OHxd (15g) 
 
H2N
HN
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O
N
H
H
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H
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O
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O
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H
N
O
O
O
N
H
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5.4mg of 14g (3.7µmol) were treated with 1mL 20% piperidine in DMF.  
HPLC purification: gradient (time/solvent B) of 0min (5%B) → 15min (50%B) → 17min 
(100%B), retention time: 14.3min. 
Yield: 3.5 mg colorless solid (3.4µmol, 92%) 
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C53H78N10O10 (1015.25) 
1H-NMR (CD3OD, 400 MHz): δ = 0.82 (3H, dd, J = 6.3, 3.1 Hz, CH3 Ile), 0.87 (3H, d, J = 
6.5 Hz, CH3 Ile), 0.90-1.00 (6H, m, 2x CH3 Leu), 1.17-1.72 (10H, m, CH2 Ile + δ-CH2 Lys + γ-
CH2 Lys + β-CH2 Leu + β-CH2 Lys), 1.73 (3H, d,  J = 6.6 Hz, CH3 Hxd), 1.83-2.04 (5H, m, β-
CH2 Pro + γ-CH2 Pro + γ-CH Leu), 2.04-2.13 (1H, m, β-CH Ile), 2.89-3.04 (4H, m, 2x 1H β-
CH2 Phe + ε-CH2 Lys), 3.17-3.26 (2H, m, 2x 1H β-CH2 Phe), 3.32-3.52 (1H, m, ε-CH2 Pro), 
3.72-4.02 (8H, m, ε-CH2 Pro + 3x α-CH2 Gly), 4.10 (1H, m, α-CH), 4.21-4.28 (2H, m, 2x α-
CH), 4.49-4.56 (2H, m, 2x α-CH), 4.62 (2H, d, J = 6.5 Hz, CH2 Hxd), 5.62 (1H, ddd, J = 13.2, 
6.7, 6.7 Hz, CH=CHCH3), 5.71-5.82 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 14.9, 10.5 Hz, 
CH=CHCH3), 6.27 (1H, dd, J = 14.6, 10.0 Hz, CH2CH=CH) and 7.19-7.35 (5H, m, Ar Phe) 
ppm. 
HPLC (Method A): tr = 18.6 min 
LC-MS (Method A): tr = 15.7 min, m/z 1015.7 [M+H]+ (calc. 1015.6) 
MALDI-TOF: m/z 1015.9 [M+H]+ (calc. 1015.6), 1037.8 [M+Na]+ (calc. 1037.6), 1053.8 
[M+K]+ (calc. 1053.5). 
[ ]20Dα : - 25.7 (c = 0.2, MeOH) 
 
H-Lys-Phe-Pro-Ile-Lys(Mtt)-Leu-Gly-Lys(Mtt)-Ala-Gly-OHxd (15h) 
 
H2N
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9.6mg of 14h (4.6µmol) were treated with 1mL 20% piperidine in DMF.  
HPLC purification: gradient (time/solvent B) of 0min (5%B) → 15min (50%B) → 20min 
(100%B), retention time: 16.8min. 
Yield: 5.3 mg colorless solid (3.2µmol, 71%) 
C97H127N13O11 (1651.13) 
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1H-NMR (CD3OD, 400 MHz): δ = 0.86-0.94 (12H, m, 2x CH3 Ile + 2x CH3 Leu), 1.16-1.40 
(4H, m, CH2 Ile + γ-CH2 Lys), 1.43-2.00 (23H, m, 2x γ-CH2 Lys + 3x δ-CH2 Lys + 3x β-CH2 
Lys + γ-CH Leu + β-CH2 Leu + γ-CH2 Pro + β-CH2 Pro), 1.74 (3H, d,  J = 6.6 Hz, CH3 Hxd), 
2.06-2.10 (1H, m, β-CH Ile), 2.36 (6H, br s, 2x CH3 Mtt), 2.85-3.02 (7H, m, β-CH2 Phe + 3x ε-
CH2 Lys), 3.18 (1H, dd, J = 14.0, 4.7 Hz, β-CH2 Phe), 3.44-3.62 (2H, m, ε-CH2 Pro), 3.75-3.96 
(5H, m, 2x α-CH2 Gly + α-CH Lys), 4.09-4.20 (1H, m, α-CH Pro), 4.22-4.39 (4H, m, α-CH 
Leu + α-CH Ile, 2x α-CH Lys), 4.49-4.52 (1H, m, α-CH Ala), 4.56 (2H, d, J = 6.5 Hz, CH2 
Hxd), 4.55-4.60 (1H, m, α-CH Phe), 5.57 (1H, ddd, J =14.1, 6.6, 6.6 Hz CH=CHCH3), 5.70-
5.79 (1H, m, CH2CH=CH), 6.05 (1H, dd, J = 15.0, 10.5 Hz, CH=CHCH3), 6.24 (1H, dd, J = 
15.0, 10.4 Hz, CH2CH=CH) and 7.12-7.20 (4H, m, Ar Mtt), 7.22-7.32 (12H, m, Ar Mtt), 7.35 
(5H, m, Ar Phe), and 7.42-7.47 (12H, m, Ar Mtt) ppm. 
ESI-MS: m/z 1651.6 [M+H]+ (calc. 1651.0) 
MALDI-TOF: m/z 1139.1 [(M-2Mtt)+H]+ (calc. 1138.7), 1161.1 [(M-2Mtt)+Na]+ (calc. 
1160.7), 1177.0 [(M-2Mtt)+K]+ (calc. 1176.8) + Mtt peak. 
 
H-Lys-Cys-Gly-Val-Phe-Gly-OHxd (16) 
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4.2mg (5.4µmol) of peptide 15e were dissolved in 800µl of a degassed solution of 0.1M 
ammonium bicarbonate: DMF (5:3) in argon atmosphere. 12µl of DTT (0.14mmol) dissolved 
in 200µl degassed DMF was added to the peptide solution and the mixture was stirred under 
argon at room temperature for 2.5h. The crude product was dried by lyophilization, 
redissolved in DMF, filtered and purified by reversed-phase HPLC. 
Yield: 2.7 mg colorless solid (3.9µmol, 72%) 
C33H51N7O7S (689.87) 
1H-NMR (CD3OD, 400 MHz): δ = 0.73 (3H, d, J = 6.8 Hz, CH3 Val), 0.82 (3H, d, J = 6.8 
Hz, CH3 Val), 1.28-1.33 (1H, m, SH), 1.47-1.54 (2H, m, γ-CH2 Lys), 1.63-1.72 (2H, m, δ-CH2 
Lys), 1.74 (3H, d, J = 6.6 Hz, CH3 Hxd), 1.86-1.92 (2H, m, β-CH2 Lys), 2.00-2.07 (1H, m, β-
CH Val), 2.81-3.03 (4H, m, ε-CH2 Lys + β-CH2 Phe), 3.20 (2H, dt, J = 8.8, 5.0 Hz, β-CH2 Cys), 
3.77 (1H, d, J = 16.1 Hz, α-CH Val), 3.94 (2H, s, α-CH2 Gly), 3.98 (1H, t, J = 6.4 Hz, α-CH 
 137
Experimental Section 
Lys), 4.07 (2H, t, J = 6.4 Hz, α-CH2 Gly), 4.53 (2H, t, α-CH), 4.62 (2H, d, J = 6.6 Hz, CH2 
Hxd), 4.66 (2H, t, J = 5.0 Hz, α-CH), 5.58-5.65 (1H, m, CH=CHCH3), 5.72-5.81 (1H, m, 
CH2CH=CH), 6.03-6.10 (1H, ddd, J = 15.0, 10.4 Hz, CH=CHCH3), 6.25-6.32 (1H, dd, J = 
15.1, 10.5 Hz, CH2CH=CH) and 7.18-7.30 (m, 5H, Ar Phe) ppm. 
HPLC (Method A): tr = 16.8 min 
MALDI-TOF: m/z 691.0 [M+H]+ (calc. 690.4), 713.0 [M+Na]+ (calc. 712.4), 729.0 [M+K]+ 
(calc. 728.3). 
 
H-Lys-Phe-Pro-Ile-Lys-Leu-Gly-Lys-Ala-Gly-OHxd (17) 
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5.0mg of 15h (3.0µmol) were treated with 0.5mL of DCM:TFA:TES (85:5:10) at room 
temperature for 35 minutes. The reaction was stopped by adding 27µl DIPEA in 1mL MeOH 
and directly purified by HPLC. Combined fractions containing the desired product were 
collected and lyophilized. 
Yield: 0.53 mg colorless solid (0.47µmol, 16%) 
C57H95N13O11 (1138.45) 
1H-NMR (CD3OD, 400 MHz): No Mtt signal 
ESI-MS: m/z 1138.9 [M+H]+ (calc. 1138.7) 
MALDI-TOF: m/z 1138.1 [M+H]+ (calc. 1138.7), 1161.1 [M+Na]+ (calc. 1160.7), 1177.1 
[M+K]+ (calc. 1176.8) 
 
 
6.2.5. Synthesis of other diene and dienophile peptides 
 
N-acryloyl-glycine-methylester (33) 
 
N
H
O
O
O  
 
Glycine methyl ester (2.51g, 20mmol) and triethylamine (3.4mL, 24mmol) were dissolved in 
100mL DCM. The solution was cooled to 0°C and acryloyl chloride (1.8mL, 22mmol) 
dissolved in 10mL DCM was added dropwise over 1 hour. The reaction mixture was allowed 
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to warm up to room temperature and stirred overnight. 200mL EtOAc were added and the 
formed solid was filtered off. The organic phase was washed 3x KHSO4 1M, 3x 5% NaHCO3 
and 1x brine, dried over MgSO4 and concentrated in vacuum. 
Yield: 1.3g (9.1mmol, 46%) colorless solid 
C6H9NO3 (143.06) 
1H-NMR (CD3OD, 400MHz):  δ = 3.62 (3H, s, OCH3), 3.91 (2H, d, J = 6.0 Hz, α-CH2 Gly), 
5.62 (1H, dd, J = 10.2, 2.1 Hz, HCH=CH), 6.09 (1H, dd, J = 17.1, 2.1 Hz, HCH=CH), 6.27 
(1H, dd, J = 17.1, 10.2 Hz, CH2=CH) and 8.50-8.56 (1H, m, CONH) ppm. 
13C-NMR (CD3OD, 100MHz): δ = 41.3 (α-CH2 Gly), 52.4 (OCH3), 126.6 (CH2=CH), 131.7 
(CH2=CH), 165.7 (C=O) and 171.0 (C=O) ppm. 
ESI-MS: 144.07 [M+H]+ (calc. 144.06) 
 
N-acryloyl-glycine-OH (32) 
N
H
O
OH
O  
N-acryloyl-glycine methyl ester 33 (0.42g, 2.9mmol) was dissolved in 7mL MeOH. 3mL 
NaOH 1M (3.0 mmol) were added and the mixture was stirred at room temperature during 30 
minutes. MeOH was removed under reduced pressure and the resulting solution was 
neutralized by adding HCl 1M and lyophilized. The crude solid was washed many times with 
methanol. The solvent was removed under vacuum and the product was recrystallized from 
MeOH/Et2O. 
Yield: 0.32g (2.5mmol, 86%) colorless solid 
C5H7NO3 (129.11) 
1H-NMR (D2O, 400MHz): δ = 3.71 (2H, br s, α-CH2 Gly), 5.65 (1H, dd, J = 10.2, 0.6 Hz, 
HCH=CH), 6.08 (1H, dd, J = 17.2, 0.7 Hz, HCH=CH) and 6.19 (1H, dd, J = 17.2, 10.2 Hz, 
CH2=CH) ppm. 
13C-NMR (D2O, 100MHz): δ = 43.5 (α-CH2 Gly), 127.6 (CH2=CH), 130.7 (CH2=CH), 168.5 
(CONH) and 176.8 (CO2H) ppm. 
 
N-acryloyl-Gly-Tyr-Ser-Leu-Ala-Gly-OH (31) 
 
N
H
H
N
N
H
H
N
N
H
H
N
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O
O
O
O
O
OO
OH
OH
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Starting from 274mg Fmoc-glycine loaded Wang resin (0.31mmol). The same procedure for 
the synthesis of the maleimido-peptides was applied here (Section 6.2.2.2). N-acryloyl-glycine 
32 was coupling using HBTU/HOBt activation. 
Yield: 114mg light yellow solid (0.18mmol, 60%) 
C28H40N6O10 (620.65) 
1H-NMR (DMSO-d6, 400 MHz): δ = 0.83 and 0.86 (3H, d, J = 6.5 Hz, CH3 Leu), 1.19 (3H, d, 
J = 7.1 Hz, CH3 Ala), 1.40-1.52 (2H, m, β-CH2 Leu), 1.55-1.65 (1H, m, γ-CH Leu), 2.59-2.67 
and 2.86-2.90 (2H, dm, β-CH2 Tyr), 3.53-3.82 (6H, m, α-CH2 Gly + β-CH2 Ser + α-CH2  N-
acryloyl-Gly), 4.22-4.72 (5H, m, 4x α-CH + OH Tyr), 5.57 (1H, dd, J = 10.2, 1.9 Hz, 
CHH=CH), 6.05 (1H, dd, J = 17.1, 1.9 Hz, CHH=CH), 6.22-6.29 (1H, dd, J = 17.2, 10.2 Hz, 
CH2=CH), 6.58 (2H, d, J = 8.4 Hz, Ar Tyr), 6.99 (2H, d, J = 8.4 Hz, Ar Tyr), 7.92 (1H, dd, J = 
8.1, 3.0 Hz, CONH), 8.00-8.08 (3H, m, 3x CONH), 8.15 (1H, d, J = 7.7 Hz, CONH) and 8.30 
(1H, t, J = 5.9 Hz, CONH) ppm. 
LC-MS (Method A): tr = 15.4 min; m/z: 621.1 [M+H]+ (calc. 621.3). 
FAB-HRMS: 643.2732 [M+Na]+ (calc. 643.2704). 
 
2-(cyclopentadienyl)-ethanamine (39) 
 
H2N H2N
+
a b  
In an oven-dried flask under argon atmosphere, 4.64g of chloroethylamine hydrochloride 
(40mmol) was suspended in 100mL dry THF and the mixture was cooled to 0°C. Then 40mL 
of a 2M solution of sodium cyclopentadienide in THF (80mmol) was added via syringe into 
the reaction mixture, whose colour became clear pink. After reacting 4 hours at 0°C, the 
reaction was allowed to warm up to room temperature overnight. The reaction was quenched 
by adding 150mL of water. The organic compounds were extracted 3x EtOAc. The combined 
organic layers were extracted 3x 10% acetic acid. The combined acidic extractions were 
alkalinized from pH 5 to 13 by adding NaOH 4M. The product was extracted with 3x 
diethylether. The organic solution was washed with brine, dried over MgSO4 and concentrated 
in medium vacuum (350mbar, 40°C). 
Yield: 3.0g yellow oil (28mmol, 70% overall, 45% 39a and 55% 39b determined by NMR) 
C7H11N (109.17) 
1H-NMR (CDCl3, 400MHz):  δ = 1.41 (2H, br s, NH2), 2.39-2.43 (2H of 39b, m, CH2), 2.44-
2.48 (2H of 39a, m, CH2), 2.76-2.81 (2H, m, CH2 + 2H of 39a, m, CH2 Cp), 2.86-2.88 (2H of 
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39b, m, CH2 Cp), 5.97-5.99 (1H of 39b, m, Cp), 6.11-6.13 (1H of 39a, m, Cp), 6.16-6.19 (1H of 
39a, m, Cp) and 6.31-6.36 (2H of 39b, m, Cp + 1H of 39a, m, Cp) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 34.5/35.3, 41.6/41.8, 42.4/43.6, 127.7/128.0, 131.1/132.5, 
134.2/134.5 and 144.6/146.9. 
GC-MS (Method B): tr= 3.67 min; m/z: 109 [M]+ 
 
Glycine-(2-cyclopentadienyl)ethylamide (40) 
 
N
H
H2N
O
 
 
1) Coupling: Fmoc-Ala-OH (1.93g, 6.2mmol) and 2-(cyclopentadienyl)-ethanamine 39 (0.61g, 
5.6mmol) were dissolved in DCM (20mL) and the solution cooled to 0°C. HOBt (961mg, 
6.7mmol) and DIC (0.97mL, 6.2mmol) were added and the solution was allowed to warm up 
to room temperature and stirred overnight. After 18 hours, the reaction mixture was 
concentrated in vacuum, and dissolved in EtOAc:cHex. The urea precipitate was filtered off 
and the filtrate transferred to a separation funnel. The organic phase was washed again with 
NaHCO3 saturated solution and brine, dried over MgSO4 and concentrated in vacuum. The 
product was purified by flash chromatography eluting with cHex:EtOAc (5:1 to 2:1) to give a 
colorless solid (742mg, 1.8mmol, 34% yield). 
2) Fmoc deprotection: The Fmoc-peptide (251mg, 0.62mmol) was treated with 20% 
piperidine in DCM (18mL) at room temperature for 30 minutes. Piperidine was removed by 
coevaporation with methanol and the product purified by flash chromatography (DCM to 
DCM:MeOH (8:2)) 
Yield: 103mg light yellow oil (0.57mmol, 92% last step, 31% over the two steps) 
C10H16N2O (180.25) 
1H-NMR (DMSO-d6, 400MHz):  δ = 1.17/1.18 (3H, J = 7.0 Hz, NH2), 2.45-2.55 (2H, m, 
CH2), 2.89-2.94 (2H, m, CH2), 3.18-3.34 (2H, m, CH2 Cp), 3.45 (1H, m, α-CH), 6.07-6.09, 
6.20-6.21, 6.24-6.27, 6.38-6.43 and 6.45-6.47 (3H, m, Cp) and 8.14 (1H, t, J = 7.0 Hz, CONH) 
ppm. 
 
Alanine-furfurylamide (42) 
N
H
H2N
O
O
 
1) Coupling: Fmoc-Ala-OH (1.34g, 4.3mmol) and furfurylamine 39 (0.38mL, 4.3mmol) were 
dissolved in 30mL THF:DCM (2:1) and the solution cooled to 0°C. HOBt (0.74g, 5.2mmol) 
 141
Experimental Section 
and DIC (0.73mL, 4.7mmol) were added and the solution was allowed to warm up to room 
temperature and stirred overweekend. After that, the reaction mixture was concentrated in 
vacuum, and dissolved in EtOAc:cHex. The urea precipitate was filtered off and the filtrate 
transferred to a separation funnel. The organic phase was washed with 3x HCl 1M, 3x 
NaHCO3 saturated solution and 1x brine, dried over MgSO4 and concentrated in vacuum to 
give a colorless solid (1.5g, 3.8mmol, 88% yield). 
2) Fmoc deprotection: The Fmoc-peptide (750mg, 1.9mmol) was treated with 20% 
piperidine in DCM (24mL) at room temperature for 30 minutes. Piperidine was removed by 
coevaporation with methanol and the product purified by flash chromatography (DCM to 
DCM:MeOH (8:2)) 
Yield: 175mg light yellow oil (1.0mmol, 55% last step, 51% over the two steps) 
C8H12N2O2 (168.19) 
1H-NMR (CDCl3, 400MHz): δ = 1.33 (3H, d, J = 7.0 Hz, CH3 Ala), 3.50 (1H, m, α-CH), 
4.36-4.42 (2H, m, CH2), 6.20 (1H, dd, J = 3.2, 0.7 Hz, Fur), 6.30 (1H, dd, J = 1.9, 3.2 Hz, Fur), 
7.33 (1H, dd, J = 1.8, 0.8 Hz, Fur) and 7.59 (1H, br s, CONH) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 21.9 (CH3), 36.3 (CH2), 50.9 (α-CH), 107.4 (Fur), 110.6 
(Fur), 142.3 (Fur), 151.7 (Fur) and 175.7 (CO) ppm. 
 
 
6.2.6. Diels-Alder ligation of peptides 
 
General procedure for the Diels-Alder ligation 
Diene- and dienophile-peptides were dissolved in water to an approximate concentration of 
10mM. In some cases, methanol or DMF were added in minimum amounts to help peptide 
solubilization. After appropriate reaction time, the ligation product was directly purified by 
reversed phase HPLC and finally lyophilized. 
 
HO-cyclo-NH (3) 
NH
HO
O
O
 
 
Trans,trans-2,4-hexadien-1-ol (92mg, 0.94mmol) and maleimide (92mg, 0.94mmol) were 
dissolved in 2mL MeOH:H2O (13:7) and stirred for 5h. The formed solid was separated by 
filtration, washed with water and diethylether and finally dried under reduced pressure. 
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Yield: 0.18g colorless solid (0.92mmol, 99% determined by NMR)  
C10H13NO3 (195.22) 
1H-NMR (CD3OD, 400MHz): δ = 1.39 (3H, d, J = 7.4 Hz, CH3), 2.40-2.49 (2H, m, H6 + H3), 
3.10 (1H, dd, J = 8.5, 7.1 Hz, H5), 3.30 (1H, m, H4), 3.91 (1H, dd, J = 11.0, 7.9 Hz, CH2), 4.03 
(1H, dd, J = 11.0, 6.9 Hz, CH2) and 5.74-5.86 (2H, m, CH1=CH2) ppm. 
13C-NMR (CD3OD, 100MHz): δ = 16.0 (CH3), 31.0 (C6), 38.9 (C3), 44.3 (C4), 46.5 (C5), 62.3 
(CH2), 130.1 (C1), 134.6 (C2), 179.7 (C=O) and 180.1 (C=O) ppm. 
GC-MS (Method B): tr = 6.84; m/z: 165 [M-30]+,  tr = 7.00; m/z: 195 [M]+, 178 [M-OH]+
ESI-MS: 196.3 [M+H]+ (calc. 196.1) 
FAB-HRMS: 196.0973 [M+H]+ (calc. 196.0974). 
 
Val-Ala-Gly-O-cyclo-N-Gly-Tyr-Thr-Gly-OH (18a) 
 
H
N
O
N
H
O
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O
H
N
O
OH
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N
H
H
N
O
OO
H2N
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O
O
 
 
Val-Ala-Gly-trans,trans-2,4-hexadienyl ester 9 (11mg, 0.033mmol) and N-maleoyl-Gly-Tyr-Thr-
Gly-OH 5a (19mg, 0.039mmol) were dissolved in 1mL H2O:MeOH (10:3) and stirred at room 
temperature overnight. After 20h, complete consumption of the diene-peptide 9 was observed 
by HPLC. The Diels-Alder reaction product was purified by reversed-phase HPLC (gradient 
(time/solvent B) of 0min (5%B) → 5min (5%B) → 8min (10%B) → 15min (100%B), 
retention time: 11.5min). Fractions containing the desired product (evaluated by MALDI-
TOF) were combined and lyophilized. 
Yield: 23mg colorless solid (0.029mmol, 87% isolated)  
C37H51N7O13 (801.84) 
1H-NMR (CD3OD, 400MHz): δ = 1.03 (3H, d, J = 6.8 Hz, CH3 Val), 1.06 (3H, d, J = 6.9 Hz, 
CH3 Val), 1.14 (3H, d, J = 6.4 Hz, CH3 Thr), 1.39 (3H, d, J = 7.2 Hz, CH3 Ala), 1.40 (3H, d, J 
= 7.0 Hz, CH3 cyclo), 2.14-2.24 (1H, m, β-CH Val), 2.44-2.52 (1H, m, H6), 2.65-2.72 (1H, m, 
H3), 2.88 (1H, dd, J = 13.7, 7.8 Hz, β-CH2 Tyr), 3.02 (1H, dd, J = 13.9, 6.3 Hz, β-CH2 Tyr), 
3.12 (5%, m, H5 exo), 3.18 (1H, dd, J = 8.4, 7.2 Hz , H5 endo), 3.39 (1H, dd, J = 8.5, 6.1 Hz , H4 
endo), 3.47 (5%, m, H4 exo), 3.67 (1H, d, J = 5.6 Hz, α-CH Val), 3.84-4.09 (6H, m, 3x α-CH2 
Gly), 4.13-4.20 (1H, m, β-CH Thr), 4.31 (1H, t, J = 3.5 Hz, α-CH), 4.47 (1H, ddd, J = 14.3, 
 143
Experimental Section 
7.1, 3.2 Hz, CH2 cyclo), 4.51-4.63 (3H, m, CH2 cyclo + 2x α-CH), 5.71-5.79 (2H, m, CH=CH), 
6.69 (2H, d, J = 7.4 Hz, Ar Tyr) and 7.04 (2H, d, J = 8.5 Hz, Ar Tyr) ppm. 
HPLC (Method A): tr = 8.0 min 
LC-MS (Method A): tr = 16.0 min; m/z = 802.4 [M+H]+ (calc. 802.4) 
MALDI-TOF: 802.9 [M+H]+ (calc. 802.4), 824.9 [M+Na]+ (calc. 824.3),  840.9 [M+K]+ (calc. 
840.3). 
[ ]20Dα : + 11.7 (c = 1.0, DMF) 
 
Lys-Pro-Phe-Leu-Gly-O-cyclo-N-Gly-Tyr-Thr-Gly-OH (18b) 
 
H
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O
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Hexadienyl peptide ester 15a (10mg, 0.015mmol) and N-maleoyl-Gly-Tyr-Thr-Gly-OH 5a 
(7mg, 0.015mmol) were dissolved in 1000µl H2O:MeOH (4:1) and stirred at room 
temperature for 1 day. HPLC analysis revealed a ratio of 80:20 for the formation of the 
cycloadduct in comparison with the starting diene. The Diels-Alder reaction product was 
purified by reversed-phase HPLC (gradient (time/solvent B) of 0min (5%B) → 3min (5%B) 
→ 5min (10%B) → 20min (100%B), retention time: 10.5min). Fractions containing desired 
product (evaluated by MALDI-TOF) were combined and lyophilized. 
Yield: 10mg colorless solid (0.009mmol, 60% isolated)  
C55H76N10O15 (1117.25) 
1H-NMR (CD3OD, 400MHzδ = 0.90 (3H, d, J = 6.0 Hz, CH3 Leu), 0.94 (3H, d, J = 6.0 Hz, 
CH3 Leu), 1.14 (3H, d, J = 6.4 Hz, CH3 Thr), 1.39/1.40 (ratio: 1/1, 3H, d, J = 7.3 Hz, CH3 
cyclo), 1.51-1.74 (7H, m, γ-CH2 Lys + δ-CH2 Lys + β-CH2 Leu + γ-CH Leu), 1.87-2.09 (5H, γ-
CH2 Pro + β-CH2 Lys + β-CH2 Pro), 2.16-2.26 (1H, m, β-CH2 Pro), 2.45-2.51 (1H, m, H6), 
2.64-2.73 (1H, m, H3), 2.87 (1H, dd, J = 13.9, 7.8 Hz, β-CH2 Tyr), 2.92-3.15 (5H, m, β-CH2 
Tyr + ε-CH2 Lys + β-CH2 Phe), 3.13/3.20 (ratio: 1/1, 1H, dd, J = 8.6, 7.2/8.2, 7.2 Hz, H5), 
3.38/3.46 (ratio: 1/1, 1H, dd, J = 8.4, 6.2/8.7, 6.3 Hz, H4), 3.55-3.64 (1H, m, δ-CH2 Pro) , 
3.67-3.74 (1H, m, δ-CH2 Pro), 3.83-4.11 (6H, m, 3x α-CH2 Gly), 4.13-4.19 (1H, m, β-CH Thr), 
4.23-4.28 (1H, m, α-CH), 4.32 (1H, t, J = 3.7 Hz, α-CH), 4.39-4.46 (1H, m, CH2 cyclo), 4.48-
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4.52 (1H, m, CH2 cyclo), 4.54-4.65 (4H, m, 4x α-CH), 5.70-5.78 (2H, m, CH=CH), 6.69 (2H, 
d, J = 8.4 Hz, Ar Tyr), 7.03 (2H, d, J = 8.5 Hz, Ar Tyr) and 7.18-7.31 (5H, m, Ar Phe) ppm. 
ESI-MS: m/z 1117.6 [M+H]+ (calc. 1117.6) 
MALDI-TOF: m/z 1118.0 [M+H]+ (calc. 1117.6), 1140.0 [M+Na]+ (calc. 1139.5),  1156.0 
[M+K]+ (calc. 1155.5). 
[ ]20Dα : - 23.2 (c = 0.3, MeOH) 
 
Lys-Leu-Gly-Lys(Mtt)-Ala-Gly-O-cyclo-N-Gly-Thr-Gln-Phe-His-Gly-OH (18c) 
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Hexadienyl ester 15d (2.0mg, 2.2µmol) and N-maleoyl-Gly-Thr-Gln-Phe-His-Gly-OH 5b 
(1.6mg, 2.2µmol) were dissolved in 200µl H2O:MeOH (10:1) and stirred at room temperature 
for 1 day. Approximately 95% of diene 15d was consumed after 24h as shown by HPLC 
analysis. Partial removal of Mtt protection groups from lysine side chain took place during 
reaction, giving two cycloadducts 18c (with Mtt) and 18c´(without Mtt). These compounds 
were isolated by reversed-phase HPLC (gradient (time/solvent B) of 0min (5%B) → 3min 
(5%B) → 15min (60%B) → 17min (100%B), retention time: 17.0min (18c) and 13.0min 
(18c´)) and dried by lyophilization. 
Overall yield: 74% cycloadduct isolated. 
  18c: 1.3mg colorless solid (0.80µmol, 43%), compound with Mtt group 
C83H111N17O18 (1634.87) 
1H-NMR (CD3OD, 400MHz): δ = 0.94 (3H, d, J = 6.7 Hz, CH3 Leu), 0.96 (3H, d, J = 6.7 Hz, 
CH3 Leu), 1.20 (3H, d, J = 6.2 Hz, CH3 Thr), 1.39 (6H, d, J = 7.1 Hz, CH3 Ala + CH3 cyclo), 1.3-
2.3 (m, CH2 Lys + CH2 Gln + CH2,CH Leu), 2.37 (3H, s, CH3 Mtt), 2.44-2.51 (1H, m, H6), 
2.63-2.72 (1H, m, H3), 2.9-3.4 (m, β-CH2 Phe + β-CH2 His + β-CH2 Lys + H5 + H4), 3.7-4.7 
(5H, m, α-CH2 Gly + α-CH  + CH2 cyclo), 5.72-5.76 (2H, m, CH=CH), 7.17-7.49 (20H, m, Ar 
Phe + Ar Mtt + CH His) and 8.73 (1H, br s, NH His) ppm. 
HPLC (Method A): tr = 16.9 min 
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MALDI-TOF: m/z 1379.1 [(M-Mtt)+H]+ (calc. 1378.7), 1417.1 [(M-Mtt)+K]+ (calc. 1416.8),  
Mtt peak. 
 18c´: 0.8mg of colorless solid (0.58µmol, 31%), compound without Mtt group 
C63H95N17O18 (1378.53) 
1H-NMR (CD3OD, 400MHz):  δ = 0.95 (3H, d, J = 6.6 Hz, CH3 Leu), 0.98 (3H, d, J = 6.6 
Hz, CH3 Leu), 1.20 (3H, d, J = 6.4 Hz, CH3 Thr), 1.40 (6H, d, J = 7.5 Hz, CH3 Ala + CH3 cyclo), 
1.4-2.3 (m, CH2 Lys + CH2 Gln + CH2,CH Leu), 2.47-2.53 (1H, m, H6), 2.67-2.74 (1H, m, H3), 
2.9-3.4 (m, β-CH2 Phe + β-CH2 His + β-CH2 Lys + H5 + H4), 3.7-4.7 (m, α-CH2 Gly + α-CH  
+ CH2 cyclo), 5.73-5.77 (2H, m, CH=CH), 7.35 (1H, br s, CH His), 7.18-7.29 (5H, m, Ar Phe) 
and 8.71 (1H, br s, NH His) ppm. 
HPLC (Method A): tr = 13.0 min. 
MALDI-TOF: m/z 1379.5 [M+H]+ (calc. 1378.7), 1401.4 [M+Na]+ (calc. 1400.7), 1417.4 
[M+K]+ (calc. 1416.8). 
 
Lys-Leu-Gly-Lys(Mtt)-Ala-Gly-O-cyclo-N-Gly-Ser-Glu-Trp-Ile-Gly-OH (18d) 
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Hexadienyl ester 15d (2.0mg, 2.2µmol) and N-maleoyl-Gly-Ser-Glu-Trp-Ile-Gly-OH 5c 
(1.6mg, 2.2µmol) were dissolved in 200µl H2O:DMF (10:1) and stirred at room temperature 
for 2 days. Approximately 84% of diene 15d was consumed after 47h as shown by HPLC 
analysis. Partial removal of Mtt protection groups from lysine side chain took place during the 
reaction, giving two cycloadducts 18d (with Mtt) and 18d´ (without Mtt). These compounds 
were isolated by reversed-phase HPLC (gradient (time/solvent B) of 0min (5%B) → 3min 
(5%B) → 15min (60%B) → 17min (100%B), retention time: 17.1min (18d) and 16.1 (18d´)) 
and dried by lyophilization. 
Overall yield: 64% cycloadduct isolated. 
  18d : 1.2mg colorless solid (0.73µmol, 40%), compound with Mtt group 
C84H113N15O19 (1636.89) 
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1H-NMR (CD3OD, 400MHz): found δ = 1.40 (3H, d, CH3 Hxd), 2.38 (3H, s, Mtt), 5.67-5.75 
(2H, m, CH=CH) 7.1-7.5 (signals for Mtt group) ppm and expected peaks for all amino acids.  
HPLC (Method A): tr = 18.4 min. 
MALDI-TOF: 1381.5 [(M-Mtt)+H]+ (calc. 1380.7), 1403.4 [(M-Mtt)+Na]+ (calc. 1402.7), 
1419.4 [(M-Mtt)+K]+ (calc. 1418.7), Mtt peak. 
  18d´ : 0.6mg of colorless solid (0.43µmol, 24%), compound without Mtt group 
C64H97N15O19 (1380.54) 
1H-NMR (DMSO-d6 400MHz): found δ = 1.2 (CH3 Hxd) and 5.02-5.75 (2H, m, CH=CH) 
ppm and expected peaks for all amino acids.  
HPLC (Method A): tr = 15.0 min 
MALDI-TOF: m/z 1381.3 [M+H]+ (calc. 1380.7), 1403.2 [M+Na]+ (calc. 1402.7), 1419.2 
[M+K]+ (calc. 1418.7). 
 
Pro-Cys(StBu)-Ser-Met-Gly-O-cyclo-N-Gly-Tyr-Thr-Gly-OH (18e) 
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Hexadienyl peptide ester 15b (2.0mg, 3.0µmol) and N-maleoyl-Gly-Tyr-Thr-Gly-OH 5a 
(3.5mg, 7.3µmol) were combined in 500µl H2O:MeOH (3:2) and stirred at room temperature 
for 24 hours. After this time, complete consumption of the diene-peptide 15b was observed 
by HPLC. The cycloadduct was purified by reversed-phase HPLC (gradient (time/solvent B) 
of 0min (10%B) → 1min (30%B) → 4min (30%B) → 10min (50%B), retention time: 7.2min). 
Fractions containing desired product (evaluated by MALDI-TOF) were combined and 
lyophilized. 
Yield: 1.1mg colorless solid (0.97µmol, 32% isolated)  
C49H71N9O16S3 (1138.33) 
1H-NMR (CD3OD, 400MHz): δ = 1.14 (3H, d, J = 6.5 Hz, CH3 Thr), 1.35 (9H, br s, tBu Cys), 
1.40 (3H, d, J = 7.0 Hz, CH3 cyclo), 1.89-2.21 (6H, m, γ-CH2 Pro + β-CH2 Pro + β-CH2 Met), 
2.08 (3H, s, CH3 Met), 2.42-2.65 (3H, m, H6 + γ-CH2 Met), 2.66-2.72 (1H, m, H3), 2.85-2.92 
(1H, β-CH2 Tyr), 2.97-3.05 (3H, m, β-CH2 Tyr + β-CH2 Cys), 3.16-3.22 (1H, m, H5), 3.37-3.45 
(1H, m, H4), 3.57-4.19 (11H, m, δ-CH2 Pro + β-CH2 Ser + 3x α-CH2 Gly + β-CH Thr), 4.29-
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4.45 (3H, m, 3x α-CH), 4.53-4.66 (4H, m, 2x α-CH + CH2 cyclo), 4.69-4.73 (1H, m, α-CH 
Cys), 5.68-5.80 (2H, m, CH=CH), 6.68 (2H, d, J = 8.4 Hz, Ar Tyr) and 7.03 (2H, d, J = 8.3 Hz, 
Ar Tyr) ppm. 
ESI-MS: m/z 1138.4 [M+H]+ (calc. 1138.4) 
MALDI-TOF: m/z 1139.1 [M+H]+ (calc. 1138.4), 1161.0 [M+Na]+ (calc. 1160.4), 1177.0 
[M+K]+ (calc. 1176.4). 
[ ]20Dα : - 31.5 (c = 0.1, MeOH) 
 
Lys-Phe-Pro-Ile-Gly-Leu-Phe-Gly-O-cyclo-N-Gly-Ala-Lys-Thr-Ser-Ala-Glu-Ser-Tyr-
Ser-Gly-OH (18f) 
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Hexadienyl peptide ester 15f (2.8mg, 2.9µmol) and maleimide-undecapeptide 5d (3.3mg, 
2.9µmol) were dissolved in 300µl H2O and the solution was stirred at room temperature for 2 
days. 93% ligation production was formed after 48h reaction (in comparison with diene 15f 
consumption) as indicated by HPLC. The cycloadduct was purified by reversed-phase HPLC 
(gradient (time/solvent B) of 0min (5%B) → 15min (50%B), retention time: 11.6min). 
Fractions containing desired product  were combined and lyophilized. 
Yield: 3.5mg colorless solid (1.7µmol, 69% isolated)  
C98H143N21O30 (2095.31) 
1H-NMR (CD3OD, 400MHz):  δ = 0.81-1.00 (12H, m, 2x CH3 Ile + 2x CH3 Leu), 1.19 (3H, 
d, J = 6.3 Hz, CH3 Thr), 1.19-1.77 (22H, m, 2x β-/γ-/δ-CH2 Lys + 2x CH3 Ala + CH2 Ile + β-
CH2 Leu), 1.43 (3H, d, J = 7.3 Hz, CH3 cyclo), 1.81-2.20 (8H, m, β-CH2 Glu + β-CH2 Pro + γ-
CH2 Pro + γ-CH Leu + β-CH Ile), 2.41-2.46 (2H, m, γ-CH2 Glu), 2.47-2.53 (1H, m, H6), 2.66-
2.74 (1H, m, H3), 2.89-3.26 (11H, m, 2x ε-CH2 Lys + β-CH2 Tyr + 2x β-CH2 Phe + H5), 3.34-
3.57 (3H, m, H4 + ε-CH2 Pro), 3.71-4.00 (14H, m, 3x β-CH2 Ser + 4x α-CH2 Gly), 4.06-4.68 
(15H, m, 13x  α-CH + CH2 cyclo), 5.71-5.77 (2H, m, CH=CH), 6.68 (2H, d, J = 8.4 Hz, Ar 
Tyr), 7.08 (2H, d, J = 8.5 Hz, Ar Tyr) and 7.17-7.34 (10H, m, Ar Phe) ppm. 
HPLC (Method A): tr = 16.1 min. 
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LC-MS (Method A): tr = 14.1 min; m/z 1048 [M+H]++ (calc. 1048). 
MALDI-TOF: m/z 2098 [M+H]+ (calc. 2096), 2120 [M+Na]+ (calc. 2118), 2135 [M+K]+ 
(calc. 2134). 
[ ]20Dα : - 22.9 (c = 0.1, MeOH) 
 
Lys-Phe-Pro-Ile-Gly-Leu-Gly-Phe-Gly-O-cyclo-N-Gly-Ala-Lys-Thr-Ser-Ala-Glu-Ser-
Tyr-Ser-Gly-OH (18g) 
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Hexadienyl peptide ester 15g (2.8mg, 2.7µmol) and maleimide-undecapeptide 5d (3.1mg, 
2.7µmol) were dissolved in 270µl H2O and the solution was stirred at room temperature for 2 
days. 92% ligation production was formed after 48h reaction (in comparison with diene 15g 
consumption) as indicated by HPLC. The cycloadduct was purified by reversed-phase HPLC 
(gradient (time/solvent B) of 0min (5%B) → 16min (50%B), retention time: 11.5min). 
Fractions containing desired product were combined and lyophilized. 
Yield: 3.2mg colorless solid (1.5µmol, 67% isolated)  
C100H146N22O31 (2152.36) 
1H-NMR (CD3OD, 400MHz):  δ = 0.82-1.00 (12H, m, 2x CH3 Ile + 2x CH3 Leu), 1.19 (3H, 
d, J = 6.3 Hz, CH3 Thr), 1.20-1.74 (22H, m, 2x β-/γ-/δ-CH2 Lys + 2x CH3 Ala + CH2 Ile + β-
CH2 Leu), 1.43 (3H, d, J = 7.3 Hz, CH3 cyclo), 1.83-2.19 (8H, m, β-CH2 Glu + β-/γ-CH2 Pro + 
γ-CH Leu + β-CH Ile), 2.41-2.47 (2H, m, γ-CH2 Glu), 2.47-2.53 (1H, m, H6), 2.66-2.74 (1H, m, 
H3), 2.89-3.26 (11H, m, 2x ε-CH2 Lys + β-CH2 Tyr + 2x β-CH2 Phe + H5), 3.32-3.57 (3H, m, 
H4 + ε-CH2 Pro), 3.70-4.02 (16H, m, 3x β-CH2 Ser + 5x α-CH2 Gly), 4.06-4.68 (16H, m, 14x 
α-CH + CH2 cyclo), 5.73-5.77 (2H, m, CH=CH), 6.68 (2H, d, J = 8.6 Hz, Ar Tyr), 7.06-7.09 
(2H, m, Ar Tyr) and 7.17-7.33 (10H, m, Ar Phe) ppm. 
HPLC (Method A): tr = 16.0 min 
LC-MS (Method A): tr = 14.0 min; m/z  1076 [M+H]++ (calc. 1076) 
MALDI-TOF: m/z 2155 [M+H]+ (calc. 2153), 2177 [M+Na]+ (calc. 2175), 2193 [M+K]+ 
(calc. 2191). 
[ ]20Dα : - 22.2 (c = 0.1, MeOH) 
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Lys-Phe-Pro-Ile-Lys-Leu-Gly-Lys-Ala-Gly-O-cyclo-N-Gly-Ala-Lys-Thr-Ser-Ala-Glu-
Ser-Tyr-Ser-Gly-OH (18h) 
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An aliquot of 90µl of 5mM solution of diene decapeptide 17 (0.44µmol) were combined with 
90µl of 5mM solution of maleimide undecapeptide 5d (0.44µmol) and the reaction solution 
was mixed at room temperature. Past 48h, production of the Diels-Alder ligation peptide, in 
comparison with diene consumption, was of 87% determined by HPLC. The cycloadduct was 
isolated by HPLC (gradient (time/solvent B) of 0min (10%B) → 3min (10%B) → 15min 
(60%B), retention time: 9.2min), dried by lyophilization and analysed.   
Yield: approximately 0.5mg colorless solid (0.2µmol, ca. 50%)  
C104H163N25O32 (2275.56) 
1H-NMR (CD3OD, 400MHz):  found δ = 1.4 (CH3 cyclo), 5.7 (CH=CH cyclo) ppm. 
HPLC (Method A): tr = 13.7 min 
MALDI-TOF: m/z 2277 [M+H]+ (calc. 2276), 2315 [M+K]+ (calc. 2314). 
 
Lys-Cys-Gly-Val-Phe-Gly-O-cyclo-N-Gly-Thr-Gln-Phe-His-Gly-OH (19) 
An aliquot of 87µL of 10mM solution of diene hexapeptide 16 (0.87µmol) were added to 
87µL of 10mM solution of maleimido-hexapeptide 5b (0.87µmol) in H2O:MeOH (4:1) and 
the reaction solution was agitated at room temperature under argon for 2 days. HPLC analysis 
of the reaction mixture after 48h showed that 93% of starting dienophile was consumed and 
two new products were formed in 73:27 ratio. Reserved-phase preparative HPLC was used to 
isolated the products (gradient (time/solvent B) of 0min (5%B) → 15min (50%B), retention 
time: 10.0min (major product) and 11.6min (minor product)), which were identified by mass 
spectroscopy.  
 Major product: resulted from double ligation: nucleophilic adition and Diels-Alder 
reaction:  KC(mal-GTDFHG)GVFG-O-cyclo-N-GTDFHG-OH (68% determined by 
HPLC). 
C97H129N25O29S (2141.28) 
HPLC (Method A): tr = 14.9 min. 
MALDI-TOF: m/z 2143 [M+H]+ (calc. 2142), 2180 [M+K]+ (calc. 2180). 
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  Minor product: resulted from only one ligation (25% determined by HPLC). 
C65H90N16O18S (1415.57) 
HPLC (Method A): tr = 16.3 min. 
MALDI-TOF: m/z 1416.5 [M+H]+ (calc. 1415.6), 1454.4 [M+K]+ (calc. 1453.6). 
 
HO-Gly-HNC(O)-O-cyclo-N-ethylamine (20) 
 
N
ON
H
O
O
NH2
O
H
H
HO
O  
 
Glycine tran,trans-2,4-hexadienyl carbamate 24 (10mg, 0.051mmol) and N-maleoylthylamine 54 
(13mg, 0.051mmol) were dissolved in 500µl H2O:MeOH (4:1) and stirred at room 
temperature for 5h. The reaction mixture was concentrated using lyophilization, redissolved in 
deuterated methanol and analyzed by NMR. The spectrum indicated 91% Diels-Alder product 
formation. The cycloadduct was purified by reversed-phase HPLC (gradient (time/solvent B) 
of 0min (5%B) → 3min (5%B) → 16min (50%B), retention time: 8.6min). Fractions 
containing desired product (evaluated by MALDI-TOF) were combined and lyophilized. 
Yield: 11mg colorless solid (0.032mmol, 74% isolated)  
C15H21N3O6 (339.34) 
1H-NMR (CD3OD, 400MHz): δ = 1.41 (3H, d, J = 7.4 Hz, CH3), 2.47-2.56 (2H, m, H6), 2.65-
2.72 (1H, m, H3), 3.06 (2H, t, J = 6.1 Hz, CH2), 3.19 (1H, dd, J = 8.4, 7.0 4 Hz, H5), 3.38 (1H, 
dd, J = 8.5, 6.2 Hz, H4), 3.70 (2H, t, J = 5.8 Hz, CH2), 3.82 (2H, br s, α-CH2 Gly), 4.49 (1H, 
dd, J = 10.9, 8.6 Hz, CH2 cyclo), 4.57 (1H, dd, J = 10.9, 6.6 Hz, CH2 cyclo) and 5.72-5.83 (2H, m, 
CH=CH) ppm. 
13C-NMR (CD3OD, 100MHz): δ = 15.9 (CH3), 30.9 (C6), 35.6 (CH2), 36.0 (C3), 37.7 (CH2), 
41.9 (CH2), 42.8 (C4), 45.2 (C5), 62.2 (CH2), 129.5 (C1), 135.0 (C2), 157.9 (HNCOO), 172.4 
(COOH), 177.9 (C=O) and 178.1 (C=O) ppm. 
HPLC (Method A): tr = 11.5 min. 
ESI-MS: m/z 340.5 [M+H]+ (calc. 340.1). 
MALDI-TOF: m/z 340.5 [M+H]+ (calc. 340.1), 362.5 [M+Na]+ (calc. 362.1),  378.4 [M+K]+ 
(calc. 378.1). 
FAB-HRMS: m/z 340.1538 [M+H]+ (calc. 340.1509). 
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Gly-O-cyclo-N-βAla (21) 
N
O
H2N
O
O
OH
O
O
H
H
 
Glycine trans,trans-2,4-hexadienyl ester 26 (6mg, 0.038mmol) and N-maleoyl-β-alanine (7mg, 
0.038mmol) were dissolved in 400µl H2O:MeOH (9:1) and stirred at room temperature for 4h. 
The reaction mixture was concentrated using lyophilization, redissolved in deuterated 
methanol and analyzed by NMR. The spectrum indicated complete consumption of diene 26. 
The cycloadduct was purified by reversed-phase HPLC (gradient (time/solvent B) of 0min 
(5%B) → 3min (5%B) → 16min (30%B), retention time: 10.5min). Fractions containing 
desired product (evaluated by MALDI-TOF) were combined and freeze-dried. 
Yield: 5mg colorless solid (0.015mmol, 44% isolated)  
C15H20N2O6 (324.33) 
1H-NMR (CD3OD, 400MHz):  δ = 1.42 (3H, d, J = 7.4 Hz, CH3), 2.44-2.51 (3H, m, H6 + α-
CH2 βAla), 2.69-2.74 (1H, m, H3), 3.11 (1H, dd, J = 8.4, 6.9 Hz, H5), 3.32 (1H, dd, J = 8.5, 6.2 
Hz, H4), 3.64 (2H, t, J = 7.3 Hz, β-CH2 βAla), 3.87 (2H, s, α-CH2 Gly), 4.67 (1H, dd, J = 11.0, 
8.1 Hz, CH2 cyclo), 4.74 (1H, dd, J = 11.0, 7.2 Hz, CH2 cyclo) and 5.73-5.78 (2H, m, CH=CH) 
ppm. 
13C-NMR (D2O, 100MHz): δ = 16.1 (CH3), 30.8 (C6), 32.2 (CH2), 34.7 (CH2), 34.9 (C3), 40.3 
(CH2), 42.7 (C4), 45.1 (C5), 66.6 (CH2), 127.9 (C1), 135.8 (C2), 168.3 (C=O), 175.4 (COOH), 
180.1 (C=O) and 180.3 (C=O) ppm. 
HPLC (Method A): tr = 11.3 min. 
ESI-MS: m/z 325.5 [M+H]+ (calc. 325.1). 
MALDI-TOF: m/z 325.5 [M+H]+ (calc. 325.1), 347.5 [M+Na]+ (calc. 347.1),  363.5 [M+K]+ 
(calc. 363.1). 
FAB-HRMS: m/z 325.1387 [M]+ (calc. 325.1400). 
 
Gly-Gly-Gly-O-cyclo-N-βAla (22) 
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Gly-Gly-Gly-trans-trans-2,4-hexadienyl ester 27 (7.6mg, 0.028mmol) and N-maleoyl-β-alanine 
(5.0mg, 0.028mmol) were dissolved in 300µl H2O:MeOH (5:1) and stirred at room 
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temperature overnight. After 22h, the reaction was monitored by HPLC analysis, which 
indicated consumption of most starting diene-peptide (ratio: 91:9 (cycloadduct:diene). The 
Diels-Alder reaction product was purified by reversed-phase HPLC (gradient (time/solvent B) 
of 0min (5%B) → 3min (5%B) → 16min (30%B), retention time: 11.7min). Fractions 
containing desired product (evaluated by MALDI-TOF) were combined and lyophilized. 
Yield: 3.7mg colorless solid (0.0084mmol, 32% isolated)  
C19H26N4O8 (438.43) 
1H-NMR (CD3OD, 400MHz):  δ = 1.40 (3H, d, J = 7.4 Hz, CH3), 2.43-2.51 (3H, m, H6 + α-
CH2 βAla), 2.65-2.70 (1H, m, H3), 3.11 (1H, dd, J = 8.4, 7.1 Hz, H5), ~3.30 (H4, hidden by 
solvent peak), 3.64 (2H, t, J = 7.1 Hz,  β-CH2 βAla), 3.74 (2H, s, α-CH2 Gly), 4.00 (4H, br s, 2x 
α-CH2 Gly), 4.56 (1H, dd, J = 10.9, 8.2 Hz, CH2 cyclo), 4.64 (1H, dd, J = 10.9, 7.3 Hz, CH2 
cyclo) and 5.71-5.76 (2H, m, CH=CH) ppm. 
HPLC (Method A): tr = 11.9 min. 
ESI-MS: m/z 439.5 [M+H]+ (calc. 439.2). 
MALDI-TOF: m/z 439.5 [M+H]+ (calc. 439.2), 461.5 [M+Na]+ (calc. 461.2),  477.4 [M+K]+ 
(calc. 477.1). 
 
Cycloadduct (41) 
N
O
O O
OHN
H
H2N
O
 
 
Cyclopentadienyl peptide 40 (5.9mg, 0.03mmol) and maleimide 4 (5.1mg, 0.03mmol) were 
dissolved in 0.5mL D2O and stirred for 2h. The reaction mixture was directly analyzed by 
NMR. 
Yield: complete consumption of the diene determined by NMR 
C16H21N3O5 (335.36) 
1H-NMR (D2O, 400MHz):  δ = signals for the new olefin group δ = 5.61 (br s), 5.85 (d) and 
5.98-6.10 (m) ppm. No diene signals. 
ESI-MS: 336.2 [M+H]+ (calc. 336.2) 
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6.2.7. Synthesis of the biotinylated compounds 
 
Biotin-ACA-Val-Ala-Gly-hexadienylether (44) 
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N-(+)-Biotinyl-6-aminocaproic acid (48mg, 0.13mmol) was dissolved in hot dry DMF (3mL), 
cooled down and added to a solution containing Val-Ala-Gly-hexadienylether 6 (0.10mmol in 
1mL DMF). Afterwards, triethylamine (28µl, 0.20mmol), HOBt (31mg, 0.20mmol) and EDC 
(26mg, 0.13mmol) were added and the reaction mixture stirred for 20 hours at room 
temperature. Product was directly purified by reversed-phase HPLC (gradient (time/solvent 
B) of 0min (10%B) → 10min (50%B), retention time: 9.5min). Fractions containing the 
product were combined and lyophilized. 
Yield: 28.5mg (0.043mmol, 43%) colorless solid 
C32H52N6O7S (664.86) 
1H-NMR (DMSO-d6, 400 MHz): δ = 0.79 (3H, d, J = 6.8 Hz, CH3 Val) 0.82 (3H, d, J = 6.8 
Hz, CH3 Val), 1.20 (3H, d, J = 7.1 Hz, CH3 Ala), 1.21-1.64 (12H, m, 3x CH2 ACA + 3x CH2 
biot), 1.72 (2H, d, J = 6.6 Hz, CH3 Hxd), 1.90-1.97 (1H, m, β-CH Val), 2.02 (2H, t, J = 7.4 Hz, 
CH2), 2.05-2.19 (2H, m, CH2), 2.54 (1H, d, J = 12.4 Hz, CH2S biot), 2.79 (1H, dd, J = 12.4, 5.0 
Hz, CH2S biot), 2.94-2.99 (2H, m, CH2), 3.05-3.09 (1H, m, SCH biot), 3.72-3.91 (2H, m, α-CH2 
Gly), 4.09-4.16 (2H, m, 2x α-CH), 4.26-4.31 (2H, m, 2x CH biot), 4.54 (2H, d, J = 6.4 Hz, CH2 
Hxd), 5.59 (1H, ddd, J = 13.0, 6.4, 6.4 Hz, CH=CHCH3), 5.69-5.78 (1H, m, CH2CH=CH), 
6.05 (1H, dd, J = 15.0, 10.6 Hz, CH=CHCH3), 6.25 (1H, dd, J = 15.2, 10.6 Hz, CH2CH=CH), 
6.34 (1H, s, NH urea), 6.40 (1H, s, NH urea), 7.70 (1H, t, J = 5.5 Hz, CONH),  7.76 (1H, d, J = 
8.8 Hz, CONH), 7.95 (1H, d, J = 7.4 Hz, CONH) and 8.25 (1H, t, J = 5.8 Hz, CONH) ppm. 
MALDI-TOF: m/z 665.9 [M+H]+ (calc. 665.4), 688.0 [M+Na]+ (calc. 687.4), 704.0 [M+K]+ 
(calc. 703.3). 
FAB-HRMS: m/z 664.3636 [M]+ (calc. 664.3618). 
[ ]20Dα : - 16.8 (c = 0.7, MeOH) 
 
 
 
 154
Experimental Section 
Biotin-Cy5 (71) 
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Biotinylated amine 72 (13.5mg, 0.036mmol, provided by Maja Köhn, MPI Dortmund) and 
Cy5 (23.5mg, 0.036mmol) were dissolved in 4mL dry DMF. Then triethylamine (10µl, 
0.072mmol), HOBt (11mg, 0.072mmol) and EDC (15.5mg, 0.054mmol) were added 
consecutively and the deep-blue reaction mixture was stirred for 21 hours at room 
temperature. Product was directly purified by reversed-phase HPLC (gradient (time/solvent 
B) of 0min (10%B) → 10min (20%B) → 15min (50%B), retention time: 12.5min). Fractions 
containing the product were combined and lyophilized. 
Yield: 21mg intense blue solid (0.021, 58%) 
C49H68N6O11S3 (1013.29) 
1H-NMR (CD3OD, 400 MHz): δ = 1.28-1.49 (9H, m, CH3 Cy5 + 2x CH2 Cy5 + CH2 biot), 
1.50-1.88 (20H, m, 4x CH3 Cy5 + 2x CH2 Cy5 + 2x CH2 biot), 2.16-2.23 (4H, m, CH2 Cy5 + 
CH2 biot), 2.66 (1H, d, J = 12.8 Hz, CH2S biot), 2.89 (1H, dd, J = 12.7, 4.9 Hz, CH2S), 3.16-
3.25 (1H, m, SCH biot), 3.30-3.35 (2H, m, CH2 Cy5), 3.47-3.54 (4H, m, 2x CH2 eg), 3.56-3.64 
(4H, m, 2x CH2 eg), 4.09-4.20 (4H, m, 2x CH2 eg), 4.29 (1H, dd, J = 7.8, 4.4 Hz, CHN biot), 
4.47 (1H, dd, J = 7.8, 4.9 Hz, CHN biot), 6.31-6.37 (1H, m, Cy5), 6.64-6.73 (1H, m, Cy5), 7.32-
7.35 (2H, m, Cy5), 7.86-7.90 (3H, m, Cy5) and 8.27-8.35 (2H, m, Cy5) ppm. 
ESI-MS: m/z 1013.6 [M+H]+ (calculated: 1013.4). 
MALDI-TOF: m/z 1013.5 [M+H]+ (calc. 1013.4), 1051.5 [M+K]+ (calc. 1051.4). 
 
 
6.2.8. Synthesis of the maleimide-derived fluorophores 
 
2-(tert-butoxycarbonyl)ethanolamine (55) 
 
HO
H
N
O
O
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Ethanolamine (1.53g, 25mmol) and 4-dimethylaminopyridine (334mg, 2.75mmol) were 
dissolved in 30mL acetonitrile. Di-tert-butyldicarbonate (6.0g, 25.5mmol) was added to this 
solution (gas evolution observed). The reaction mixture was stirred at room temperature for 
3h. The solvent was removed by evaporation and the crude product was redissolved in 
EtOAc. The organic solution was washed with KHSO4 1M (2x), brine (1x), dried over Na2SO4 
and concentrated under reduced pressure. No further purification step was performed. 
Yield: 3.2g colorless oil (90% pure, 18mmol, 76%) 
TLC: Rf = 0.54 (EtOAc) 
C7H15NO3 (161.2) 
1H-NMR (CDCl3, 400MHz): δ = 1.38 (9H, s, C(CH3)3), 3.20 (2H, t, J = 5.1 Hz, CH2), 3.32 
(1H, br s, OH), 3.61 (2H, t, J = 5.1 Hz, CH2) and 5.20 (1H, br s, NH) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 28.6 (C(CH3)3), 43.3 (C(CH3)3), 62.3 (CH2), 82.6 (CH2) and 
156.9 (C=O) ppm. 
 
2-(maleimido)ethylamine (54) 
N
O
O
NH2 .TFA
 
Step 1: A solution of triphenylphosphine (2.7g, 10.3mmol) in 20mL dry THF was cooled to -
78°C and DIAD (2.0mL, 10.3mmol) was added slowly. Afterwards, a solution of maleimide 
(1.0g, 10.3mmol) and 2-(tert-butoxycarbonyl)ethanolamine 55 (2.0g, 11mmol) in 15mL dry 
THF was added via syringe and the reaction mixture was stirred for 10 minutes at -78°C and 
then allowed to reach room temperature by stirring overnight. The solvent was removed in 
vacuum and the product purified by flash silica gel chromatography, eluting with EtOAc:cHex 
(3:1). Fractions containing the intermediate product were collected and concentrated (2.25g 
colorless solid, GC-MS (Method A): = 4.27min; m/z: 240 [M]+, 167 [M-OtBu]+). 
Step 2: 2.25g of N-(tert-butoxycarbonyl)-2-(maleimido)ethylamine were dissolved in 50mL 
DCM, cooled to 0°C and treated with 20mL trifluoroacetic acid for 30 minutes. After 
evaporation of DCM, excess of TFA was removed by coevaporation with toluene. The 
residue was dissolved in MeOH and the product was precipitated by adding Et2O, separated 
by filtration, redissolved in MeOH:H2O and dried by lyophilization. 
Yield: 1.42g colorless solid (5.6mmol, 55%) 
C6H8N2O2.TFA (140.14 + 114.02) 
1H-NMR (CDCl3, 400MHz):  δ = 3.17 (2H, t, J = 5.8 Hz, CH2), 3.81 (2H, t, J = 5.7 Hz, CH2) 
and 6.88 (2H, s, CH=CH) ppm. 
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13C-NMR (CDCl3, 100MHz): δ = 35.0 (CH2), 38.7 (CH2), 134.6 (CH=CH) and 171.2 (C=O) 
ppm. 
N-dansyl-2-(maleimido)ethylamine (52) 
 
N
O
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H
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2-(maleimido)-ethylamine 54 (38mg, 0.15mmol), dansyl chloride (54mg, 0.20mmol) and 
DIPEA (78µl, 0.45mmol) were dissolved in 2.0mL dry DMF and the reaction solution stirred 
at room temperature for 1h. 120µl acetic acid was added and the solution concentrated under 
high vacuum. The residue was redissolved in DCM and the organic solution was washed with 
HCl 0.1M (3x), brine (1x), dried over Na2SO4 and concentrated. The product was purified by 
reversed-phase HPLC (gradient (time/solvent B) of 0min (10%B) → 20min (100%B), 
retention time: 7.1min) and freeze-dried. 
Yield: 45mg light yellow solid (0.12mmol, 80%), fluorescent 
C18H19N3O4S (373.43) 
1H-NMR (CD3OD, 400MHz):  δ = 3.09-3.13 (2H, m, CH2), 3.11 (6H, s, N(CH3)2), 3.45 (2H, 
t, J = 5.7 Hz, CH2), 6.45 (2H, s, CH=CH maleoyl), 7.56 (1H, d, J = 7.7 Hz, Ar), 7.62-7.68 (2H, 
m, Ar), 8.19 (1H, d, J = 7.3 Hz, Ar), 8.44 (1H, d, J = 8.6 Hz, Ar) and 8.48 (1H, d, J = 8.6 Hz, 
Ar) ppm. 
13C-NMR (CD3OD, 100MHz): δ = 37.2 (CH2), 40.3 (CH2), 45.3 (N(CH3)2), 116.8 (Ar), 122.5 
(Ar), 124.5 (Ar), 127.8 (Ar), 128.1 (Ar), 128.5 (Ar), 129.4 (Ar), 129.5 (Ar), 133.5 (CH=CH) and 
170.9 (C=O) ppm. 
MALDI-TOF: m/z 374.5 [M+H]+ (calc. 374.1), 396.5 [M+Na]+ (calc. 396.1),  412.5 [M+K]+ 
(calc. 412.1). 
FAB-HRMS: m/z 373.1098 [M]+ (calc. 373.1096). 
 
N-fluorescein-2-maleimido-ethylamine (53) 
N
O
O
H
N
O
O
O
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2-(maleimido)ethylamine 54 (9mg, 0.035mmol), fluorescein succinimidyl ester (15mg, 
0.028mmol) and DIPEA (16µl, 0.106mmol) were dissolved in 1.0mL dry DMF and the 
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reaction solution stirred at room temperature for 2.5h. 15µl acetic acid were added and the 
product directly purified by reversed-phase HPLC (gradient (time/solvent B) of 0min (5%B) 
→ 3min (5%B) → 15min (40%B) → 22min (100%B), retention time: 15.5min). 
Yield: 6.5mg yellow solid (0.013mmol, 46%), fluorescent 
C27H18N2O8 (498.44) 
1H-NMR (CD3OD, 400MHz):  δ = (I/II, ratio 1:0.65) 3.49/3.61 (2H, t, J = 6.1 Hz, CH2), 
3.67/3.78 (2H, t, J = 5.0 Hz, CH2), 6.22-6.67 (2H, m, Xan), 6.71/6.82 (2H, s, CH=CH maleoyl), 
6.71-6.82 (2H, m, Xan), 6.78-6.80 (2H, m, Xan), 7.31 (1H, d, J = 8.0 Hz, Ar [II]), 7.54 (1H, s, 
Ar [I]), 8.03 (1H, d, J = 8.0 Hz, Ar [I]), 8.11 (1H, d, J = 8.0 Hz, Ar [I+II]) and 8.34 (1H, s, Ar 
[II]) ppm. 
ESI-MS: 499.5 [M+H]+ (calc. 499.1) 
MALDI-TOF: m/z 499.5 [M+H]+ (calc. 499.1), 521.5 [M+Na]+ (calc. 521.1),  537.5 [M+K]+ 
(calc. 537.1). 
 
 
6.2.9. Synthesis of the diene cross-linker 
 
Pimeloyl diene ester (59) 
 
O
OO
HO  
 
To a solution of pimelic acid (3.2g, 20mmol), trans,trans-2,4-hexadien-1-ol (393mg, 4mmol) 
and DMAP (49mg, 0.4mmol) in 30mL THF was added a solution of DIC (619µl, 4mmol) in 
5mL THF dropwise over a 30-minutes period at room temperature. The reaction mixture was 
stirred overnight. The solvent was then evaporated and urea co-product was removed by 
precipitation with EtOAc/cHex. The filtrate was concentrated under reduced pressure and 
product was purified by flash silica gel chromatography, eluting with cHex:EtOAc (10:3). 
Yield: 401mg colorless oil (1.7mmol, 43%) 
TLC: Rf = 0.16 (cHex:EtOAc, 10:3) 
C13H20O4 (240.3) 
1H-NMR (CDCl3, 400MHz):  δ = 1.33-1.41 (2H, m, CH2), 1.60-1.68 (4H, m, 2x CH2), 1.75 
(3H, d, J = 6.6 Hz, CH3 Hxd), 2.32 (2H, t, J = 7.4 Hz, CH2), 2.35 (2H, t, J = 7.4 Hz, CH2), 
4.56 (2H, d, J = 6.6 Hz, CH2 Hxd), 5.61 (1H, ddd, , J =13.6, 6.4, 6.4 Hz, CH=CHCH3), 5.70-
 158
Experimental Section 
5.79 (1H, m, CH2CH=CH), 6.04 (1H, dd, J = 15.1, 10.5 Hz, CH=CHCH3) and 6.24 (1H, dd, J 
= 15.2, 10.4 Hz, CH2CH=CH) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 18.3 (CH3), 24.5 (CH2), 24.8 (CH2), 28.7 (CH2), 34.0 (CH2), 
34.3 (CH2), 65.1 (CH2 Hxd), 123.9 (CH2-CH=CH), 130.6 (CH2-CH=CH), 131.5 (CH=CH-
CH3), 135.1 (CH2-CH=CH), 173.6 (COOhxd) and 179.9 (COOH) ppm. 
LC-MS (Method B): tr = 8.36 min; m/z 263.1 [M+Na]+ (calc. 263.1). 
MALDI-TOF: 263.2 [M+Na]+ (calc. 263.1),  279.2 [M+K]+ (calc. 279.1). 
 
Pimeloyl succinimidyl hexadienyl ester (49) 
 
O
OO
ON
O
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Pimeloyl diene ester 50 (160mg, 0.66mmol), N-hydroxysuccinimide (96mg, 0.83mmol) and 4-
dimethylaminopyridine (8.6mg, 0.07mmol) were dissolved in 6mL dry THF. Then DIC 
(118µl, 0.76mmol) was added dropwise at room temperature and the reaction mixture allowed 
to react overnight. The solvent was removed under reduced pressure and urea co-product was 
precipitated by adding EtOAc/cHex solution and separated by filtration. The crude product 
was purified by flash silica gel chromatography using a gradient elution solvent system starting 
from cHex:EtOAc (3:1) to (1:1). 
Yield: 184mg colorless oil (0.55mmol, 82%) 
TLC: Rf = 0.31 (cHex:EtOAc, 1:1) 
C17H23NO6 (337.37) 
1H-NMR (CDCl3, 400MHz):  δ = 1.38-1.46 (2H, m, CH2), 1.60-1.68 (2H, m, CH2), 1.69-1.77 
(2H, m, CH2), 1.73 (3H, d, J = 6.6 Hz, CH3 Hxd), 2.30 (2H, t, J = 7.5 Hz, CH2), 2.58 (2H, t, J 
= 7.5 Hz, CH2), 2.80 (4H, br s, 2x CH2 NHS), 4.54 (2H, d, J = 6.6 Hz, CH2 Hxd), 5.59 (1H, 
ddd, , J = 14.0, 6.6, 6.6 Hz, CH=CHCH3), 5.68-5.77 (1H, m, CH2CH=CH), 6.02 (1H, dd, J = 
15.0, 10.7 Hz, CH=CHCH3) and 6.21 (1H, dd, J = 15.1, 10.5 Hz, CH2CH=CH) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 18.3 (CH3), 24.4 (CH2), 24.5 (CH2), 25.8 (2x CH2 NHS), 
28.4 (CH2), 30.9 (CH2), 34.1 (CH2), 65.0 (CH2 Hxd), 123.9 (CH2-CH=CH), 130.6 (CH2-
CH=CH), 131.4 (CH=CH-CH3), 135.0 (CH2-CH=CH), 168.7 (CONHS), 169.4 (2x C=O 
NHS) and 173.4 (COOhxd) ppm. 
LC-MS (Method B): tr = 9.09 min; m/z : 360.1 [M+Na]+ (calc. 360.1). 
MALDI-TOF: 360.2 [M+Na]+ (calc. 360.1),  376.2 [M+K]+ (calc. 376.1). 
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FAB-HRMS: 360.1448 [M+Na]+ (calc. 360.1423). 
 
6.2.10. Synthesis of the diene Cys-linkers to be used in EPL 
 
Fmoc-Cys(StBu)-βAla-βAla-OH (60) 
 
N
H O
H
N
O
H
N
S
S
OH
O
O
O
 
 
1) Loading on 2-Cl trityl resin: 2 equivalents of the Fmoc-βAla-OH and 4 equivalents of 
DIPEA were combined in DCM (10mL per gram resin) and added to the resin (480mg, 
0.77mmol, pre-swelled in DCM). After stirring the mixture for 4 hours, the resin was washed 
3x with DCM/MeOH/DIPEA (17:2:1), then 3x DCM, 2x DMF, 2x DCM and finally dried 
under reduced pressure. The loading was quantitative (determined by UV measurement). 
2) Peptide chain assembly: general procedure (section 7.2.1) 
3) Cleavage: The peptidyl resin was treated four times with a solution of 1% TFA in DCM 
(approximately 10mL/g resin) for 5-10 minutes. The filtrates were combined and a solution of 
10% pyridine in methanol was added (1/2 volume from peptide solution). The solvent was 
partially removed under reduced pressure and the peptide was precipitated by adding water. 
The solid was removed by filtration, dissolved in a mixture of methanol/water and finally 
dried by lyophilization. 
Yield: 342mg colorless solid (0.60mmol, 78%) 
C28H35N3O6S2 (573.72) 
1H-NMR (CD3OD, 400 MHz): δ = 1.32 (9H, s, tBu), 2.38 (2H, t, J = 6.7 Hz, α-CH2 βAla), 
2.49 (2H, t, J = 6.8 Hz, α-CH2 βAla), 2.92 (1H, dd, J = 13.4, 8.8 Hz, β-CH2 Cys), 3.12 (1H, dd, 
J = 13.4, 5.1 Hz, β-CH2 Cys), 3.35-3.44 (4H, m, 2x β-CH2 βAla), 4.23 (1H, t, J = 6.7 Hz, CH 
Fmoc), 4.28-4.45 (3H, m, CH2 Fmoc + α-CH Cys), 7.31 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.39 (2H, t, 
J = 7.3 Hz, Ar Fmoc), 7.66 (2H, d, J = 7.4 Hz, Ar Fmoc) and 7.78 (2H, d, J = 7.5 Hz, Ar Fmoc) 
ppm. 
13C-NMR (CD3OD, 100 MHz): δ = 29.1, 33.5, 35.2, 35.3, 35.9, 42.0, 43.6, 54.9, 67.0, 119.7, 
125.1, 127.0, 127.6, 141.4, 144.0, 157.0, 171.7, 172.5 and 174.8 ppm. 
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MALDI-TOF: m/z 574.3 [M+H]+ (calc. 574.2), 596.3 [M+Na]+ (calc. 596.2), 612.2 [M+K]+ 
(calc. 612.2). 
LC-MS (Method B): tr = 8.8 min, m/z: 574.2 [M+H]+ (calc. 574.2). 
[ ]20Dα : - 65.5 (c = 0.7, MeOH) 
 
H-Cys(StBu)-βAla-βAla-hexadienylether (57) 
 
H2N
O
H
N
O
H
N
S
S
O
O  
 
1) Esterification: 100mg Fmoc-protected peptide 60 (0.17 mmol) were dissolved in 4mL 
DCM:DMF (3:1) and combined with a solution containing trans,trans-2,4-hexadien-1-ol (23mg, 
0.23mmol) and triethylamine (48µl, 0.35mmol). After cooling the mixture to 0°C, HOBt 
(53mg, 0.35mmol) and EDC (43mg, 0.23mmol) were added. Next, the cooling bath was 
removed and reaction was stirred overnight at room temperature. After 16h, the solvents were 
removed under vacuum and the resulting solid was dissolved in 20mL chloroform and washed 
3x 5% NaHCO3, 3x water, 1x brine, dried over Na2SO4 and concentrated in high vacuum. The 
product was purified by flash chromatography eluting with ethylacetate:cyclohexane (2:1) to 
give 56mg of a colorless oil (0.086mmol, 50% yield). TLC: Rf = 0.33 (EtOAc). 1H-NMR 
(CDCl3, 400 MHz): δ = 1.33 (9H, s, tBu), 1.74 (3H, d, J = 6.7 Hz, CH3 Hxd), 2.37 (2H, t, J = 
5.6 Hz, α-CH2 βAla), 2.50 (2H, t, J = 5.9 Hz, α-CH2 βAla), 3.03-3.13 (2H, m, β-CH2 Cys), 
3.40-3.59 (4H, m, 2x β-CH2 βAla), 4.21 (1H, t, J = 7.1 Hz, CH Fmoc), 4.32-4.45 (3H, m, α-CH 
Cys + CH2 Fmoc), 4.56 (2H, d, J = 6.6 Hz, (CH2 Hxd), 5.57 (1H, ddd,  J = 13.8, 6.8, 6.8 Hz, 
CH=CHCH3), 5.68-5.76 (1H, m, CH2CH=CH), 5.92 (1H, br s, CONH), 6.01 (1H, dd, J = 
15.0, 10.5 Hz, CH=CHCH3), 6.21 (1H, dd, J = 15.2, 10.5 Hz, CH2CH=CH), 6.40 (1H, br s, 
CONH), 7.15 (1H, br s, CONH), 7.30 (2H, t, J = 7.5 Hz, Ar Fmoc), 7.39 (2H, t, J = 7.5 Hz, Ar 
Fmoc), 7.59 (2H, d, J = 7.4 Hz, Ar Fmoc) and 7.75 (2H, d, J = 7.5 Hz, Ar Fmoc) ppm. LC-MS 
(Method B): tr = 10.6 min; m/z : 676.4 [M+Na]+ (calc. 676.2). [α]D: - 12.3 (c = 1.1, CHCl3). 
2) Fmoc- deprotection: 39mg Fmoc-protected peptide (0.06 mmol) were treated with 1.0mL 
20% piperidine in DCM for 40 minutes at 0°C. The reaction mixture was coevaporated with 
methanol to remove excess of piperidine. The product was purified by reversed-phase-HPLC, 
fractions containing the product were combined and dried by lyophilization.  
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Yield: 16mg colorless oil (0.037mmol, 60% last step, 30% overall yield) 
C19H33N3O4S2 (431.61) 
1H-NMR (CD3OD, 400 MHz): δ = 1.36 (9H, s, tBu), 1.74 (3H, d, J = 6.7 Hz, CH3 Hxd), 2.42 
(2H, t, J = 6.7 Hz, α-CH2 βAla), 2.54 (2H, t, J = 6.7 Hz, α-CH2 βAla), 3.07 (1H, dd, J = 14.2, 
7.7 Hz, β-CH2 Cys), 3.19 (1H, dd, J = 14.2, 5.8 Hz, β-CH2 Cys), 3.41-3.50 (4H, m, 2x β-CH2 
βAla), 4.04 (1H, dd, J = 7.6, 5.8 Hz, α-CH Cys), 4.58 (2H, d, J = 6.6 Hz, CH2 Hxd), 5.62 (1H, 
ddd, J = 13.8, 6.6, 6.6 Hz, CH=CHCH3), 5.71-5.80 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 
15.0, 10.6 Hz, CH=CHCH3) and 6.26 (1H, dd, J = 15.2, 10.4 Hz, CH2CH=CH) ppm. 
ESI-MS: m/z  432.2 [M+H]+ (calc. 432.2) 
MALDI-TOF: m/z 432.6 [M+H]+ (calc. 432.2), 454.6 [M+Na]+ (calc. 454.2), 470.6 [M+K]+ 
(calc. 470.2). 
[ ]20Dα : - 26.9 (c = 0.3, MeOH) 
 
H-Cys(StBu)-Gly-Pro-Ala-Gly-O-hexadienylester (58) 
 
N
N
H
OH2N
O
S NH
O
H
N
O
O
O
S
 
 
1) Solid-phase synthesis using sulfonamide resin: (see general procedure in 7.2.4.1.) 
Starting from 291mg Fmoc-Gly loaded sulfonamide resin (0.24mmol). Purified by flash 
chromatography, eluting with DCM and DCM:MeOH 100:1→20:1 to give 70mg of a 
colorless solid (0.09mmol, 37%) of Fmoc-Cys(StBu)-Gly-Pro-Ala-Gly-O-hexadienylester 
C40H51N5O8S2 (793.99). TLC: Rf : 0.31 (DCM:MeOH, 10:1). MALDI-TOF: m/z 816.6 
[M+Na]+ (calc. 816.3), 833.5 [M+K]+ (calc. 833.3). 
2) Removal of the Fmoc protecting group: (see general procedure 7.2.4.2.) 70mg of Fmoc-
protected peptide (0.09mmol) was treated with 1.5mL 20% piperidine in DCM. 
HPLC purification: gradient (time/solvent B) of 0min (10%B) → 2min (10%B) → 15min 
(70%B), retention time 13.8min. 
Yield: 18mg colorless solid (0.05mmol, 35%) 
C25H41N5O6S2 (571.75) 
1H-NMR (CD3OD, 400 MHz): δ = 1.37 (9H, s, tBu), 1.38 (3H, d, J = 7.3 Hz, CH3 Ala), 1.75 
(2H, d, J = 6.7 Hz, CH3 Hxd), 1.86-2.38 (4H, m, β-CH2 + γ-CH2 Pro), 3.07 (1H, dd, J = 8.5, 
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14.3 Hz, β-CH2 Cys), 3.26 (1H, dd, J = 5.2, 14.1 Hz, β-CH2 Cys), 3.52-3.74 (2H, m, δ-CH2 Pro), 
3.89-4.01 (2H, m, α-CH2 Gly), 4.05-4.17 (3H, m, α-CH2 Gly + α-CH Cys), 4.36-4.46 (2H, m, 
2x α-CH), 4.62 (2H, d, J = 6.6 Hz, CH2 Hxd), 5.61 (1H, ddd, J = 13.8, 7.1, 7.1 Hz, 
CH=CHCH3), 5.72-5.81 (1H, m, CH2CH=CH), 6.06 (1H, dd, J = 15.1, 10.5 Hz, 
CH=CHCH3) and 6.28 (1H, dd, J = 15.2, 10.4 Hz, CH2CH=CH) ppm. 
LC-MS (Method B): tr = 5.7 min, m/z 572.3 [M+H]+ (calc. 572.3), 594.3 [M+Na]+ (calc. 
594.2). 
MALDI-TOF: m/z 572.7 [M+H]+ (calc. 572.3), 594.7 [M+Na]+ (calc. 594.2), 610.7 [M+K]+ 
(calc. 610.2). 
FAB-HRMS: m/z 571.2521 [M]+ (calc. 571.2498). 
[ ]20Dα : - 18.5 (c = 0.2, MeOH) 
 
(6-aminohexyl)-2,4-hexadienyl carbamate (61)  
 
 
H2N
H
N O
O  
 
CDI (486mg, 3mmol) was added to a solution of trans,trans-2,4-hexadien-1-ol (294mg, 3mmol) 
in dry DMF (5mL) and the reaction solution was stirred at room temperature for 3 hours. A 
mixture of 6-diaminehexane (1.74g, 15 mmol) and triethylamine (2.0mL, 15 mmol) in 10mL 
dry DMF was slowly added to the reaction solution (over 10 minutes) and the resulting 
solution was stirred for 80 minutes. 150mL DCM were added and the organic solution was 
washed with 3x 50mL sat. NaHCO3, 1x 50mL brine, dried over Na2SO4 and concentrated 
under high vacuum at 55°C. The product was isolated with satisfactory purity.  
Yield: 553mg colorless solid (2.3 mmol, 77%) 
C13H24N2O2 (240.34) 
1H-NMR (CDCl3, 400MHz):  δ = 1.21-1.33 (4H, m, 2x CH2), 1.37-1.47 (4H, m, 2x CH2),      
1.71 (3H, d, J = 6.7 Hz, CH3), 2.64 (2H, t, J = 7.1 Hz, CH2), 3.10-3.15 (2H, m, CH2), 4.51 (2H, 
d, J = 6.2 Hz, CH2 Hxd), 4.85 (1H, br s, NH), 5.59 (1H, ddd, J = 13.7, 6.5, 6.5 Hz, 
CH=CHCH3), 5.65-5.74 (1H, m, CH2CH=CH), 6.01 (1H, dd, J = 14.9, 10.5 Hz, 
CH=CHCH3) and 6.19 (1H, dd, J = 15.1, 10.5 Hz, CH2CH=CH) ppm. 
13C-NMR (CDCl3, 100MHz): δ = 18.3 (CH3), 26.7 (2x CH2), 30.1 (CH2), 33.7 (CH2), 33.7 
(CH2), 41.1 (CH2), 42.8 (CH2), 65.3 (CH2 Hxd), 124.8 (CH2-CH=CH), 130.8 (CH2-CH=CH), 
131.1 (CH=CH-CH3), 134.5 (CH2-CH=CH) and 156.7 (CONH) ppm. 
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ESI-MS: 241.4 [M+H]+ (calc. 241.2) 
FAB-HRMS: 241.1935 [M+H]+ (calc. 241.1916). 
 
H-Cys(StBu)- (6-aminohexanyl)-2,4-hexadienyl carbamate (59) 
 
H2N
O
S
S
H
N
N
H
O
O
 
 
1) Coupling: 100mg of carbamate 61 (0.42mmol) were dissolved in 3mL DCM:DMF (2:1) 
and combined with 180mg Fmoc-Cys(StBu)-OH (0.42mmol) in 5mL DCM. The mixture was 
cooled to 0°C and HOBt (77mg, 0.50mmol) and DIC (78µL, 0.50mmol) were added and the 
reaction was stirred at room temperature overnight. 20mL DCM were added and the solution 
was washed 1x KHSO4 1M, 3x NaHCO3 5%, 1x brine, dried over Na2SO4 and concentrated 
under reduced pressure. Urea was removed by precipitation in ethyl acetate/cyclohexane and 
the product was purified by flash chromatography eluting with cyclohexane:ethyl acetate (2:1), 
affording 121mg of colorless solid (0.19mmol, 45% yield). 1H-NMR (CDCl3, 400MHz):  δ = 
1.23-1.38 (4H, m, 2x CH2), 1.34 (9H, s, tBu), 1.39-1.49 (4H, m, 2x CH2), 1.74 (3H, d, J = 6.6 
Hz, CH3 Hxd), 2.99-3.18 (4H, m, CH2 + β-CH2 Cys), 3.19-3.26 (2H, m, CH2), 4.21 (1H, t, J = 
7.0 Hz, CH Fmoc), 4.31-4.48 (3H, m, CH2 Fmoc + NH), 4.54 (2H, d, J = 6.0 Hz, CH2 Hxd), 
4.82 (3H, m, α-CH Cys), 5.60 (1H, ddd, J = 13.5, 6.2, 6.2 Hz, CH=CHCH3), 5.66-5.76 (1H, m, 
CH2CH=CH), 5.86 (1H, d, J = 7.4 Hz, NH), 6.03 (1H, dd, J = 15.0, 10.6 Hz, CH=CHCH3), 
6.21 (1H, dd, J = 15.1, 10.4 Hz, CH2CH=CH), 6.44 (1H, br s, NH), 7.29 (2H, t, J = 7.5 Hz, 
Ar Fmoc), 7.39 (2H, t, J = 7.4 Hz, Ar Fmoc), 7.58 (2H, d, J = 7.4 Hz, Ar Fmoc) and 7.75 (2H, d, 
J = 7.5 Hz, Ar Fmoc) ppm. 
2) Fmoc-deprotection: Same procedure as for compound 57. Starting from 90mg of Fmoc-
protetcted peptide (0.14mmol). 
Yield: 48mg of colorless solid (0.11mmol, 80%) 
C20H37N3O3S2 (431.66) 
1H-NMR (CD3OD, 400MHz):  δ = 1.30-1.41 (4H, m, 2x CH2), 1.36 (9H, s, tBu), 1.46-1.59 
(4H, m, 2x CH2), 1.74 (3H, d, J = 6.7 Hz, CH3 Hxd), 3.06-3.28 (6H, m, 2x CH2 + β-CH2 Cys), 
4.04 (1H, dd, J = 6.1, 7.1 Hz, α-CH Cys), 4.50 (2H, d, J = 6.2 Hz, CH2 Hxd), 5.60 (1H, ddd,  J 
= 6.3, 6.3, 14.7 Hz, CH=CHCH3), 5.68-5.77 (1H, m, CH2CH=CH), 6.05 (1H, dd, J = 10.5, 
15.0 Hz, CH=CHCH3) and 6.24 (1H, dd, J = 10.5, 15.0 Hz, CH2CH=CH) ppm. 
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13C-NMR (CDCl3, 100MHz): δ = 17.0 (CH3), 26.2 (2x CH2), 28.8 (CH2), 28.9 (tBu), 29.6 
(CH2), 39.5 (CH2), 40.4 (CH), 41.3 (CH2), 52.7, (CH2), 64.8 (CH2 Hxd), 124.8 (CH2-CH=CH), 
130.2 (CH2-CH=CH), 130.8 (CH=CH-CH3), 133.8 (CH2-CH=CH), 157.8 (C=O) and 167.0 
(C=O) ppm. 
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6.3. Protein ligation by Diels-Alder reaction 
 
 
6.3.1. Material and general procedures 
 
Proteins  
Streptavidin from Streptomyces avidinii specific activity: 14µg biotin/mg protein (Sigma, product 
number S4762); avidin from egg white specific activity: 10.8µg biotin/mg solid (Sigma, 
product number A9275). 
Rab7∆C3-MESNA thioester, Rab7 wild type and REP-1 were expressed and purified by 
members of Dr. Kirill Alexandrov´s group at the MPI Dortmund. 
 
Bradford assay for determination of protein concentration 
Bradford Assay was employed to determine the total protein concentration of a sample. The 
assay is based on the observation that the absorbance maximum for an acidic solution of 
Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein 
occurs.[119] The assay sample was prepared by combining 900µl of the dye stock solution with 
100µl volume of H2O containing 1-10µg of the protein to be quantified. The protein 
concentration of a test sample was determined by comparison to that of a series of 
streptavidin standards. 
 
Analysis by polyacrylamide electrophoresis 
Discontinuous PAGE was performed according to the method of LaemmLi. Native and SDS 
polyacrylamide gels were prepared using the recipes described in Table 9. Electrophoresis was 
performed in a Bio-Rad gel system. After the run was stopped, the gels were directly scanned 
for fluorescence using an ultraviolet illuminator (Reprostar II, Camag, 302nm wavelength). 
Finally, Coomassie staining of the gels was achieved by incubation with Staining Solution for ca 
15 minutes and subsequent destaining. 
 
 
 
 
 
 166
Experimental Section 
Table 9. Recipes for preparation of polyacrylamide gels 
 
Basic gel PAGE (15%) 
(for preparation of 5 gels) 
Acidic gel PAGE (15%) 
(for preparation of 2 gels) 
SDS-PAGE (15%) 
(for preparation of 1 gel) 
Separating 
gel 
8.8mL water 
9.0mL 1.5M Tris-Cl pH 8.8 
18mL 
30%acrylamide/0.8%bis-
acrylamide 
180µl 10% fresh APS 
18µl TEMED 
4.0mL 1.5M acetate-KOH pH 
4.3 
3.0mL 50% glycerol 
6.7mL 30% 
acrylamide/0.8%bis-
acrylamide 
160µl 10% fresh APS 
20µl TEMED 
 
1.14mL water 
1.25mL 1.5M Tris-Cl pH 8.8 
2.50mL 
30%acrylamide/0.8%bis-
acrylamide 
50µl SDS 
30µl 10% fresh APS 
10µl TEMED 
 
Stacking 
gel 
9.15mL water 
3.75mL 0.5M Tris-Cl pH 6.8 
2.0mL 30% 
acrylamide/0.8%bis-
acrylamide 
25µl 10% fresh APS 
15µl TEMED 
6.4mL water 
2.5mL 0.25M acetate-KOH 
pH 6.8 
1.0mL 30% 
acrylamide/0.8%bis-
acrylamide 
100µl 10% fresh APS 
10µl TEMED 
 
1.13mL water 
0.5mL 0.5M Tris-Cl pH 6.8 
0.33mL 30% 
acrylamide/0.8%bis-
acrylamide 
20µl SDS 
10µl 10% fresh APS 
5µl TEMED 
 
Running 
buffer 
(10x): 
29g Tris Base 
144g glycine 
water up to 1 liter 
(1x): 
25g β-alanine 
6.4mL acetic acid 
water up to 800mL liter 
pH adjust to 4.3 
 
(10x): 
15g Tris Base 
72g glycine 
5g SDS 
water up to 500mL 
 
Loading 
Buffer 
(2x): 
167µl 3.0M Tris-Cl pH 8.45 
500µl 0.1% bromophenol 
blue 
2.0mL glycerol 50% 
water up to 10mL 
(5x): 
1.45mL glycerol 50% 
0.5mL 0.25M acetate-KOH 
pH 6.8 
traces of methyl green 
 
(2x): 
2.5mL 0.5M Tris-Cl pH 6.8 
4.0mL 10% SDS 
500µl 0.1% bromophenol 
blue 
1.0mL β-ME 
2.0mL glycerol 50% 
water up to 10mL 
 
Staining 
Solution 
0.25% Coomassie Brilliant Blue in H2O:MeOH:AcOH (4:5:1) 
Destaining 
Solution 
Water, methanol 15%, acetic acid 10% 
 
 
Protein purification by ultracentrifugation 
Depending on the amount of solution to be diafiltered, the following centrifugal filter devices 
were used: Amicon Ultra 15 low binding regenerated cellulose 10kDa MWCO (Milipore), 
Microcon YM-10 regenerated cellulose 10kDa MWCO (Milipore) or Vivaspin 500 
polyethensulfan membrane 30kDa MWCO (Vivascience). Centrifugation was carried out at 
room temperature using Eppendorf centrifuge 5415D. 
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Protein purification by spin gel-filtration columns 
An aliquot of 10-20µl of protein solution was loaded on the top of small spin gel filtration 
columns (DyeEx columns from Qiagen) and the columns were spinned for 3 minutes at 3000 
g in an Eppendorf centrifuge 5415D. 
 
Protein purification by dialysis 
Up to 100µl of protein solution was pipeted inside small dialysis tubes (Slide-A-Lyser 7KDa 
MWCO from Pierce) and the solution was dialyzed against 1L of buffer at 4°C for 
approximately 24 hours with slow stirring. 
 
 
6.3.2. Labeling of a (strept)avidin-biotin complex 
 
6.3.2.1. Biochemical Methods 
 
Preparation of the streptavidin-biotinylated diene complex (45a) 
Streptavidin was dissolved in water at a concentration of 1mg/mL. 200µl of this solution 
(200µg protein, estimated binding capacity: 7.6µg biotinylated diene 44) was combined with 
5.7µl of 10mM biotinylated hexadienylester 44 solution in DMF (37.9µg, 5-fold relative to 
streptavidin binding capacity) in an 1.5mL Eppendorf tube. After shaking for 30 minutes at 
room temperature, the solution was placed into an Amicon diafiltration device and diafiltered 
using five changes of water. The final volume was approximately 0.20mL.  
 
Preparation of avidin-biotinylated diene complex (45b) 
Avidin (2.0mg, estimated binding capacity: 59µg diene 44) was dissolved in 1mL water  and 
treated with 48µl of 10mM solution of biotinylated diene 44 in DMF (323µg, 5-fold relative to 
avidin binding capacity) for 30 minutes at room temperature. After purification via 
diafiltration (same procedure as above), the resulting avidin-complex solution was 
approximately 0.25mL. 
 
Preparation of streptavidin-biotinylated cycloadduct complex (48a) 
Aliquots of 10µl streptavidin-biotinylated diene complex 45a (concentration: 3.5mg/mL, 35µg 
of protein complex contains estimately 1.3µg (2.0nmol) biotinylated diene) were placed into a 
0.5mL eppendorf tubes containing 3.0µl of water. To these solutions, 2.0µl of 50mM 
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dienophile 46 solution (100nmol, 50-fold related to diene content) was added and the 
combination allowed reacting for 48h at 25°C. After this time, the mixtures were transferred 
to a Vivaspin membrane ultrafiltration apparatus and diafiltered with three changes of water. 
The resulting solution was placed in an Eppendorf tube and submitted to fluorescence scan 
(Figure 11A). The ligation reaction was analyzed by basic native gel electrophoresis (Figure 
13A) and MALDI experiments. 
 
Preparation of avidin-biotinylated cycloadduct complex (48b) 
Aliquots of 10µl avidin-biotinylated diene complex 45b (concentration: 8mg/mL, 80µg of 
protein complex contains estimately 2.4µg (3.5nmol) biotinylated diene) were placed in 
eppendorf tubes and treated with the following amounts of a 50mM maleimido-fluorescently 
labeled peptide 46 solution: 0.78, 1.94, 3.88 and 7.76µl, corresponding respectively to addition 
of 10-, 25-, 50- and 100-fold of dienophile in comparison with diene content. The solutions 
were agitated for 2 days at 25°C and purified by a Microcon diafiltration device using three 
changes of water. The resulting solutions were transferred into eppendorf tubes and scanned 
for fluorescence detection (Figure 11B). Small samples from these solutions were analysed by 
acidic native gel electrophoresis (Figure 13B) and MALDI experiments. 
 
Preparation of streptavidin-biotinylated cycloadduct complex (48c) 
In a 1.5mL eppendorf tube, 100µl of the streptavidin-diene complex 45a at 1mg/mL 
concentration (100µg of protein complex contains estimately 3.8µg (5.7nmol) biotinylated 
diene) was mixed with 57.1µl maleimide-peptide 5d 5mM solution (285nmol, 50-fold) and 
allowed to react for 24 hours at 25°C with stirring. Unligated peptide was removed by 
membrane ultrafiltration (Amicon, five water changes) and the resultant solution was analyzed 
by mass spectroscopy.  
 
Control experiments  
Following the same procedure described above, all reactions were performed with wild-type 
streptavidin or avidin in replacement of the protein-diene complex for the investigation of 
unspecific reactions. 
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6.3.2.2. Analysis of the complexes 
 
Preparation of samples for MALDI-TOF measurements 
Aliquots of 2-5µl of sample solution were mixed in 1:1 ratio with isopropanol and heated to 
boiling for some seconds. 1µl of this solution was combined with 1µl sinapinic acid matrix 
(saturated sinapinic acid in acetonitrile/0.3% TFA 1:2), placed on the MALDI plate and 
analysed (Table 10).   
 
Table 10. MALDI-TOF mass spectra of the ligands from the streptavidin-biotin avidin-biotin 
complexes. 
 
Streptavidin (avidin)-
biotinylated diene complex  
45a and 45b 
The expected mass peak for biotinylated diene 44 was found: 
687.6 [M+Na]+ (calc. 687.4),  703.5 [M+K]+ (calc. 703.3). 
Streptavidin-biotinylated 
cycloadduct  
48a and 48b 
The expected mass for the DA ligation product of diene 44 
and dienophile 46 (C72H109N15O20S2, MW: 1568.85) was 
observed: 1569.0 [M+H]+ (calc. 1568.7),  1591.0 [M+Na]+ 
(calc. 1590.7), 1607.0 [M+K]+ (calc. 1606.7). 
Streptavidin-biotinylated 
cycloadduct complex  
48c 
The correct mass for the DA ligation product of biotinylated 
diene 44 and dienophile 5d (C79H120N18O28S, MW: 1801.97) 
was observed (1801.8 [M+H]+ (calc. 1801.8),  1824.8 
[M+Na]+ (calc. 1823.8), 1839.8 [M+K]+ (calc. 1839.7)). 
 
 
Native gel electrophoresis 
Nondenaturating discontinuous polyacrylamide gel electrophoresis was applied to investigate 
the behavior of the streptavidin/avidin-biotinylated complexes upon ligation conditions. 
Streptavidin was analyzed by basic PAGE protocol, while acidic native electrophoresis was 
utilized for avidin due to its high basic nature (pI ~ 10.5). The recipes described in Table 9 
were used for preparation of the gels. Before electrophoresis, samples were mixed with 
Loading Buffer and directly loaded into the gel wells. The basic gels were run at constant 
125V while the acidic gels at constant 35mA.  
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6.3.3. Bioconjugation of streptavidin by Diels-Alder ligation 
 
6.3.3.1. Biochemical Methods 
 
Preparation of the streptavidin-diene conjugate (51) 
Streptavidin (1.09mg, 21nmols) was dissolved in 450µl water and incubated with 2.5µl of a 
freshly prepared 50mM solution of the diene cross linker in DMF (125nmol, 6-fold relative to 
streptavidin) for 2h at 25°C. The reaction mixture was transferred to a Microcon centrifugal 
filtration device, diafiltered with four changes of water (centrifuged ca 30 minutes at 13 x g) 
and concentrated to a final volume of 55µl. Protein concentration for this solution was 
19mg/mL. The protein solution was stored at -80°C. 
 
Diels-Alder ligation between streptavidin-diene conjugate (51) and fluorescently 
labeled dienophiles 
  In water: An aliquot of 10µL of streptavidin-diene conjugate 51 at 5mg/mL 
concentration (50µg, 0.9nmol) was combined with 2.7µL of a 10mM solution of dienophile 
46, 52 or 53 (27nmol, 30-fold) and kept at 25°C for 24 hours while shaking. After this time, 
excess of dienophile was removed by passing the reaction mixture through a DyeEx spin gel 
filtration column. The purified solution was placed into 0.5mL Eppendorf tubes and analyzed 
by ultraviolet radiation (see Scheme 22). Samples of the cycloadduct conjugate solution were 
taken for realization of SDS-PAGE and MALDI-TOF tests.  
 At different pH: An aliquot of 8µl of conjugate solution 51 (at 5mg/mL concentration) 
was diluted with 2.5 µl sodium phosphate buffer 0.1M (at different pH: 5.5, 6.0, 6.5 and 7.0) 
and combined with 7.5 µl of a 10mM solution of maleimide 46. After 24h, the ligated protein 
was purified as described above.  
 
Control experiments 
The same procedures described above were performed using wild type streptavidin instead of 
the streptavidin-diene conjugate as a negative control experiment. 
 
 
 
 
 171
Experimental Section 
6.3.3.2. Analysis of the conjugates 
 
MALDI-TOF measurements 
Mass spectra of the conjugated proteins were performed using sinapinic acid as matrix 
(saturated sinapinic acid in acetonitrile/0.3% TFA 1:2). Only the mass of monomeric 
streptavidin gave well-defined peaks. Because the composition of the streptavidin subunits 
varies from 123 to 125 amino acids, a range of different mass peaks were found between 
13115 and 14000 for the spectrum of streptavidin (Figure 15A). The largest subunit peak, 
experimentally found at mass 13180 (± 6) Da, was taken as reference for calculation of the 
expected protein conjugate mass. 
 
Denaturating SDS-PAGE 
Discontinuous SDS-PAGE was performed according to the method of LaemmLi (1970). The 
gels were prepared following the recipes indicated in Table 9. Before electrophoresis, samples 
were mixed with Loading Buffer and loaded into the gel wells. In the cases where visualization 
of the streptavidin subunits was desired, the sample-mix was heated at 80°C for 5 minutes 
prior loading. Electrophoresis was run at constant 35mA.  
 
Titrimetric assays for the determination of biotin binding capacity of streptavidin 
 Assay 1: A sample of 1mL of a streptavidin at 0.1 mg/mL concentration in ammonium 
carbonate buffer 0.2 M pH 8.9 was added to a 1 mL UV-cuvette and the absorbance was read 
at 233 nm (A0). Aliquots of d-biotin (0.1 mg/mL in ammonium carbonate buffer 0.2 M) were 
added in increments of 2 µL stepwise. The solution was stirred after each addition with the 
help of a magnetic stirrer and the absorbance recorded at 233 nm (A). The titration curve was 
built by plotting the differential absorbance (A-A0) vs volume of biotin added (Figure 17A). 
The amount of biotin at the inflection point is divided by concentration of the streptavidin 
samples to give the specific activity: 
Units/mg = V1.C1/V2.C2
where: V1 = volume of biotin at inflection point, C1 = concentration of the biotin solution, V2 
= volume of the streptavidin sample, C2 = concentration of the streptavidin sample. 
 
 Assay 2: To a 1 mL UV-cuvette, 1mL of a streptavidin sample at 0.1 mg/mL 
concentration in sodium phosphate buffer 0.1 M pH 7.0 was added together with 25µL of a 
solution of HABA 10mM in 10mM sodium hydroxide. The absorbance was read at 500 nm 
(A0). Aliquots of d-biotin (2mM in sodium phosphate buffer 0.1 M) were added in increments 
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of 2 µL stepwise. The solution was stirred after each addition with the help of a magnetic 
stirrer and the absorbance recorded at 500 nm (A). The titration curve was built by plotting 
the differential absorbance (A-A0) vs volume of biotin added (Figure 17A).  
 
 
6.3.4. Site-specific labeling of Rab proteins 
 
6.3.4.1. Biochemical methods 
 
Cystein ligation of the Rab7∆C3 thioester and peptides 57 or 58. 
An aliquot of 100µL of a stock solution of Rab7∆C3 thioester (6.8 mg/mL in buffer 25mM 
sodium phosphate pH 7.5, 25mM NaCl, 0.5 M MESNA, 10µM GDP, 2mM MgCl2, 30nmol) 
was combined with 13µL of ligation buffer (25mM sodium phosphate pH 7.5, 100mM NaCl, 
100mM MESNA, 2% CHAPS, 50µM GDP, 1mM MgCl2) and 10µL of peptide 57 or 58 
(60mM in methanol, 600nmol) was added. The final concentrations were 250µM for Rab7 
thioester and 5mM for the peptide (approximately 20 equivalents). The ligation reaction 
mixture was incubated overnight at 16°C with slightly shaking. Small samples were removed 
for analysis by ESI-MS and SDS-PAGE. The resulting ligated protein solution was directly 
submitted to the next step without further purification.
 
Protection of cysteine residues with Ellmann´s reagent 
An aliquot of 85µL of the dienyl Rab7 solution resulting from the cystein ligation (ca. 5.7 
mg/mL) was mixed with 115µL of DTNB 30mM (in 60mM sodium phosphate pH 8) at 25°C 
for 4 hours. Next the yellowish reaction solution was dialyzed against DA buffer (5mM 
sodium phosphate buffer pH 6.0, 20mM NaCl, 0.2mM MgCl2 and 20µM GDP). The final 
concentration was approximately 1.2-1.5 mg/mL of a colorless solution. Small samples were 
removed for analysis by ESI-MS and SDS-PAGE. The protein solution was frozen and stored 
at -80°C. 
 
Diels-Alder ligation of Rab7 hexadienyl ester 62 and maleimide compounds 
In different scale experiments, 10-300 µl of Rab7 hexadienyl ester 62 solution in DA buffer 
(5mM sodium phosphate buffer pH 6.0, 20mM NaCl, 0.2mM MgCl2 and 20µM GDP) at 
concentration of approximately 1 mg/mL (ca. 40µM protein) were combined with 30 to 100 
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equivalents of maleimide compounds 46 or 52. The ligation mixture was incubated at 25°C for 
20-24h. Under these conditions, the ligated protein usually precipitated gradually during the 
reaction course. 
 Analysis: The reaction was quenched by adding DTT 200mM (50 equivalents relative to 
the amount of dienophile added). The deprotection of the cystein residues was visually noticed 
by the development of a yellow coloration upon addition of DTT resulted from the release of 
the TNB groups into solution. After 2h, the reaction mixture was analyzed by SDS-PAGE 
electrophoresis (Figure 35) and ESI-MS (Figure 36). 
 Purification: The reaction mixture was centrifugated and the supernadant was removed. 
The pellet was washed with methanol (2x) to remove excess of dienophile and redissolved in 
denaturating buffer (100mM Tris-HCl pH 8.0, 6M guanidinium-HCl, 100mM DTE, 1% 
CHAPS and 1mM EDTA) to a concentration of ca. 1 mg/mL (solution became yellowish 
because of the TNB group release) and incubated overnight at 4°C. The protein was refolded 
by diluting it 25-fold dropwise with folding buffer (100mM HEPES pH 7.5, 5mM DTE, 2mM 
MgCl2, 100µM GDP, 1% CHAPS) and incubated at room temperature for 3h with slightly 
stirring. After that, an equimolar of the REP-1 was added and the solution was incubated 
overnight at 4°C. The resulting complex was dialysed against 25mM HEPES pH 7.5, 40mM 
NaCl, 3mM DTE, 2mM MgCl2 and 20µM GDP, concentrated by ultracentrifugation (Amicon 
10KDa cut-off) and stored at -80°C. 
 
Control experiments with Rab7 wild type 
 Without DTNB blocking: 20µL of a stock solution of Rab7wt[4] (10 mg/mL in 25mM 
HEPES pH 7.2, 40mM NaCl, 3mM DTE, 2mM MgCl2 and 10µM GDP) was dialyzed against 
DA buffer (5mM sodium phosphate buffer pH 6.0, 20mM NaCl, 0.2mM MgCl2 and 20µM 
GDP) to a final concentration of 5.2 mg/mL. 10µL of this solution (2.1nmol of protein) was 
treated with 6.3µL of maleimide 46 (10mM, 63nmol) at 25°C for 22h. The reaction was 
analyzed by SDS-PAGE (Figure 33A) and ESI-MS: found 23717 (Rab7wt: 23719), 25526 
(calculated for Rab7wt + 2 addition of 46: 25527) and 26430 (calculated for Rab7wt + 3 
addition of 46: 26431).  
 With DTNB blocking: 50µL of the stock solution of Rab7wt was dialyzed against 5mM 
sodium phosphate buffer pH 7.5, 20mM NaCl, 0.2mM MgCl2 and 20µM GDP to a final 
concentration of 8.7 mg/mL. 23µL of this solution was combined with 46µL of DTNB 
30mM (in 60mM sodium phosphate buffer pH 8) for 2 hours at 25°C. The resulting yellowish 
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solution was dialyzed against DA buffer (5mM sodium phosphate buffer pH 6.0, 20mM NaCl, 
0.2mM MgCl2 and 20µM GDP) to a final protein concentration of 1 mg/mL. The protected 
Rab 7 was analyzed by ESI-MS: found 24311 (calculated for Rab7wt + 3 TNB groups: 24310) 
and 24703 (calculated for Rab7wt + 5 TNB groups: 24704). 25µL of the protected Rab 7 
hexadienyl ester solution in DA buffer (25µg, 1nmol) was treated with 3µL of maleimide 46 
(10mM, 30nmol) at 25°C for 20h. The reaction was quenched by addition of 8µl of DTT 
200mM (solution became yellow) and analyzed by SDS-PAGE (Figure 33A) and ESI-MS 
(Figure 33B): found 23719 (Rab7wt: 23719). 
 
 
6.3.4.2. Analysis of the modified Rab proteins 
 
Denaturating SDS-PAGE 
Discontinuous SDS-PAGE was performed according to the method of LaemmLi (1970). The 
gels were prepared following the recipes indicated in Table 9. Before electrophoresis, samples 
were mixed with Loading Buffer, heating at 75°C for 5 minutes and loaded into the gel wells. 
Electrophoresis was run at constant 35mA. 
 
ESI-MS mass spectra 
Approximately 20-30µg of protein solution sample was submitted to ESI-MS experiments 
(Method C). The spectra are illustrated in Figure 36. 
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6.4. Protein immobilization on glass slides 
 
 
Avidin conjugates 
Diene succinimidyl esters 65, 66 and 67 were synthethized and provided by Dr. José Palomo 
(MPI Dortmund). 1mg of avidin (150nmols) was dissolved in 200µl water and incubated with 
1.0 to 2.0µl of a freshly prepared 100mM solution of the diene cross linkers 65, 66 or 67 in 
DMF (450 to 900nmol, 6- to 12-fold relative to avidin) for 4h at 25°C. The reaction mixture 
was centrifugated and the solution was transferred to a Microcon centrifugal filtration device 
and diafiltered with four changes of water (centrifuged ca 30 minutes at 13 x g). The 
conjugates solutions were analyzed by MALDI-TOF (Figure 37). 
 
Glass Slides  
PAMAM dendrimer-activated glass slides were kindly provided by Chimera Biotec GmbH 
(Dortmund).[116] The functionalization of these glass slides with maleimido groups was 
performed by Maja Köhn (Department of Chemical Biology, MPI Dortmund) as indicated in 
Scheme 32. The slides were stored at 4°C and used within two weeks. 
 
Spotting and binding with Biotin-Cy5  
5µL of each protein solution were spotted on the activated slides using an Eppendorf pipette 
and the slide was incubated overnight inside a satured wet chamber at room temperature. The 
slide was washed with water and dried under reduced pressure. After that, aliquots of a 10nM 
solution of biotin-Cy5 71 was added over each protein spot (25 µL) or added throughout the 
entire glass slide surface (1 mL) and incubated for 30 minutes at room temperature. The slide 
was washed with buffer (10mM sodium phosphate buffer pH 7.5, 0.05% Tween-20) and 
water, dried under vacuum and scanned for fluorescence. 
 
Fluorescence Scan 
The fluorescence intensity of the spotted slides was measured using a microarray laser 
scanning system (Axon) at Chimera Biotec GmbH by Dr. Ron Wacker.  
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8. ABBREVIATIONS   
 
 
AA Amino acid 
ACA Aminocaprionic acid 
APS Ammonium persulfate 
Ar  Aromatic  
calc. calculated 
CBD Chitin binding domain 
CDI 1,1´-Carbonyl-diimidazole 
CHAPS 3-(3-cholamidopropyl)-dimethyl-ammoniopropane sulfonate 
cHex Cyclohexane 
Da Dalton 
DA Diels-Alder 
Dan Dansyl 
Dansyl 5-Dimethylaminonaphtalene-1-sulfonyl 
DCM Dichloromethane 
DIC N,N´-Diisopropylcarbodiimide 
DIPEA Diisopropylethylamine 
DMAP 4-Dimethylaminopyridine 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
DTNB 5,5´-dithio-bis-nitrobenzoic acid 
DTT Dithiolthreitol 
DVD Divinylbenzene 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
EDT Ethanedithiol 
EPL Expressed protein ligation 
Eq. Equivalent  
ESI Electron-spray inonization  
FAB Fast atom bombardment  
Fmoc 9-Fluorenylmethoxycarbonyl 
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GC Gas chromatography 
GDP Guanosine 5´-diphosphate 
GNP Phosphoaminophosphonic acid guanylate ester  
HABA 2-(4-Hydroxyphenylazo)benzoic acid 
HBTU 
HEPES                 
2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV Human immunodeficiency virus 
HOBt N-Hydroxybenzotriazole 
HPLC High performance liquid chromatography 
Hxdn 2,4-Hexadienyl 
Kd Dissociation constant 
LC-MS Liquid chromatography – mass spectroscopy 
MALDI-TOF Matrix-assisted laser desorption ionization time-of-flight  
ME Mercaptoethanol 
MESNA 2-mercapto-ethane sulfonate 
MS Mass spectrometry 
Mtt 4-Methyltrityl 
MW Molecular weight 
MWCO Molecular weight cut-off 
NCL Native chemical ligation 
NHS N-Hydroxysuccinimide 
NMP N-Methylpyrrolidinone 
NMR Nuclear magnetic ressonance 
NOE Nuclear Overhauser effect 
NTA Nitrilotriacetic acid 
o.n. Overnight  
OHxdn 2,4-Hexadienyl ester 
PAGE Polyacrylamide gel electrophoresis 
PG Protecting group  
PyBOP Benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluophosphate 
Quant. Quantitative  
Rab Ras-like protein from rat brain 
RP Reversed-phase 
SDS Sodium dodecylsulfate 
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Abbreviations 
SPPS Solid-phase peptide synthesis 
StBu Thio-tert-butyl 
tBu tert-Butyl 
TEMED N,N,N',N'-Tetramethylethylenediamine 
TES Triethylsilane 
TFA Trifluoracetic acid 
TGF Transforming growth factor 
THF Tetrahydrofuran 
TIS Triisopropylsilane 
TLC Thin layer chromatography 
TNB 5-thio-2-nitrobenzoic acid 
Tris Tris-hydroxymethyl-aminomethane 
UV Ultraviolet 
wt Wild type 
GTP Guanosine 5´-triphosphate 
Na-Pi Sodium phosphate buffer 
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